var title_f41_6_42080="Erythromycin: Patient drug information";
var content_f41_6_42080=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"10\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Erythromycin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <div class=\"block note\" id=\"F12804619\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <p>",
"     Information for this drug is presented separately based upon the following methods of administration:",
"    </p>",
"   </div>",
"   <div class=\"sec_xr rmolist\" id=\"F12804620\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <ul xmlns=\"\">",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/61/4052?source=see_link\">",
"       Erythromycin (ophthalmic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/23/22901?source=see_link\">",
"       Erythromycin (systemic): Patient drug information",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/47/756?source=see_link\">",
"       Erythromycin (topical): Patient drug information",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12428 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-27.109.116.13-23EAA62341-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42080=[""].join("\n");
var outline_f41_6_42080=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   DRUG INFORMATION",
"   <br/>",
"   [by method of administration]",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?3/61/4052?source=related_link\">",
"      Erythromycin (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/23/22901?source=related_link\">",
"      Erythromycin (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?0/47/756?source=related_link\">",
"      Erythromycin (topical): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_6_42081="Lead induced side effects";
var content_f41_6_42081=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F63076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F63076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 646px\">",
"   <div class=\"ttl\">",
"    Summary of lowest lead levels for key lead-induced health effects in adults",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 626px; height: 676px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PbB: blood lead concentration; GFR: glomerular filtration rate.",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: ATSDR, US Department of Health and Human Services. Toxicological Profile for Lead, 1990.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42081=[""].join("\n");
var outline_f41_6_42081=null;
var title_f41_6_42082="Hypospadias PI";
var content_f41_6_42082=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F83947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F83947&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 558px\">",
"   <div class=\"ttl\">",
"    Hypospadias",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 538px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    In a penis with hypospadias, the hole that urine comes out of can be close to the tip, somewhere along the shaft of the penis, or down by the testicles.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Bottom image reproduced from: Centers for Disease Control and Prevention. Birth Defects: Facts about hypospadias. Available at:",
"     <a href=\"file://www.cdc.gov/ncbddd/birthdefects/Hypospadias.html\">",
"      file://www.cdc.gov/ncbddd/birthdefects/Hypospadias.html",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42082=[""].join("\n");
var outline_f41_6_42082=null;
var title_f41_6_42083="Perforating dermatosis";
var content_f41_6_42083=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F86478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F86478&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Acquired reactive perforating dermatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 332px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFMAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwCjFFDDEqxxqp/QVE4YuFUZ7detXmKCXaygepFQPGrRZBIGTivlrLofr/LcjRXWfy2GfpTromNiuOn5/jUkIHzHOF7d6Zf7X3YUH5cdetGgW0OZvbomdjzszhTj0qaymkjYZI243HnPWq1xFiRhztU4GatWMO+EgKQ7Hr29sf410SS5TlgpOep0Me2WNSy7tnI46H1rRhQiNGVMnnA6VT023aMDeT8vIrYi3AjkVzaM65OyIwgEa5GWXoaayb/QDuSO9TyhQg7HvRHEzKowOeQadjPm6lRo1ON5OPzqLyEkBwORk5q95KlgCS2O4/UUFFRiqcIARnHWlbuWqnYz57RWjUlS2Bk802K1GzhOcjcK2FiDQg4wPXFDwM5XsSBwTjJo5Q9v0M9LQvJu4Jxk+1T29qAqEDk8gnirzwBI2KsArfKeOgos4gm5SMnPUdvWq5UZSrNoZbBwSVbhl/nVqNSWYuQScbcckYoWBHPl7SAy/K3b8KnSJVcKwKoO4/xq4pnPOaY2MHzmcDG7gAdBVmWJCsWDt45B607ywWVU6k4ZhzUUqsZNhIO0cDpir2Wpz83M9BJSRJsBGzO7pSwkYwMDPPtT0jZ0Z+WPRR3z6U1FZXOVBGOcnGKV9bhdWsEaty+QQTjjuKRUfkYGxRgn9afhwgQMu4/NuH8Ip6BjGQzbO5Hr70W6CbK5VAp54PUD09KjkRUKpgEnkGh4igI3EsT+VKUAjQMGyTj6fWp8jRepJGczxORlehA9e9WFzmRANoA9ex9KZb/JgyIfLByD3PoanjK7SzpjJICnt6VaMZsrmIiKQdW4YEdgOtQ7fODpgf7Jx2q+qq65+VUxyR39ahzteRYwhJwhHTA7Gk19w4zZkX0AIbYF3qDux7d65HVYWZ1dRlUYE44yDxXYXOXDEsFdX5z3rKNq779/MMjbDjt3FYP4ro9TDT5V7xlNKwV02EgA4PrVzQVdLZEHysu5156j/GniNhHJa9+g3dlBziptKzHOilcZX9D/APWoTbaOipJODsbsIEk8bkjOM8fSrMTbn2EL93JzUGmxqXbeD8ikr2HWmxCQTqx4Qr+da3tY8iSu2uxYMgAjVhlOc/X0ptqy+X5kwIyzADHJ9qSRNkMUhJC7mzj9DU0EhAh3ldqKScjp6H61STuQ/h0Et9ousY2xKhyc9TVVzucHgEEj1GKurJG53IeGypHTJ9RUBVfJ8xNoWMFG7FqTWgReupSlgDoNzFcD06094125C/xcA+gqYoV8sc5XDsX70lw0e1uckYAIzjJNRZGym3ZGbJC+4ZI+bJ5P61VWLarKeVPXPar8rh7hSE+Udye9NkiJhOcfe5JFS/I6Yza3M+ZdhBXp1x7Vn7gXAbJI5Fas0eHcnJVRj61zl6zhiSxC5yT0qetjrp+8tC8uGGMdAec9adcKWPA+VBismwuiWbJIHQ57Gta3dXVWY5XO761VraDauiCaJWXnknkgjpWJf2/yu69B1FdOzIRI4UsQMZx3NZd5GGiK7evbtVKVncwqQurnGXcQJwR2rmdXtspJg8V2l9EQ7Y5I44rFu7XehxnJruoz5ZJnzuOw3Mmkc5aqI7Xc4x8uAR/niobyIvKoBXd0BrTuLYxEjBxx9KQWe+RWbqB1HNdiqL4jxXRk1yktlHtjQcHinXESfM2CM9TjmrkUBWPaeOO3elkj+Tnk9ax5/eudbpNRsc/cxAEMoCqR1HSsmWPYxUnketdJdQdWUjIzxn/OKx7mIHd0yR3/AK120Znm1oO5mgcE9+350vXPOakdSD05xUROccDHrW5zXHEcZ44569KQgdx1689KCD0AyT6UOfz+tO3YEJjK9ODRSjOCc/8A16KWnUdz6Puo2dwUzuPBHvTgq5AYY3AkkVZlOzGOFXnn1quzsSDg8ZPAxz3+tfKI/T0OFuvDLz7dqrz2+YgSCD3xV6ElkDY5PTIxUhU4Ct6dR1oJb6HLfY8yKQMDnJIzmrlhYshIBLEYxx0HtWg9rh8dAeOe1X4UwAM4IGAfX607vYHaOoWagRKpA3bepq3Gp8slcfN+YNNityWII3Y6+1TIgbkjPJyQKEjnnJNjB94qQOO9PVSZV4GT8yqemO1SGJVX5gHIXjFToqEnHygLj6e1Wk2YynYpmLCk/Lnr06GpERWC+bjpkmrIhV2LHjkAipPso3/u87gO9HKyXVXUpi3wgXJC9MgU+KEhUJYFwxGG5zVtYyUIGSuQAO1MMRiO9cHLcLnP51Vrake0voRy27dHAwQcZNPEBjZuRnABI5zU8KE7ZABuDYINHDM20YZ+QW5xVcq3I9o9hEtSJXbI2IuR7emaarbRknJUEn0apHcCFvLcHOOP7xqleTNFC/yZjGAxHr7USsthQUpuzLyzgAkgq5HTPekPV5ZMbgwBUdSayEuXknxEDlsYHXjHNaMLFnjyM7+CT0yOlCncqVLkLMRO1yikfMCD2FNkLEAEqQOSMY4NTmMtATn5wScNxiiNT8xDKTjHI61dmYcy3IFhxDxj5Rg7u4zVPzdzY38jJXnrzVq/DQqwhbgICD61zT3RICFgu5uM+vesZtJ2OrD03UTZ0K3Ksu1Vxlh16ippPlkEW0sxXj0aorMrIV3KFfGDhcgHsRVmSB3P7vaTGCd3TI9hV6tGEmoysQruBOOY0Gwq1SqpeBZCcNnDKP50kyOTCy5KkYNWokjWMMzMcZRsdvQU1G+hEpWVyhLI/lOvylG+cY7EdvaiEZi2lwHb5DjsKnvFG5wh6/MSenuPftVRo380Ip6gAkdPY1LunqXFqUewl1AXnIY7j6D+LioZ4lVnCKDnDrx1Pf8AKrD5BBA+ccjPO4Z5pyKRbqEwxDfMCfwFJxTbNFJpI5nVi3mI642uOg65JqG3WVZoAAxlJKkdBj0rcms33T+au0qxYEe3pTpYYnPm7SNsfyj1Y96x5Xud8cRFRUbE+lMxs5HcgsijaD3HoatlRFCny5kRMsfY1UELRRypuyAobH97/JqVpPMkUyKcrncq8dK3Wi1PPmuaV1sNulMgCZIjQg/U1WW58oFFx8zc9+lWgzGLYcfMAvTqe5qjBDuud3YsSARjOKT3uaQtZqXQngl3wR7cHa3cdDTXfDiJiWLEMcevcGnLHIk7uVGN+8gdAT0olhdyXjUliAcn260mn0H7tyxcSRsGXfufaAD6f/WFVpHxDI21fvj7o74pkjDc4YBcYG7vUTSBoWkSPbtHGed/v9KTldhCFkEeJl6KApyO2DUSSGSWFVXJz0bndVK7ma2LR5G7aMjtg0kN2F25Uq3qetTfodapO10XLiFjGehG4k8d/wD61c7qduTGCUbaCPxrrYnSaCLB5weR6mqlxYlovnJEYYkD1xRydh0a/I7SOMu43FwznB3YA/AYrQgby0jDLk4PXpRd7Y5BI4+VQTg9c9qqJdNI7F1AIOFXuR7VLuzvsmtDWVwRkEBifpVS7USKARtHT5e+KZbzq5XJ65PHWp5l+XKngDPAovoZSj0MK6gLyMMYwpwcVlSxAj3xXSiNsF24OOPes65tdoYgrgda2hPozhnTutTnWt+MkcfyNMjtwrEgda1Jo8/Lj6imCL5CT0Fb8xwSwqvoUzFzz1qKRBtIHerzoQM4zVeReoyPrWkWYVaSRlTpngY54BxWXPBktkD2BHB/wrcmXH4dDVGfhlHOOcYFdEJWZ5Famc7PGTgqMgjFU3GAeg56d62Z4yWDAEAjNZs0RzyOTnPau6E7rU8upDldyuwwOhIP5U0gZ/rUjr69B09KYw+bnArXdmaEyQMUUemAMUUrMND6bJBkYMMgDk+tOCrIvHUcfjSyfOvC7RSRBkj5HuTXyh+m9B2MbR6U/aWBByaYreYVVfrntVqKNmYdPlHJPb0ppESdtxiRKWAY9ec+1SpCOAQQ2ePcUImDkgZIzgHg+lWCB5ThiS78Z7U7GMpMWIKvcg4+Wl8vI++2R1pUB42jPGM+tTKVdnLEcdAKpK5g3YYUxJs7rjPP61KIyGPbtk96TYvmoEz7tUyopcfMcDuTVqJnKQRJ8m/APce+e9SqCoAGFOdoNMYtjYQAe2KmSMDblfkGWJznOapLsZSfcYwGSAGA7Z65xSrGRjgDL/hipS2FVCBgt37H61KYtkjMpIUHp6GrUTNzsRNCu7IOAoJweh/xqNowy5Y/MDjj0qYsBtz9/oP/AK/tUaP5jvuGAP4gKHYE3uOlSJYCFXL5wCO1U7qyLhixyG5I9D6ir6BWlVthOPTvU6+VIu5wQ57LRyqQlVcHoYlvZorSn5hIw3K2euKsiJjEHKgncCT6Yq7JGYnR9qrxnj3pWK8RcHdk9aXIkinWctSq64f75+ZSeei/SrAiMSEFcllB981OFUqFz04XI6juKWZgHTd83pj0quW2rMnNvQpSxttjVxyeu719qy7q0iedU2AscbhjpW46O6jgrEPm46k1XkUMS+GyBuXPc1Djc2pVXHYhit3yqKARnlicVbUqPP3N8pXaCR+RpLVwxBO3Z0/xFWXCeZuwFzwoI4x6YqlFWujKc23ZlZBlF3ArnhyPX1pGTPz7m8sjHHByOM1bcKkGAMs2OAeoFLFF5geMHdMTuHptp8vQjntqZ7ZQLGV+YnaePzH5VYjcRPuVM7PkbI6r606KAGQqM/e47496R5FCeYehbaf96km1qU3zaFW9jMNwyoFymAD04NRyOyJvAVQsgwMdc9zVmQKjMz4ZgRvLHPUdvWoXKPaomeI3wWx1+tQ1qzWL0VyvczKiuuS0ig4HbB9Krwv/AKO67ecZH+yOpplxC/7ssFBU4Zu5H/6qyG1IrMFz9717gVk5a3O2lR5l7ptQyZkKhW2ugyev4U9N3lk5JONozznPNV47yNrQlSobCtgenpWigUyM+4hN3bnJA4q4q5nO8d0QyRl4ofLO0k5Jx07k1Y3bvMkCgsvKnH5mpWhCqOPkZMKPx5z+tSG3CId+FDkg+w9q0SdzndRFWWD/AFrK4KbgQccNWddtPEYA3yvKpKjvitGN5PljUFSmSc+3emXIRreOQs4nRj8+P4e2PSosmtDWEnF2epz8kheNC/CF9pKj8ala6Zl2kyAL9z5cDHoa07HSt0bQz4B/1y/L944+7VW+h8uDyohkMeCw5z3xU8skrs61Vpylyozp4/tImlRTgD5ePXsaoFZfMVlB/ujJrp7WKG2ii3BmT+6OM8dT75qpfxfvSIo1VMAhepFKULK7ZrTxGvKloRaEZREWI+WNsnirV38yrGHOQcD8fWpYY1gto+D82QD/AHqqyqGc7shuWyPXoKLWVjFyU6jkYmoW+93cqpCjA+ucVjy27KQuPmByjen411ohOQrDJ25J96oy2nBycZOR7VHLbVHoUq6tysxrWMq+1wSx6nH45q7Im87V3AkgVZghC7nkwCeF+tPRVUBmXhQcH0FTYcppszpUDkK33ic/h6VTlVdzHA2nt6VqmPBIxuLd/aqtzD8pBT2pkSjcwpYx5hcgYPI9qhCgAHZjH3iRkGr0yAzhgcKvHPQYqKQ745AowTya0UjmkjNkKuOQQRzjGMiqc6nHpVqaTBIOcGoJTngHgdK6YnHVSaKMigjiqcyDLEHmtGXAU+1VXCj3x2raLPKrQ1MG8jKAEfMOhz6VRYBuODtyeRya37qMEP2AFZKwt8wOc59K64VNNTy6tJ82hUliUqG9fY1RkXazArj2NbDxYCghlAHc9arzRggjPvnrj6VvGZyThczR0PuO9FTmMEjdnp37UVpzGSTPpaNirZK/UGp3w42jC4HJNMRQWwSdpPWnTRlSNvAyT1618stEfpDabI4ocEFs8Hnmr6NtXBGD93NQwMVKqQCG7f41O4ZgDgZx+FVtsZ1JXeoowWwpABIGPwp0akEY5yeAe1MSIZQYIUncSexqwwwvAPX/ACaa11MZO2g5QSxXkAcnHTNOII5CqcDOSKFJBxyQx4bH6VMihhj3456CrMW7ESLj5mGM9KngwQTzjJxxzTo5AmeMkcc1IQCgYtyegz1zVpGUpdxk6MSrOF+bOeKltww2kgEDoBxzSSjZgygtzgCpowjFCvI4HoRVR3M5S90apBkxtPU8emKmeNt2/ccMCTjrmkjQn5sscHBqT5EkIL5yp6Dp61SRk3roQc9ZFJAXqKlWFlUxgDy8DJJ7mnx4dSqnK5BGOpA/rSufNfD4wTnPTkVSSJcncj8rZvJG4AEA9Oe1LjylZMgDIGAOTU+d8cg8wHjIXHP1FPiVGIeVeepA7npT5ddCHPuVAdmSVOFfCg85/GmpEC2X2AgbgB1Of8Kn8kkiPOSo3cdFGc5psfzuB19PUCptrqXzdiSMeSGCtuVsZL84NMdY/PzsLbeCM8mpokaVgAyAx8t79qJ7dkVioO7PJz37U7O2xmpJPViJFuQrnGfuj1P1qJY97hMESLk4HP4CrUIDRx7gVHfPv2qo8pilViHAJ5GP1FN20CLbbSEtoHRmljA2qNuOpA9TU81vtJhDKRGQysDnGffvRC7OjnBCnIcg/eGaciFm+6ypjaoz0PrQoq1glJ3uxFj80l1wGIPJHI9/6U+2VY5Fct06bepprLJFcDzDt+XHy/qKSJGcEglARlBjgmqWnqQ9VvoV5X8yaRh8uflyO5qCVN+4yNkAYweK0J1USRnG1k48sDPbk/mab5R/dSDa24Zz6getZSjdmsZpWMa7gZ12bsiM4k5+Xb2I96eY1j2EEEglee4xwavFHzuCqQeOmflPr9KZfW5kkwoGwKVJPGPcVm49TdVb2izBvBJ9nkRssRhsZrkL9lURyqpwJBgd/f8ACu6uodrtNEPkiCgseciuZntGa3nBBAQFgMe+awmnc9jB1FYZbyYhUkAcsc+uO30rp4HVbeJY/wB58itx2rlYGZrd0UAu+Bk/wgntXS2KSJCFXrGDk/hxVQYsYka0TAiMSKTGeQv8smpXl8yVSwztIG3oP/r1HDOY0jWMjz8L29KfYLHFFL5zM5OdgHUHPWuqPRHiyVrsiudxbBQK2dzsf4snoPaob0o0LfIFG8KQOgH+NXkURrK208oRkntxUMqj7PukLbZRu49c4qWtyoT1RnXEoVd+5yAu0Adh2rPZllmKqTuK5yR3/wAK1roRiA7CitI5G0/woOc4rGaVVEsy5ht89uo9vrWck29TuoarREct95UmZCWl6HPSkknbfnJG3j1J9apTBi7tKWYsAyn07066ZZVVlDKTggHOR/jWerO5Uo6F1rxSyKXBC5b6ilZy04A6HYce1YcULrJNP5p2hCu3t+Faen5WNFAXnAalza6hOlGCui25ZpGI+VS+0f1ppQyAbFHJIGegAqwUG0iPJAyVU9yarTADf5QYgJtOOlN6GMXfYgeElmAAYJTZ0UblOAMADBqxGrplecDGTj9Kryks2BgcE5+tS1oaxbbIyg2lmIy3yj6etVJoWIBJ+6OnvTpJyJBzuAAGD2p5kErhu3X/AAqTdRaOd1U+UjKeMkDA/Wsma5Dx7OgHI5rR1sOXXPI5/OsQAtIRt6mtqaVrnNWbT0FkGRzznv3qEsN3pipZ5MZ9BwAaoNKcZ449K6InBXmoskfpwai2ZkbIpY2yc5z/AI1IeBj1q0cjSlqU5eMgY/Gs+aEEthOnf3rTdgDn09KrSpk5HJPOa0i7HFUiUHUdWUE+pHFU54uHJIHPzD3rTn+5luducfWqUv8AqzhjuA6Ct4SZxygloUnQsSdpz1x/jRVohWTGQMDIorXm0MORHv8AErrISxwc1aaN9gJAAHanIEKjeeS3UdeKkjYOykHGT3OM14CR91Kb3EgTax3Ahh69M1MhCyFygLMMdeooUHd97kdfepWj24IYHjJzVowlK71AY3gdhyDUki7ySGJ4GBjqfWoySNoByDycdqeSRiTlApCj1+tNGTJVHAO3BByeeKeqByoJwwJOV/lTkKyIAO45xz071MViSQugxx1x/OtFExcrEUaEZdDtJOBx/OpovlIVjkD5iSKjEpJUuQD2ZaRpAsRKkkk4Zm6e1NWRDTZOyZ2Lzk5PqDQzFVXCkY6+v0NRB1KJsc5Ucc9PenAyEltvygYxT9Cbdy1bOCygRkIM9O5x3p4kXIBwCeD7+1QFAoZ2OTjG31qvLEyzqHyVHLKlU5NKxmoKT3LaRr57nJjCNjI7E1VupVQBI2K78gnqGGatBiYyWBIcgEis+7YRTlkjG7G1eeB74qXsXTV5ajobqdHkZ3GRhOOwPpWpZzZK5zh8fN6YrIRTE7Rcudo6DgE+lasUZijRVPG3GcdBRG6Yq6jYtNhmLK+Q65yOmPQ1Vmd1jUqhOB1XvVmJWAZo+V+7imyM+9woXaBjgdfwq3sc0XZjkMlvIFSMNEcZBGR9R7ipZiWRnxs3nAB/ujvUTMAqBh+7XBIz1OOlOKgMiuzZYfKQeKtPp0Ie9yWMBlR3JYAduCfeoGQuwCnIX5OaZGMMSjnAHOR+lSHOYigMgH3h04ounuFrMI4yrMwAIBxt7gd6Ulo3yQGeT58e3pUTJKVZkzuzgnPBqwAViT7TG/znJKnp74prsDIp2V5g6HeHHzDHSpUl3OkajLqu/g8MBSqhktDHGqqVkztHWoIoOZdgCnbwabve/cWjVuwy5leBjJHvM4Ibcx55qMbnRJG2hHJJJ6qfp6VKkAeIeazNuBYYPPHb8KhhhL27tgBRgnOSQfb61i0zZOKQqSkuflAMv7sDgAY/xphvSyKmSIojzx19zUsdr5i5Y7d7Z3ehpn2dREUfgXCEnHBRs+tL3hpwvqYN9NhxCQyNy2Sue3pWaHlimTzECybfmT+8p/8ArVr3ts7ytMG3yj5Cp78+vYYqmLWSZIoZtjtbyE7x12H+H6CsXHS561KcFH8yqlkMExnaACFGOCf8RWxGkkMcwYFgTsDZyS1LJGscYVV4Gfm9Tnp+FW5gSYRGxVcg8HgH/OaIRsZVazna5lq7Xdyo3sihdzEDgHoFFasfm7IFZQFCkFj3BptrCLUzhQGZ1UB1GSPYCrShmdTcMoZAEK9gP8mtYRstdznq1E3ZbDRGBMuYwyqR9MngVBJFIziJuSNwCnrmtX7QyWwUsGVRwQvHXOPrmkcx212Zdq3G5dxJyPn9PzrX2a7nNGrJPY525tmuNiDc8yAl8dgvAWuemYRwwzSjeCxLIRx6jP1rrZjIlwyIBl0EeR3Y8msltIa4i3KCAifNGOrKDy34Vi4XfurU9XD1lFe+9DnrO++3xSFUZFLkjttPt7VGYrmYI0JZHHB7D610tvp0NoQHYNGkhMh6cHtiqUcbDcFcKjMQMHAJ7ms5xatzHbHERu+RaGe9sYvsysQzOctg9R71sW0Ss2FUDjBP+0Tz+lEdqNzShQyEbE56Mf8AAc063jZZVywCI2M1NrPYyqVedbk4EaZA+ZASwP0GPyqu8ymfBYY4UjHBPoalLI0kmHO4nAJHBHXH51XubZSGfgtgYP8Adaq9DGFr+8RzTA7VGRuJDVGIDKdy42qu5j7elK8QBVPvbl288Z55NW4F/dP8h2uwDAcZFSld6mzfItDlbq1nN7CwkKKMll9c1PGp5IPTOfp0rXu0GT8wO8hV4ql5aFOFO3OPqBUNWOuNXmRkalCpTLoQpXAGeRz1/SucaHaZXJ5Xj612N6vm2xKnhDnJ9K5/UEDRhkXaFJyfWnBtMiauc3e5XABPHJ+tUJV2gkHr+VatzHvBxyvSqbRfMBgAD0rrizxcRTfMxseVjGc5UUhk5Ixz6U+VSAAMccmqjqynd15496pM5p3joSOpbGOeefamyD5SB+FTwjJJ7dKivvlHyjkDGapPUiUbRuULlv3Rx68Csu4uCGcIuCMfN3rQlbdkMG6c57VnyoNzF2IOQCfWumlZPU82sm9is85YjnB74/rRUtzbGOIsMAdRj+VFbxaa0ObWOjR9JJgHIYbjzTpYVfYFwDnNVMkfMPXirlvKeN4BOdvTNfPppn3Uk46osJuPlq4Ab/PNSqgOA+PvZJNEYTKsSS3v0pWOCo+XJ547Vpa25yt62QojQiRiwwDxk8fhURP7wMCT25psku1AiqMnselQpO7XJ+Udemf1p6FRi3dlu2ZhKwUDB75rQH7zcPpj3PqazrZi8nuWx05q9GGMvJAz0z06VUTCqtR0+EViFBboD24qjK+52CEk4HsAfWpJ5CuSxwcBiCKzJr1WcOn3WfaPXNEmXRptmxAu7ym6KScj29atFzErLG3XKs3XI/pWdZTKVLgMy4ySf8K0TAjDIY4yMYP3quLfQwqKztIBINq4Uydw3ZanQEoxYYzgDHJFRuBGxwCAV5GM4zUkUPlygBiQBvx1/GrMJNWCDJYo6joSMcc1UuArHfOy4X58Y6jvitBF2xsPMyWBPHJBqrLFHukcg7sYA6Ci2gQl71ytZOpdGyWLlmUHj/8AXWnDKZPLCgYGWI7cVXt0AeNY490Yix0yV7k1YhUhSv8AeG7njH+RQk0FVpsGlZtyybwG5+X/AD0qS5ZBI0pIXkAY7j6U6ARkh5CXTuBUCCOW4VnGVJIO49z0x9KLOxirX9CyJI9284IPzc9/XA9akDCQKAQpwWwf4R2zVMvGrAFiz+Zgn6d/pU+6NWZhGVd8qwz29R7VomRKBZRBHgSN1Yduh9KZKuWZVyse7OAOlVvPDLgsdwO07emR0zTxKzT/AD7lDjqOhPrRdX0J5JLVknmpyg+RUIYjsDn9Kmln/erK4LK3JHt2xVUMTdPJtwAOTjIOKfIWlG4cFnATnAU+v41Sk9QcVcntnHnuuMFlwFPA98e4qEyB5VEaHKnJI71M0ikOQ6h9vltj+H3FU9/luzoGAf8Ad8nkmiWlhRV7smVZJfP8sKGzkMBjaO4/Go4QrxARFnlQ5BDY3D0pYpJAkql8sPkOOwFNt3MLJ5eSVO4Z4+tRdXLs9Rzf6xo84BbII/UUsf8Apai3QHzMkkdSfcUFVuXAZQkBcqH68kfzNJDlGZ43dZQPLY9CuDwQfpQlr5C6eZXmT7S8LIgTbGUPuwPOarXKIGhNtGojHyKMcsepzV9fI+VbgSFc7uB79fyqnKNs52Any2DDjgj396iWxvTk72IkLtvQZDAkKpHGSeppYixWYn5wrAnFORnhvPMbOGUEAHvShvLmeN0DIMFwP5ZrNeZo32HFzJ5Q8smbaegwV7j9KljVSu/ABcZX046ilLYvWYAvFwjc4O3sKbE5TzFwV2t8iY4xnOT7VqrGT20LcZC722F9qEMBgAt2FVpvNhCecR5SsVWPuGIzk06SOVo0G1Q7OYwPQ9hn15qyLdW85zgSEqFjfJI4+8T+FaJN6Iyuo6syYvMtnkjlTfMAGU/88yT1+tR+W9whCqd0eIW56uTknitTyWkZVjHmOVDM2MA4Oc+/OKqxK9pGJY9rPhzIp6Lu4yPwzS5badDoVS+q3KdxHLNFHCdi4Yyybjk9OCfoBWNcrgRSkkxr0XGOfWtW6kYQIk3PV3PqP8MVm3N4YYWcxjLDapY8ke3tXNVaZ3UFLoPiuYYGwqE7FJBfgAnvjvVWeSOOJTGeR97HY1FMWhaXzmxJkbh6Oeg/Kq0rASLb7wpdiZMc7VWs9XodcKSvcuQ3A+UOuHxnk9M9M/hVmF2mYABTGo3tnp6CsaKRtjBwgVzkMeuFrStJllLOCVjOACR6DmnG+w6tPl1RYVUILK251GBkdyen5VIBtDDHcAAcgmmW5EeWVmAHzZPJzjAod9gkKDBU4UY4wBzVWOd3bsVbyPbgsRk5AOOnaqk8YEijO0fd4PQVbuJdzlX+bZx9T/8AWqkxJckjOT09KzkkdVK9tSrcBVjY9MnIGOwNYWoxljtwdxBJHqTXRTfMGAIbHBIPQCsq+RpAuByTnn171mdFrxOWvAoLBAVAAwPfvVAnnPfrV+/XDuyrtBzg+tZ0ikKM5y2OldUWebiLpgwDgk/Wq8iknHYDAqw4CxZx8w5qMDcevPerT7HHON9x8ceFAx2qG4j3tn9fSr0YzjPH0pJ4TnkYouaSo3joYphZtx4JA4rNuYygLfeY4/CuimhCqccE+neqFxbrJkbeD1H+FbwnZ6nm1qNtDHvJUktFXbypwSv8zRVx7Pe5HKqO3rRW8asEjjlQlN3Z7gku4+xFTQ5Yggnn0rOibauc43EAY7VsW0gIjXOBnggV4kVc+1qrlWhaBcYORlRgHvUiHOCSOTnJPOKaGXnAyegqNg4QkAZHG3tWpxWuMkBZZCWywOAQevpWeDiRA4YyE7kA/wA/WrdySJRxnGOOxqkkTTyfuRl41eRgT1C9QPel1sjpprS7NWykJUbffLdhzitHB8oeUSSe/tmsW2mPlqzBmUgEj+6OxrWgcKqAhjk/lVRZyV42dypqm4w4Q5/+tXOzq+y3OTt5PPbvXYXkKvuUDvjgd8VmSWEYYceYiAnew4B7VM4u5thq8YLUj0py6NgE/wB4itSVnjhCyA+Z2Ue/So9Ot/JgTAG3+7V9V85N0iEuQTgnpiqitDnrVE53WxV86Qyuq/MgBzk8g1qWk2QHyNoG0j+lQaeq28yiVflI+bAznHp/jUzSeV85QK2eE7Vulb3rnJVal7qRbIwB0APNRPbl2QBgOc5NV7fUEPzBPmztz2U1biY5BTaUVece9XeLRg4ygTxQqhGSRGxwCo7dxTpmTcwIBZ+oAxgdiKV3UOrRsVbrt67e2c1TaVi6hPmAyueh61TaSsYxTk7kcjHJQ4ifcMY9/WquurLp85hHJTGAOVyevNaUqDyyZnA2Dn+gzWdqu+7jhCALjA256n1rOSXK116HTRlea7dTMhuSkcpEimQkxoucZPr9KdDfzm9SFkZgAECnjj1/On6QsNpql0JwGDIYU8zny88n8fenX5jU20sO4YUrIW++TjjI9O9OMPdUrnc+Xn5bbrf5FuZJrSeSNyHdACyg9VPc+9X7QmcYhY4UbvYD1qewso5rSaQPbnzQhyWw4bHJ56g1Q01WhuJI4ZHZSSpDDA2jvWk4ezafRnnympprqjQRE2bvmDMTnnp7mrbQ7bYbSCYwSw9fcVX2lYjJyFJwuR60xmeaYI/CjBIA5I9KE+XdHK05PcVdqQxbPur87E9/agxggpHltpJAIzj3NRBikr5B8vPK9do7c1NyXkPAYjjd25p6PQp3Wo63k8tQxjCEevO7jimtHmINLtMnUbTSu5EAVG3Fch2Y9R6UxWEcg3fKrD5SfpUvsxJdUP3JFbtEyKXA3L71Xkcb12qSGXcynPJ6c/hR5RCSMgJfHyqO5HXB+nahLhRaq5OJGbv/AHcdKlvoy1HqtRrROsIZAWKHGGOcr7Ulwga3if5hMw3HuMdOato4cokEZMjk5Q/dX2HsaS42MZR8x3LkjG0Ke4pON0Cm7q5ViimurZ2t4stF8jgcsR7D0pREW8qVeWaMRgBsENjin2beTuJYL5gxJ64oMIjwiE5U9TwDzS5U1cpy1aF88/aI5UiVgkYV1HQ+31706JCbsuhDxv8AMQRyAMZJqKVHilj6KSx9uatRrlNjqRj5S3QkH19qpXejIlZK6C2DzyGN8kLnYsXGGPTB79BTWlle4mDRlZWUfKOPmzjv0HepnAggjxErnI2HPoarSvzO9xuaQDkg4zntj0rS/KrdSY+87pELTSrcSvMFjwCkZUkhMcHHtmmzxSCx2Fv3jrnJAGVA7GrDyxsY13IFSPA2gFlGc9/eonDXaIBnMqkM/tnJ+lJx31uap2s7WOfvVE9pZQhmWWUszMfuqgOe3XpXLeJNctLVoJrhyv8ACqhdwUDuRXY6nA09uoLbECrGhUAADkHJ+lcV4g0GCeMXlwGMGNqKR8re49a5pK260PZwz5o2i7S6X2u/6/AuQ3q3CESnc5kj2BQACDxn64qhfmW6u5vsibHLMy7T0UHpS6YjQ30UrKsm0q5THAVema0RbwuPt0rmMythYlHJA7j2J6VldzR6Xu0pf1/XQzYBJFYKJCTuPO4cqR2rWstwt4huJEQDEHszHp+VKYCwTJDJkMF4yCeW/QAVpxwRB41c5w3mSj3/ALv8hVcuphWrpoSKBm8ppRhS5kI+lOkhfClBu8zggdBjk/pVrDLbg/Nu3Y9Btz0H405MrK8Z4PllVHoT1A/WrSWx57qO9zBa3H2iPcX2nJA7DPUj/PaoI1EkQIVvnYk884//AFCtnUFDhWBCnG1fUL0/lWRdAwkiHqBsUGsp2R20qjmiiiCNm3Bi8rYIPQKKh1MhowVAJA+btwe1aWzey7ui9D9OcVlzo6kl+54GOp71kzqjaTOf1KJWOOihRy3r6Vl+SZHA28CuhvbaRztCHbjLc8CoLWybI3Z+Y8fStIz5UY1KSk9TFlgLKTgYzjNVxD+8JA5rpr2yyiqgC5J/Koo7BGK4UhlHOO5pqqjCeHTZnWkallJUkL1x6VK9q+WYckc4FadvaLDlhnP86YFbLhhn0NDnrcfLZWMC7h+U5BA6VSEODg5yOldLeWoePKnBBJPqazxbFFZmHQ7fxrSM7o5qlFSfMZghAYnH0orSkgKIG+9k9MdKKtSRl7BdDorCVpCFkkALudue2Otbtm48tF5D/wA65/RSXhR2j3WkRZC54wW6En61u2RLbNwxt+X6mueSaZ7F+aJuoHeNt6kADOPWgptQ/NkkdAeM0QO23G7O7A/CniPEZ5XnJBoPObszKudykgbflGT3qOydYvtKhAnmAFGY8qc4FaE1q3mfeBDLg496jXTjJKoePGBlWNCbjK6R0qrDlsyvbmPCsgaMMM7Ac4OeefTvXQWzxrENrkknb0/XFU2syBGdoG7+L19cVpW8Z3CMgLwT9KuKdzkxFSMldClSkblyOTwR6DqKEiDfK+DheMdD9akkyEOG3OeGB9B1oiiVnzgqM7jWljk5tAEKBMZAI+6B0qW2tgd20jLggmnuIyNyqckdulTwqqgKhwo6E/yq1AxlUdhtvat5iAJyRt3HgAioNVhYW0gUqFyWGTyfarhnYybEJRSTyOfxplyuWKnAIHJ7YqnFONkRGclNNmPAQsEbR7WkkB3gLggfTv8AWrbfuooVR8M+CR6H/PFMuk8skAMpBznuazbidGmiXnkcn09/rWc52VjsjH2mqNmO8yHKruVBk88kHpipgZCUZWw7ck+gPrWLGzoFbzgUAwPl5rTtWIXKDcp+Xjs3oaak3uY1KSjqi+IFcBcbW37tvbimShfnn2qpOcEeoPYdqd5zxylDhnYZB9CBUM0u2FAzHYx+dcdD/wDXrTQ5oqTZUntVklDsAwdQzeq88U+W1e4mjWLaZCpALDr6jP8AWpw7usazxk7j8rAYwOwB6GrUBWFCzKAR8oHofp/hVchpKrKK8zPa3e3VfLOzB6kZ49qvWsf7p2UFcDAY9T71dEAkmM0pwrLlQgxj8KkggJQKpwpIYIDnK57/AI0Km7+RzzxF1qLJN5ljHbNGgZT8zgfeHtVVWCXSzJkg5BD9xVnyfNeMDLYySVH6CoJgzAqpAXrtHXrxWru9WYwtsikZQ90Vg+VCMuM8fQ1VuT5RCbmdmGd2PyzUjzGDLFN0hA5I46+lVZPJ+dyWLsMjJ6Y7GsG7o76cdfIvQs6xkmMkoDuz396dCoMZZHXaQcbux9BWZA7iSRA3zBQ2CcDGOQfamfaZGmMoX90B90fwehIo5rlOi3exq2zK0jxLLhSDkkfdPrSrbqfmKr5ag5Uc49Pwqu6yJKEwNyKHkLDbjJ7/AONWoJ28siJ1XCspH8RHoaLdJGMk1rEs2gPmCTBwvp7dMUs7clwxViSWGMAZpPMdESSNwsRXBz7jpT5oGaxMkwGwIMqB94H096q2lkc/2rsqTkRpICVJ4DE9geRipIoHnYQeYse8b4mY4BH1qKNIZtQjjuBJ5BAzg+nQGoZ4potSQqEjDglQp4x9PU0ktObdbGyV/dvZ2uWZrprmMC4Vt6/eQY5I46/Sn2MnmRKsmFc/NvYknjtTYYhHI0TbwrMMkAZ+hqxOf37goXaPjKrtz3JxTTlfmbM5ONuWKHSgpLHFuXzZcSjac49vbNUcumZpZHFx82V25GOmc96ulF8zcgZZVwUXvz0P0ovC80EIDu4QkncQfn6fgKu19SYStZGSYljjjfcd6NhsjIGe3vVmAx296xcK0cQGEJyr89D6dhinrEyxqoQMSGbpkYP/AOqoGtit4yTKVIIfjGckYGfoKiKas0jfmUrpsLhFkCQSkqqhvMZVBySc4HsBXK6wBeXZuYVCQxfLFGx7gYzjpgdTXUSqq20kSsxi5ClzjOepJ71lX1qIneMxIJAoC7jlU7kn9KireS/r+v8AM68JNQlf+vP+uhy81tPLepaW6tHHPtAH9492b17n6CmGREmma3bKo3lQufuhRwSM9z1rY+xmaZ5U3TZynmjOEHd8e/YVnXennEJjJARgqx9ASepP+e1c0k1qj2YVoy91v+v6/Umg2TfOisWgIBbOd59vx4xWrahVV0GTPI3TsD/9aq1hFmNIoWCx+ZlXIxuI4BPsK1rWJY9xC4ZjsBJ/h/ib6nrVQjdnFiKi1QqJsVDKfkHzgZ/u8Kc/XtVdoJVyBxM46k9QeSfy/nVqaAbhgMse3PTOF7CmSo0aONwLYwGPUn0H44H4Vo1fc5Yy7GfPIFWWUrnHUeh6AVmzIHVUYbpDzmrepSNCsQVAVXnkd/U1SsdxVjNnP3j2IJ4A/mawnq7Ho0laPMPRVaFsfNt6/T1qpdQ7lHzA4G4g+vpWvKIxFsiGMgjAHX8az2xh84CqOp6/T8TUyjbQulNt3Mh42BYcnfgZP9aeIhjJ+U9B+FWLqIHMhOxTwQPTvSSRnZheoHGOlZs6+ZMprCeu3c3U+g9qrbcsR2z1rV24tzsJ3+tR+QFG4pkYwM0X1FoygCONvGTwaaYz8uMb855q28QOX4GB8q+tNh+/iQHZ3wORVXuJxuUpYv4nUF+gOKgljV1w/UdQOK1HbzeW4BPy/SqN0m0gocY5JPpR5mU4dSj5amMqc/L60VEs3lb/ADu5xiirV0YWsWNImlFoluEkNpJIGnTpuIPHNdVZQ7mJTcCHPLdqzrVPKikRhgr05yCev/161rQ7GGOh6g0pvmZ1SXLCyNZUyuDjC9yeBTysqQNhScDpTN2SS3Qjp61N5o8vbuHUHkfpVWXQ85tka5YMzffHUgd6liR5VchjgjkA0KdrK2ck8kf0pcKBhA+GOcdDj600Q32JUJCgHJKnBGasqgQqWfLdMdQKrKQCwcjjjAqRGyrSY7YGOPpVoxkrj2LF87hk8mnWrbQ6K4yozg84qNVJ+YqOW5GeoxS2y4Z2Kqu7OT3+lUt9SWlaxYMjCZWIDAfwGrO/lAxLAjOB39MVEq7yuV6DnB9O9TOE8tDGNp9CelaJM55NaIkCmVQVIXGcH1qC5Ij37lYqByM55qSGRs7gflxg4PGaaQzHb6nPuaqSutCI6PUzL5DIx8tsBlBGO/vWBNPLBHcJuDb9pYY7diPcV1dzGDGSRubBbOOR+FZ8+nJLtlcKzsMMo4Ax0/OsJxd7rc9DD1oxVpbGLYs9wQJWdRKRgdBkfxf0rdWRZIkgTf8AfBDevbH/ANeqSWwXYJFMaJk7AcYHp9a0ra3ixvLN5fPlBjjHfmlBOxeInF6l2HaxKuw8zlSG7HtzTL5JoovNiIwXUOB/FjoRU+5mjWRlHy7csvv0q6IsxPHJGx4AC55A9R610RjdaHlupyO4211tim2K1iFuGIEbg4GeMfnRI3mTqsrKRHyCFwfYU+O1yhxIpIwSTxg9BU6R7JZFKDjhjjPNdEpzmrSZzt0024ImgUPMHCgOW2nd2P8AhUhVkCNlBg7Rs4x9R/Wo1ZFY7wW4IbAxjmiAZPmybVUHAIPJH0p36HM+5HIVRS28gr6dMmq4jZ5GfDhiB1HPrUvEcbIhON3JIyuKSNmQF9wDtwvPFQzZaLQrajGJEUptD4xgnI+v1rKmthlN0YYA5XHetk25kdhGA5Jxj09TU01qm1JOn+yPT1FZum53ZtCv7OyOXFrPNI1sNocnzCH4+mT2AFU9TW4inlitpfJJIVDjKscc5PaullXdIJ3iDxhRCXdyMN2NVJkjRJUuNpVlLSMuNr88DHaiME1a53U8Q+a7RThnkvNItri5QJKkRSRlPDqDgZHfnmrOnu2RHOW4OHYD1wOtUZoXkeONVJL4kZd2QB249fataCNTEDvJbbzj17iok+aXoKryqOnX8C5KFh82H5V+YDCnctPuJJPKRSTlCCoI4bii2VioaLDDng8Eep+lOdjEsTsQ3+2306YrTpdHn31sU/Ldd0nKqMB164B7VaWCJyZZxtDcKRnJ96kKiS3kkYMIc/MB3IHGaZC6pDg4Iz8oI5/L1pKPQbm2tCRziRVALMflVj2A70kkRETLIMSEZ69SelWYoGeULNIA7JuUqent7GormU7IXiChQSuR1Jz3q2tHcxUrtJEdzC+8tsCPgDjr07/j3pjW8qGEB/mCdD/X8KnxmaUsS+08hTwo9qbN+6wAwA++rN8xZulNpasqMnoiElo4yS25YxuZgfmweAM/0qFYkwGIVpWbG05KrjruPvTv3qwSIRsVm3Mc5BHYY9j0pJpH8uODcVyMEAcsf6n3qbrqapPoRPNhRAYkZd37pPVu5+mKq3MEcrFtgKkfKg/i47+1SytFHPhDvihwJfX/AHE/Lmmv5saGR5AwlJATptB5K/T1NTLVam8Pd1RUWFEkMp+WMfMI+zt2GB2qlPA9xdFUUtIxPmMDjnvg9hitd0gm2Zc7l+QFjx6kkeg7CoLWFyWSNicKyo2OdndiO2ahwvZI6IVbXfUht4QGeSVVVigCAfdCj296t+RtCswBkdc89FH/ANf+VOgXam6QcbcRg8k/59KkhCr5nnSYdTggjoD1Y/0FVGKM51G2Mh3n927hAAJCzdWYdBj34pi24kneSYB8Z2jux7nH506ZDMVEQxHuzhm5b3P86bJ8iDeN+85Jxggf4U9Ool5bsydTRtsgKFRLhinUnnKj2HT8qoR2hUDk7WOWY9TjoK3ThZiJBmLG4+p+v8qoT7gMbhtzkL6Niuecb6s7qVRpcqKQQxyNnHCkDHY1VnBTEYxuPzZFSXbuIyw652k5/Wucv74CctIylSNq4PU+p+lc8mjvo03LVlq7dUZY2JDM2W5zwKjEqGUAZ2561gzX6NufcSx4HsO5/pSWupMFCk5YnHpgVnyvsdaaWh1UP7yMEEbj0BqQRNtIHyqWwO4//VVXTnXaxPRhjPua0H+basZ4bp22getUkmrmU3aVkUWti20A/dOaZMgVXC9VGTnqfrWmE5JBxjp3zUckRGARyeD9KHEFV1MySAbMLzkZI9PpVWRPmcvn6EdK1JYtzDBIVeppkkYlhYgcsMZ9aSLumc1qNp5ib0yQM8YorYurR12iNcoOmO2KKtSsYuCfQvpbhI2QEEZ5PpV62jT5TvwRzUe31GBnnFT28WMfXjipSCpPTcni5+XGMDue/rSudik4wgP4U5olVyQN3HQjPNPlVeQ+cDtV2OXmVyjNMw2lmKkDIGOM+laEEksi794PGcA8DiqzwLIeeShyOwNW7SJURQhwD6nmiN7hUceUlyPKOeSVyD6/WnWbEJlyrAnkegNNnfGFwGPPbH5UnKsPlAwfm54xjitLnPa6LTOwXMfLZ6jqKbvaN8MBkYx70vms4GVGOCKbIwclT8vOcDt71afUzS6Mu275jVmHBPfjAp/nA8M6heR/+us5JmzGhUZzwPWk80K/zdQCfqTT5yHRuy1JIxYquEIbAXoKmhmYMDIUfywQBn9aw4rkNMUf7gOEJyalMrM4Jbdjkkc0lPqaSodGbxMbxA4zjPOeeP51BO6+R+6Leu2o2DFlYttIXAHUNTYmYNulLcjjI6Vo2c6hbUigQTTlXy43DB9T9f0q6kbGQhsIcnK9j7Uy2RRPIOFduV/2T6/StCMbcMynBHyEYGPXNEI3Jq1NR8O+OEIPuFi+MZI/+tSrPGsqsFAZshlHG0+3tRG25yiqQ2cYP86gkBDK+VyTkD1/Gtdjmsm9S6xaXe4PzAhyM9alUneTLhSwJUdselQxPlQrODKeNwGAB24qVTEI2cDMjNkn+77Va7mMlbQfE8rgKoGf7vp9ahW4Y5IA2427u4Oeaife7sUKquDgHilV1VVZclMlCCMAjvSvdhyJFiAF3cN8wHI68mnMmwszQ4ZgGz7elV452aYAMqgv8u7t+NPcP9oOJQZeqgnp/hTWwnF3LCRrvL/JGu3K5fHPp/8AWqG5j2MV3sqn5hge1T25WSTKlcgYbf0+n/16kKLcylNwIx8rfd5qnG6MuZxlqZl1EsEccqlHXJymM/Wq1tHHdHldqBdzFuc/StllTa0Sg7GGDxyuP6VThQGQhCykjYABwM+lZyhrpsdEKr5X3KsFsWUfe2Oxw5xkn1qSSJmkVE2gKcjaOP8A69SJOy5j8vEpIAY8fMO3tVgzFEMnymYAfd6YPalyphKcrkMKSbpMYYO+0E9eOtNVts7AlSrHJJ/hX29KlgmAifIXewLKx6Zzzk0OFKSRK5kATI4wRmmloibu7uPhUIoAZVBfPy/eX2qJ1U/vVAZwM5PGfekWREh27tzgccfd+lWAyi28t4jw2VZzghe4FP4lZEu8XcbC6FXXI+YDZgZH/wCuoJXdpUUssQIGCvJA96kF0UiDJsEq8KSB93HT61SjaV5nePqw2rxgfhSbtZFwg7tsvwgPG3JPzAHt9ST6nFTXM6th1bl2BwecEComVbeBJSscvmEBdw6e5FRJ+989VbPl4Gdv8R75PStLvYz5U3zdCCaF/tJhVjIS+W9N3YZ9qVEijP7yZGVW25ByWI/9lqw5UbFhKy+USxYfdYkZyAapBeWUBieTk8ZHpnsKzaSehtFuS1FnDq7MU2SnPlqAPTqfSmmNRAoOHCgEEjBdu4/OnRkQwOd22d+VjQZwvT659BUDkyzoJR++2YUfwr7n3xSfd9TWKf3EVwUmhfIG4EbSw4XnJ+n4URokajrI3V3U9fRfpnmkuBEUWM+aQXAV+Ow+YnH+RT0dgBIiKUyAATgD0PqeOfyo0TNemhIdvMjYyh+Vhxj0A/rUIkDLukQtk7t2eSfU+g7/AIUMriPDrlAcKT3PoKrRO32qR2YAnO8KcKPb69KlysOMbplxXjdguBjOMjq5P8IP6VBJP5jsJCFfJwOnTjA9u1Qpu8xFwAf4eOF9SaetuWbfyYoyAW759f8AAUlJtaFcsYvUjlywcsNxLAEYxg9l/DrVNkSRw0hchflxjoo9Pqauz78KkwKgE7HJ5x61XIjMgA3bRycHsen9KiSuzeDsjD1RwibhHkAcDqPx/Q1w+v7YjF5bblfIjGMEj1x7mu11SdVM48zG/oR2B6gfX+lcfcFY7iW6aSIxrsRUxyBn7o9D7+9c6heR69NuNK5zMjOp2qCSDzjt9aDO0LqRg966SfTUnkjW3dVg3bZGV9zFjyVxWL4pe1a4/wBEjVf4WVX3At6/St+Q4ql4RckzpPDl0s0QaXI28Lj+Imumt4SLcyNKNzNj8K47wyrQwwsDlnYuAOSFHHP15rr9PRnVFfcI2Ify+gA7VzNJSsdzbdNSZc8vChiCBnApJAG5bndg+lTsjhRuAKIwj4PGQOahYtubIGBzhv502rHMncrTDdvXIKg8f1qAoySs59PumrC7CTgYYdj2pksbOn6t71L11OiLtoV2fEPBz70VK4KRZ28noKKnRblrXYs7gilcAFx1HT60WrbgwZuByR/SpplVUG5CR6UQYGXwMemKprU5uZcpZjG8DJCgeh5PFM4JIzkdvemtJj51/ICoWuWLbcZA5z6U20ZqDZZibDKmOT2xV2JfLTjacc89az7WfIBYBQRjB5NWgxYjAyQeMVUbGVSLvYsYDSKzMuO+ajDgN8oCqc4DDr60yRmxuP3R1b0qALI8yy4OduBg1TkRGF9zRTJjJO0KBxnoPXFMCBn5O5STkg1IhQhcDDYJ2jOfxp8MSsAeOevPT3qtzLmsVCFCLtJyOn09frWZeO2WRcHdzk9q2BB5bMN/scd6p39qkhkDZUNhQc8VMk2jelOKlqYQuApViG2udqnvn1PpWnYylgFDAEEjHofesqSEbHEgJZvkP+z6Yq9YwSAqDnYRgkcn61nFu53VlFxNma4BQEE8/L8o/X61XguBJK5yfKUhVJ9e/FJduFQoV+9jHOCPesV70QTHLknsR1zWkptM5aVDnTsjq458xBip3e57e1X4rlZoikStnGHz39MVy0d4z25fafKYgAE8kdj9K1bJltog5fBPykjqfY1rGZy1sPZa7myzgxqQSMDBBOSOM1VnmEskZiBUYzwe3eqst8hODsVeyt2GOlM0+cHL8fPyc8/T86bmm7GEaLiuZo0RIYkLDnsST39Pyq1ayAqZ4cZlOFBOdw78VmyzqzoFQMBxhuD9KILhUc5cNuIYkrx7D61SlZkSpNrY1GOBJHkKxydr9c9sfnRboPJTe7M27bgdRzWZFcK6yzOzHBH7zHCn1xSX1w7ZkgJ+fBBJ+6elVzLcn2Mr8peuJ4ln89wf3Q3HDdeeOKsaeDPpr3UTsksbEuXIKlfT61zzySh0jG15VbcAD7d6zLnWxbSNbQycE/OFf73+zj2PeiNSMW3L+mbrByqLlhv+h3InSYZDCJNwAwMjd3qUzCIyO7BHRQfm6p9R7+lc7ZXTSWqq0bRqrbgTjKe5x70tze71lilKsTIv7wjn35960c0tWcrwj5uU0XuyxVAWXKl5HbsO2BSxXQVBGjowdeGY5I7/AIHtXN6q8kt6qW8vlBhvCseeBwv1p9jcG40+OaQqJIzjZnDA/XuOfwqefVo6XhFyKR1luqTBSSAJAXOOS3oCKU2/luNxVlYkL6VSsXQ2qShgULbQwPJC9ePf1qwzia4QK2UI2op+8P8AEU7przOCUWpNdCREjJI+dkQELnjvSx4Lyn5ggO0qBzj3phy04aYmU7gm3OQ2OxH9KsqY1QnKCRCcIr+3X39BTSuRJ2Kf7wyRGIEyE8EDOP8ADFWLi3cRlypcqSd+7n61Xld4y3kRbQRt7nHqRVmMESspYxgIMhhx+dCtsOTas0Z8jIjrINrDO1VzgH/JqQLJ5w+b5DkcnIPOTg/1qcRB3YynliBgclvSoiNxCACQgkAL1P1HpU2NOZMsL8ykRszx7s7ccAf3iT3xSeeTL5kKxqvO1WydmehGf0qG4R0iVlcIrZIBJ6e3pTSZVwSxDgAhP7voad7OxCinqSIzoWZxuYEYjP3mJ7D+tVppELsJXw7MBgfd9ev5VOzxhFmJIHViM8nuST1NVQokTeAUUHqx659foKT7GkEt2QO8qXAkt9u5AeSOPfnuBTCWMaIGKDq24csM5zj3qadkKbFT5MbUAOOvQU6M7YRHHGBxgyNySc88/pUJdLm99E7FTy9yvgMhbjaecc9auKkrRFYlzEh4kIwc+p9qaA1u0XkElnO75h936mrrSL5QYZUBQEHp3LH2zVxSJnN6WK0wy0hjLIE4xjLNnrn0z1psSkLGVaJYgTuwOE45x71M0m+CRFbAHAAGGb1JqIxiFFGFK56DqDRbW5KelhCI8uMDyyAADyRjkf41FMAdik4DclVPI9M0+OJlmyny4UmMe/cmkYoieWVDN1Zhzmm1pqWtHoV9nmMcMSIufmGRtArM1OR8Krx4JAJAPJGeB/WtdQmMR5VQQ2Dz16D+tZ19GjBtzMQTtD9+eS2PTArGcdNDqoyXNqc5qcn7lgVjZ5gWJHYZ6/59K4PV8PJIY1f5HPy9l9/rXoc0aSK0U7AM2EUjgBBz0rEu9MjFqySvjcTJle59/f0rn1Tue1BRlDkONim+z6fMoiElxM4w5J+QA9ffPSqkdrJcXAG3MrMFGOgrs/8AhHmNzOkbeaiqNrDgZxn8hVvTdCtxsWI+ZLk5cA/IPX+dU6r2sYPDQ3lLQqaVpzGZSowFAjZs8Z6cew/rXVWUOwCXJIBw2e+KdaWLQxq3lr5QXepY/eA4AxWjDG7ZZuBxuB7VEIO+oq9dPRbEbogjxjj723HNVXjP3nfJJJI9KuSjIJJ2s+V2jtjv9KFbbGfLQGMEcsMtj6Vo4ps5oyaRmw2fl73bqOg9PrT5gqB5GXBcALjt71ZZ87gWyGJJz1FVrlN24kjCjGe1RypLQ2UnJ+8VJWLKcdF4Gewoqud8TYY8nt6/WisuY61G2xoTzAsFYZzyT/KpbcEoVb5cnJ9qrMQ4TIPc4HWp4pPnwANpHFNM5pK0bIsQogRt5ORz07VWmhDsxUtgjk+tWlJkX7wPPBPpTGALOScKBkc96GjOLadyKMKhCEHgcVOGO9W3gknGB2qIS4IAU89WpsbfM527VzyfU01ZbDab1Ze3q3yctk4PPWrMMSRq3IAIx9KyxsblRuOfvDpWgq+agj28dyD1NaRd2c9SNkTWzqcEYLDIA9PWp1l+cINu0dsVVs1CyESISoGRkdKlLKNzmQBtxB4/KqT6mEkuYR1Yo6jHGeSeoqIJiNeSCepx1x6VI5xyMbB6VPbZ2uZFAYDABPT396FuDk4q5mW9psmaRRvTn58ZI56fWnNFuDYJ+U8OB0Perjhm+6G5GPQmkuIkWB2GSxA6f3venyq2hp7Vt6mTOodQFYrIMncO+O341gssELzLKGkMijy2HGD6EeldQkJJYlMj36fWql9YLJuYhW3emOvespJ7nbRrqL5WY2jrI0+AGaNCSOOoreaQouShLEA5b0qOws2jgJjj2A4AJ7//AF6sxw7blOFdBwR9e340oxaQq9WM5N9jnNRuZ57klY8Fhgqvcj09O1Mh1KZLhY5X2Mm0MDzjHY1rXVqyu7xFgxyM8HHbn/PpVK307M0fmRIGVTljyHPbOaj3kdUalJws0benTJM7vPIFZvmbg4U+gqG6u0tzvct0Py4yB6E1LHbKE3AKZewUng+v5VRvIS80U7jeob7g6ufStG3Y4oKEp+RYsb0XEMzS3CK8HzJCcAMe4IPP0qyZfOCrFuZWPQ9f/wBYrCu2jufmlBeY8K2cnHb8R71pWMchkjYAlwuSytinz20RdSlFLm2J5mMcLPDgyn52Kg5XHv6etclfacp1B7tm8xifug/r7V3i2qPCWOFOcoQDg+oNQ/2ag+5jGMnjGKuUXJWIoYqNJsyNOuZFto4I42diRnn73fFak6A5Z8uMfOy8YY9quQ2bKEBQqB/qwBt69/rUpsAch2wM5wi8GqUXbUwqYiDldaGI8Lq8iyL5inG5hyM/Woo9PmdY4lR0Too6ZHc1072/yq3l5XPfjOO59ajkikAc78Ejad55YegHYUOBKxbtoJpb/Z4/JChVTjrzx7/zrQQMnktMxAlyVx8v4+1U7dwI1RVIfG0M2NuP6fWp2lEjuuVO3u3XHp9K1jscVRc0my7HhUd3ZlZiOPusw7H3qwI0EMTytjLdMf5z6VRmm/eKr7c4456Hrj6VYlkJZGVy4UdSccnt7VomjklF6EtuoZ3yhBUkleakBEUaIyh3+8Tu7dlx6d6ghbcDIzbIweTnGTTLmRiwli2IE/vt0Hr9TQnZXI5W5WLEjAkmYIqoN2AcAn0GO9RMwMjEERPITubGABjhfxqm1xEsSIXXcvzZJwATyPqaz2lV5zjzGnPKg5yQe5odTsb06DZpTyKsSbgJDyWXqSff0pkUgYL5qnIHIUdfbNLC5eLY4RwxIwDgH3J9qgadFV44GwB/DjJY+2eg96lt7lqPQJb3ZuA25B3YzlY89vc9KVUkKAOD5ufuLyST3I/xqC3GCTIpIB4bHUnuM9astIA7LGQoIKjDZ468nufWktdZM0kktIohUvGM7FMg6sf4Bnk5oSYOCkbAkLhSVzuPYAdvrSzOrhFyfl5PHX1Jpshwh25TJ4I60tUx77ksLE7txCsTz3yf6D2q1hEjyyF3bB2huCfes63lCEr1HPB9fepVmZkdlXCKcHHOfb3q1JETg7ikyM6/NyeuO4PUn1pzCRXdeGOQAnU//rp8bK0bFVCE8HnrjsKkV1jkIYO4AyqcDPv9KaQnK3QYFCwuzvsVRjp7/rULMDISrfKflxQxeaNXldVbOcY4wPT+gqEqNmwnbnof8aL32KjHuNJ8yNhgiDPAHU+uKjuAssfkh1wRkEdAT159hgU+1DR7lLZLAqMHkZ9qVkVYz+8Xk9cdT7CpWquza9noZU1pCI5Xx5hXgNj9fpWcbPzsqu0Ju6kfzNdJdxJtMm4AHjJ9O+feqflnCnZ8jEBVHBOf85rGdJXOuliGle5RsrLM6q4xGw2Af3uM4+pq28FuZz5ZAjI2NgYHHUe9WJVDAFARGPlBzzu9BSYHIITOflVexp8ttCXVcne5WtELSNvRti9AegHapXKgMiHDc8H1qZUdGk2SAN3LDj3xTZJMQlFIx9/OMHH196OW2hLlzO5RMqRMzuu58YOT3+npU/mtg+YACU+UDgn0qu8a3BVcj5uDjtUksgOQxYMG+8e4HSkm0bNJlWTaHUKTx94kdaZNud3UFVU/NtqSYpHIShO84BLdzUMzQlQGOSMjPcms2rG0ehUkAKPv6ZHPQ/hRTpFKvtwWcnAPoPWis3FvY6oystwnACqQAAetSRyAJ29uO1IxRo03HBI6DvTkCEH5ycdT049KzsZvbUk8wMwQ53Y/Wpo03D5ztNVU2huDg9/8asLKSPlUDj7x/pVeplJdh0iASgKCAoxg/wBacVDZCDAHv+tMUsxJY/MPWnLuDKWABJ7jOaZDugjiCqsfPGMYOKsbjEilVOMkZz3/AMaj87dNgYPYinqNw5IHoDVJdiJX+0K7biEwwfHOelEbZw2CyYwxx0Pao5W+bG09OAPSo471NhUE/LwR0JphyNrRFsHBCqM5464q6sbq4KLhz0A5/wAisiK+jLZON+eCx49wa02ugqHDEgAFdx6CtI2tqY1YSWliR1YOCWI45GPuH/CjaTG25AwJxyeTUKTnlxtwe55pYZR5uBhipwMjmi6RnysWZWIyxUHsF5AqGRf3G0ALzuPrT5lZMSBjyclT3qwqeYiBiFLDp0o8h35UmVbRC4BLMuOue3/66kjjdHOMtgEA561awEOwYC9wMcD1qIhjHJJHwwHHqcdafKugudtla6i81SCg4xtA70+CDKgSFgF+7gA8+9TwkOu6TCnOME9RUjsSyktzjaD/APXpcvUTm7cpXW3EIOGYKcnhao3RGELA+UwyPXOfTtW2pEy8jbgfdIqG7tV87eSST9OhocNNAp1rS94woLYyO4Ji3k5LMvLfX0rSS1MbQ4bYgGCQM/8A66nWMLOWC4H93A6/TuKsROiEO3BY4wnp9e1JU0i6leT2JIklUkMVVG4APt6fWrKMjqSFyw6DdgA+9MBEkxAIZ8AH0qwjgAsUAcnG8sR+QrojoefOXkKiOkTOdxBHzbRyfUZNJCpDMZEPltg46EZp8swCsu3fgfeVuSf/AK1VZPMEW8MFwRlmOc/56U27bERTluSqqFyApUc/MW4A+hqCSPLs5QyAfwg5P1p7leJWDlgOM/5/SiC5eNpNnCkYXaOW9Rn0pKz0ZaTWqKLK8juhVnUcFF4OPSpEBRnM2BtUKAvRPTJ71Msqq2RgOeWyMk4/lSg8KUXC43MPU0lE1cntYfDEkqlnCO4PYHn8as7FMgeRt8p4Cenpn0xVdYlQmQyNxwmRyR6Cof3nlyNHvVs5OT29x/Sq26GLXM9GX5JssDEoYoOeenqRWf50WxvNHyEnJB+bPv6CpFAcSKznP8JXp+FUZLOLyXLlvMzkHPQ+/tSk3uXThFaM52fVBHetHIjqpBKtH1BP/wBb8ah1PV1S5228kkpXavmSfKenIIqtq+nTRyF0Zs7uCKyRa3d9cIGViV447/WuF1mk49T6WjQoySnfSx32mai93GJFOxceWDtzgY6D0rQSGNY8ndyOucZ9vf61h6RE1rAIzkbOAAc59fzNas07yMhhVgR2znH/ANeuqErr3jxa8EptQ2JQHUhiwx0JIwMY7UebGkargIAOmOn1/wAKqs0kiJIxCgrgYGWx6/8A16aqRnO1t4zj1OPUf40c/Yj2fclhk3XDSZXcgzg9D+FOeRQiZdeDuIzz9Kj8vYSmeM7st1//AF1FIjm3PzLgnknuf60uZpWZXLFsmYruJADA88HBGanQkLucLgYBCnkE9qzoUmRyxYlTyWbv6fQCnxxvJ5YyFTPf+I/1pqb7DlBdy691GRgqOOFAOce1IkqtsLAoHB47/j/hUMQdfMUbcY+bI6/j6VFf75WAQ7uBnP8AT2puT3JUE3YsPKWUhG6EbT6n1pqAsRGGDsCMHp+tZ8l1szGEGwdc85NEsrbGZCFG7kr64qedGqos0FbDBZEw/VqZJKiFBGrbx8zAdvb64qrBIW/eK4DBckk54/xpouCHdcfMQSSOCPXFPnBUtRtxfGUiIw8DORnoPelt3USCKcFnZcgbuV9s1z2qXwtoJpgcDITA7CotG1C5uVUohR3YlNozWPtXfU7/AKp7l1odf+6U+Uk2PmyCc4A9qmSNI5SzHeWJw3bHrWfZqwjVpSArHjPX/wDXmrDhlEe1jheDjoDW8Xpexwyjra5NNJgmMPlVOcEc/Q1Tup0i5cAq/DD6e9TFwq/vhhgeo4yPSqc5X70oDMeRj+H2A70pSZVOKvqRROVZWViJFB2+wPtRLJNt3Y+XIyfXmobeJhLvk+U5yfUiprtGSdQ5BUkbWDcZrJXsdLS5rDJVRYt0pySSfcHtVWLY7bTkYOAcVJdJvAZM7V4O4/magiZSy7MhhyfpSe9jaC90sq6mOQJx+popJcKNwUqADg/zOKKHpuEV2MqOZzBvOcHgccipLS4EoYAE9sntTd4S3yo5xximxgQ5wME8mufY6mk0y0pZWBxuxwRVgT4Ubcbj6Cqsbbtu7G3oDU0bMr7gRj39aaMZK+5K8zE5RTgdP8afFIA438sBk7uMVAGV3JVevenNmTIC7gemKq7M3FbFppFDZQc5HQc/nT2J8wl+oGPY1UiAwAxY/U9as7c4IOT707tmTSQ2dWbPz5BGc9TWPNIImYZIcDAPr9a3n5Rcjqfvd6yb+3LS7mIGev07UPujXDyV7Mwkv3F0VjJIbuea6q2Y/Z0LsWB5we/tWFa2AWUgKc54b39q6GxilXaN456gGilfqb4yUGlylyBgVwcCMjg9wKtxcqrRqMdiR1qrG4zhTjP8JPSrHmL8pP3uhOOB+FbI8iaJDuO0/f8Am4B5/OrsmySHDEHg9O9U4wx+VMhi2QasW7DcUKD5fu45NaI559+xGF2gO5GxB074pxUttK45GeuSP/11ZUqMsArMfXt7H2pZQiIQoXI5GBiqUdDPn1IYlCgZVdgBAzUTgKBn7obLbu59qJstNuHI/u9Oe9Ku1CckKWyAOv41Pki/MsQMiglT+8zk8dfxoMpMhw67tvVumP6VVhm8vcVO7GeTxn/GoHugrAsS/OMgZxn1p81kJUm2yw6jk7gFUYLBskn/AAo2kInrnAx2+tQRHcpU98An3/wqwjCKRsknjjIwB9KW+pbTWhdjWM7BHwVBGO/PX8Ka7YkKoDsA+YZyc+tQNNjcfnAPBPcmoZC5Y7CCDwzOQPwFU2Yqm29S0XZYzIqyKo+XG7r7j2qF7j90fLCggZyOv40SXjJKASOFwpXisbU9QKLhQcZznrzUTkom1Ki5u1jSjlLZZmZieo7UvmCVsjOCOewOK5601CQKTLuyeFznk+orUt5WcRsT8h7Z9KzjUTOiph3Dc0UcxtkMjt0JC/yFJ5zORuJAxkkdBz+lMiVScNnJ5AIIzVnPybUGG6t8v8/8K11OV2TE810IXG2Mcklup/zzSLO8nyoSFzkccml8oFA0hzg4AXhQammVVRVYqOzYHQ+lUk9yG49hieZGjOqlX6EKM8elLKFIRC25gNvXgA9h61A9wiKVRn2r3qOW4TjbtCjs3c+tK6SGoNu40RRpJ5jSllz8oUcD1zVZ1iicski8/efptH91R604yGdii7MNxk9PrTbu3g8pNrbm3Zz2A+lZvyR0x0dpMIrhZiwXAjB7enpmpWlIQDJ29wvHFVE27sxsQAefl5/CmTyRoMfKqjrk8H6/4VKlY05E3oWPtQ8qTrsOPnPp6UiXka8lthYevSsW71NJyRE4EaDI4x+QqvHOskahyCM+nT/Gp9pY6I4S6vJWOjkuDINwIDDHXvUyzfuiQgyMnk9+/NYUV04lChmbsT0xVySUEDEhDMeVHA9qpT6mUqFrIu+YzxkKAWOOD1HtUglKBdzEMCD6kfSqMDbZOGO4kjaO/tmnGcmZWfb8vAI/wquYzdPoWSS7kqxPP8XT8aryr+9UmQlck7hStMJmJ5IHUnsKqy3BVWOSwzzjqBSclYuEHcnZlZiZgMcjOcD8agUsy7VOFIwSPSoRKJGAcAw4z6ZqWGVAQwxt6DHek2n1NeVxRPAp+Q8Dd2HoKqXTq0jou5ctgkcYFTO53Hb8o4yFNRyJmQOrAMvRj0B9frSe1kEdHdmFqWmvdsY1XEStn8avaZayRKCGbeBgAcf/AKhWhnMm05Xdw3+yKkikiVirFsnIBHWpjBXvc3nXk48th67ViISQkr0OMYz1NTkqsahc4B4UHPNBjh8oBQWzg4HU1FKwklKbgGXqR0ArbY4viZJ5qzMWcLj/AGjxVeeSRSZCpx2xTSjyojAhVPOTxT8O3llyPLJCnH9KLtlqKiV2zIVZuGPzEdPzqJwzlihDYIG8VauE2SErt3g5PfB7D8KpiMx8PwpBJ54J9TUT7G0HfVDSu8RhwSo5yvGajlUrMdqhGx2qV4yH4J3EAjnr70zZl/nYMRzgHn6VO+hsmSGQnO0MBgDJ5JopJZEDeefulcj0BoqrrqxRi3sjmpbwhWAOFA6YqeG5d1Vf4ifXtWNFukYM+Vx61PD8spQEZ649q53ubxnd6mz9oIG3oQe9WYZRjqcnt7VkOgdjsJ24Bzmr9uhEZaTOR2FJltJouhmw23PqcVJFc7FKsOT6nmqv2hYwpZshhimvPGAGJLHPWndmfJfRovwsXlJJyT+lXE3ZwuMr0561iw3CmQrknNW1uCqHrx3qkzKpSdy6X2HDf5/GoTIZH6ZIGAev51G04kGxhgdcmlMihVI+XnkZyT71RChboMyQyjITnoO1aVqAVJc8Y4OMCqDtEdh2q2Ouf504zujIUIGDn/ZxVLQJxclZF/GCoIYENnHanTOSzEMMN09PxqqZTMpy20E9R3qNZVMhj4wTxmquY+zfU0YLoAkMAvHCjoRWhBcl3B2kMRgk1jBMzLyBjnPr7CrasmSpL46nHUU4towqU4s0PNZY8qSe2aEklJLZyijueSfX3qqZQgHG4Yzk1G12+AccAfT8jVc9jFUm9kWFlkDYQ7T3Lf560ksg2ksSSOByaqi7y4cg5HPFBmLo2BjJ/L6elQ5ov2bT2Iry58sDGXHqB/Kspr+aQEQqwVT8wCnODV29WSQgScEdMNVNbWUMTG5Vc5ODj8Kzk3fQ7qMYKOu5Zsbx3PzBmHXJ64rUF2rqPkbAPGf61mQWRQqyhgQN2D6VoxI4cl1+QHcB0qoc3UxrKDd0TyNncADz1+XAH41FubEbAZYnAPp/gakZt5IYDYMEjdnNJ53yHYox90kCtdGcy9CLaxcgscjkgjAFQXMRlQAHGRxtq/H5WxixMhJzgnqf8KaUE0gw+COCxGB9Bip5bqxcalncyhZ75I/MZmiQAYL9B/StSxkQAgKsaxngL2/Oo7uIJuCjk9+34Uy2iwxMj7lzjCnpSSsypy9pG7ZcWYzPuXeTnBAPH51ejuEYEKf3a8EL29TWehFuMhG2jOCaWF2EgOwRseSo6t7mtIya3OacFLYtzPklwFUKAABySfxqN1IiDP8AdHIB6YoadhHzjnKg9/xqHAXO4OEI/E//AFqbdyYxHSKm0nJx17Z+hqruSRsLHlBwW7fSkuJipKoAmBnOc1myTso2IDk8kVEpJM6qVJtGhJcHzMhQAvGFFDM8pBIUZ5yDkVRt1wN02WJH3e1OMpDjCnb6Z4/Kpb6s09mloiyJBCp2lXbPJPQn0FZWosrAszcD+HOakuCxTzN2wZ5GeaxdRckkRZAwcKO1ZTlpY6sPRvK5nXbObweWRsHUDp+FVbnUWjkKp0X+LOPqBUd7HcERqsrE9CB1q1pOnnnzQvGWyRkis13PScuhrWl0qRqASobkseSKlnvTDGrnCgnjnp9KW2ijRA5VOnTrTLqIXDrvAKqOM96d3Yw91y1RdtLphAC5wT3A6elK1zKQpQ7Yxwc9/aqTuIEw2SqrwO2ay7bUjczNFGGIXqf6UXZHsot3Oma5LgYYonQ88sar31yI1ALcjt6+lVgNqF/mGB09azNTzdW7eWSo6Yx1o5rijSSdyf8AtAlUGflPIbPUZrRt3ckEsOmM1xlla3azCQ7sKcAse3tW/prP5gMhOwdfem99Ct1qjoYgFjORhjwOeD/9apIWkePBK7v4T2+tVPOWT92BwOfwp8TcOQR04Jq15HPKL6llplLbAckdOOvvUq8HIHbk1RUBmxu4J6nr9Km3kRgjLEHpmtE+5EoW0RZinWN9uNqd8ep/rTwwMi7Y8A8FTWf5zM275QP5mrJJAXcSuT0z1pqREqdid2JjyxAQ8KtIm1Sd+WI6DPSoC6O/XO3k+lCs3IyCnUYocieTSxbfe+QB8o6sRzioHRHL78vg4HpTVmKycnC8D1zUdwQu9snjggGm2nqOMWnYeMH5Rx1BZugHoKhY4UgDb3znnH/16immaSHDcA9sdaaZR5hO0MBgD0qeY2jBi5bySNuVJzg9P/rUU2SZ5XJUEknof50UtC9tzkn3LhUGBn61GcxXDFzkt3HaprRg+CST7n+VMvPkZHzx9en0rKwLVXLUMpYDIz/OrCXLj5nY55H4Vkx3iiTa/HTp61eLiSPcoAJ4Ioa01LjInjZwHZueKjmnwMk5z6imBiEA79Ki2kxlSRnkUmVzvoTW+oIJ9n8Y6VoLfxjG845wD71jQW0e/P8AEPSrTwKApXBKnOff1oNE+ZamqZ2LnGCpPXpj2ollOT8xA+7n0qpE4VQPzNNlkyO4ApPuUoK4/wA+RD8rkHp1psV6RgK3X+HNZ9xOd6oAA2cZz0qksjeYxXJUHgjrU3Z0qlF7nXwXoClcr6gkdD7VKLsTHnDEHjI6H1rmbWeWViCOnOD6VoK5TG38a0U2c08NFM3VvU38rkgdGPepre5ZpskHZ03e9cwJUFwyK+WRQ2COvqBWpaXBPI4Pde1PmZz1MOktDc3l8g9ucf4U9CJDuDNuxjGMYFVFlwnQhyOB/jT0LY+dsd8CqucThYdLshBfOwjnHPI9aIrpJD8vDKOmKb5gbK7Sw70giaIiQRqD657+lLVPQdla0tywSJR8mRxyTTmYhclgzdsdhURmLZJxuPrzUTunOcAj1PWquSo3JPP2su0kHocjrUwu2wScewqkHTeMgYboaVpnYnCZbsTRd9ynTT6Fp5HcfIMA8AY5zVgBFiBlyT1A6D6GqCSsVBL7WBzjGKsJ5kij5vlPPzU0ZyjYsfaUDqdgZ+g9Me1QJOWlYAfL024pjuigLtVfUjkn6VILyPYBH1HGRwaL92TyW2RaDNj94n1BwcD+lQGZVA2JnH8K+lRl2wP4VPJ7Go2lyjLEuEPfPJochRgXgVdAScZ5z159KelyyF1YL6YPLVnRSMrDeSuOgqOefghcKc5wO/vTU7aofsbuxoGaMcswBz2/rVa5m3Jn5jyeO5rN8wCQAtu+nanyO/LllwRwM/zpc10aqgk7ltf3ijoG+tMKIJdrgN9Op/Gow7MEAO4+3AqVdoXqu4c+y0XuOzQ7OcHAzjr61WMg5O4Ko4xSOxD/ACEkDk96jljTduJyO/FS22XGK6jLmYycfwiqjR71bagHsTipWbJ68DpVZnBdljYk57Cs5O51wVlZFV4GDqAgzjAIqxFH5RU9umO9Pd1UASHj1qGS4RpBtJx6DipNeZss8ZPOW/uipPMVeSVKgflWXJINuMnbnpTZJsrtGNp68YppEuC6ss3P7/CqRtHUHrUFnarG7GMAc8noDUcLbpR8xA9an84KSA3A/wA4oaHdLYvbgYiSO3fvVG62Ko5yxPT0qrqWpi3iIwCzelc3c6nKzZ349xTjFszdSNNXbOpLIEIXlgOuegpBcskm5SoA49iK51dUVIMMpZsde2apDUZS/wB7k9u1aKDMZ4hLQ7JbwMT8vy9QAcAVZjvESMBiQ3cZzXK2l7JIgUL361qRndjdwB+tJqzNIz5tGb2/IyjZyOaRGlK7i4x22is4XRVQi8DoBSfb/IxyCAenbPpU+ppy6GxCV8wbxuU+lWJSXlKcZPA9hWPa3/m7D8qq/wCBq+rBTu/i6DNUpGc4O9yxmMKVUOcdicVNBMjfewM9j/SqU0rEDeRwOMU3c4KupBK9BinzWZDp3WpdDEhymAOm89hUHnhowExsA79zVbLEsk0nytzx3P0qVyu9UXj5elF7oagluQ+a+8grng5PpU6AqMOvzdfpUaOC5bjAONvXNSeZHKHzyegA6Chb7lP0FRiQxyOT365oqvJKV4X5cd+5NFNMORnnn2+VWJB+Y9cU+S8eUDexAzUBjPOTz14ppUkZ7Vpyo4VKSFMhEwKknHNa9newoo3cfj1rHRBx6HuafLAMDcOB3FKUUy4yktTqFlVkNNOSmQRj0rPsTlAGLD68Vb83PbHHesmb8/cgnneJWGBnHJHarNjeSSp8wGcelVJ5IwD5gG3v/hU9lLG9uhUgDp060raGkKltDTTLDccAZ4prqFDEZBI60zIxkcEdqVZQ3ByTjGKGjVTKl9DI5WRRnjBweT71WhDeaFA5PT3rXHJA6cY6UkqbHBPUdCveo5TeNaxWhiYSBiWXPX/Cr4Qv0HB9aSIphskknjA6ipY9pI3A7c45NCjbcJVb6lN7UiVXUkH3Gc1rWcDBRkENSDKYTHyqeuOlWUJAyehpxSMalRtWJFDj51ACgdTT1mfzQRnb6UwyCTg59cUwtnoTx0qrnNa+5bWcO5GMHpzQZW+7ggr39aoJIfMw2OuTThIWcryR1oTug9lYkdZhl2yFBxkUZBUFX56Enk01plETKAcH3ziqxn554UjrS2LUWywzmNMduvHb3qW3k4IXAz0wetU2ZvlIIIPalSVRnDLx60c2o3C6L4lBbJTJPdj/AFo+0FQAg3YrImuWbdsIxnpUS3xzhiFJ6e9VcXse5tNdByQxGcAHPanmUAgx7dvr61hvIsiu+8YJ6UsFwqsBvY/7JpXG6CtobouEcktkkdR1zTUnIZuhz1PSs4yptDBint605JARwd3ejmI9ikabSKCATtGMk1A84VQY1PGetZjzSOGIUYHfNO847cEGQDqRwBRzDVCxMJXeQ79vtxU0akgvIcJ6+9Zhum5D4HPBxSfbdxHzZwed1CNJR+RsLIqgsmeeMUjzM421kfbSW6YX/PNMmvvmypIQetGpHs11NZphFlQwGeee9QzXAC7nYAAVlG9fcrbuc8cVXkm3MS5OPSizYXijRN08pwgAGeKkjdUIO4E57enesfzTnA9ad9o4AOMDpmjluP2kdjSuWVlLFixP3RjgVS8zaT055qBrkLn5vl9CagkuRztI9/pRYTrJbFppB6fL6ZqN5gq4AznoCazXvQWIXp2NRCcbWYv8wHQdc1XKZOqzZWYKuAcnHOab5mQWPKjmsgXgChT83tmiW7yuFbAI6/8A1qfKQ6pDqcxmk4zjtms1YPmBY89qsl+55b19ajZhk+laRVjCbUndkM5yuBSQRuXHFSqyk4zU6KAQe3rVMzjBTlct6dHMki7cc9fpW9CQF+nc1iWzMPuEkEYHFaUcihMZ96xe52wkoj7sl4zsfGeprBluHHy7ztHPWtl/niYDhWPGKzW08s3BBB71KVtynUbWg3Trh2uFGefzxXWwXDtjuw7ntWDaacqSDYfoTxg1rWo2sAo3YOTjvQ1dmlNyS11NhTuQZxg/pS7lCjdgHoKrw/vQQSAoPyqP504KScY3IeCakqwSsVccAA/maY86xrhfvdyxzmicERYBAbOFz6VHDbskgMgXgZGegouaJKxYSECMBuDnccUo2pnbkhe59aHk2Isad+SaryXQjYHqD1B60ydXqy1HGgLMVxkc55NFQPNkRCM8E5J/xoqr22Idzz4K2APy54pGGwjcwJ9jUYY54I+lKGG3I/yK3szyrosR5VlOcrnoO1XBMrfKqjYP85rMEhBqaJ9pOMZqZRNIyNWGNgFYn5T2q3tUqORn3rMjuSihHGfXNXI51I4I57Gs7a6mikguIN2BkbD1xToIlhGEGOe/WkL8gHpUcsvyjsucdaRXN2LuCzZBxUEYcXIZyQrcUhlzjnOack3GeMDg0WKU0Xwx3AhunGTUvmgoEXGB3PWqIcEA5HP6U+Nip5wc+tFjdVB6yyK+EUbPWrRlJAYrlgQDmqZYqcinrIQSSetLlLUzTafcoMfUdutTFw20F8cZCj1rISUq/wAuT39quC72MDjKn2/SpcegXReSTfg4KjvTXfYD0HoPWqAuFc7gSM9qXeFO5849jk0WY0kTAySEn17DoKhl8xeHJx169abLMqEbQcY4zVZ5C5OSPpQk0XzpFqObyyMfKR3qSWTcdwHAGSPUVQRm3DJ6dDirDMeN23HQYNFgUk9SyHVolA/dnOQfWqkrsucj8v51JGWQZYAoxwc81I91CsO0KCcY5oSE52KB8xlOQy56YplxaSGSJQm/ng46VKJWVwUc5xzTHvJpiVMhB71WpjJxe45R5T8/Me47ZqZnVpAMbcDJBqiHZD8xyaPPGSxOfc07EqtbQ1PMQqXkHH8I71C8rDgcY6gd6zDdjdkkYPIFMknl8wFG78jNHKH1hGkZ2Pykg+1NNzsHG4MaoK5jcmSQZqKW+RORjHrmmokuvoXRK8gJlG0dl9ajmulRQNwA681kPqLtITuyB0qs8+48/X6VSgzJ1jaF9uztORng4qGe+5wc57Ef0rINwVGFbApjTnGMnFXyGTreZsC+AAzyeOTUc18GI5PuKyDKepakM3pR7Mj26NVb3CEvyfaoGu3YkjgfWqHm8Uhl544HtTVNEuujQkudwA7mmvcMejEduKz/ADsHrTfN46mnyEfWEXN4HX+dI0v449KpmYAfSmeZxng1XIQ8SuhaMnXFHm56np1xVQzYBzUZnyePxquQyeJsXi+aQnJ96p+fk9TkVIshJz0pcovbplhF2HOcmrMbEjBH0qqjAip45CuOlS0dVKSWxdiYRjJUFuvPep7eYu3PfgCqDzF8BiMjuKkiI3Ic9+vpWbWh0qSZtBQCMknj8KkxkfL19KqK5K/u2J55NSpMq7RnJJxWVjSLLmQB6D3qWFmRW9D6VWaQb1zwDTvtGH2A4XrntTN4tF5ZyV4BB659KDOwIEbnHcd6rZ+Uc5zSyPjgcEDmlYvmSLmXlZXdsAdBVl5MLhAOneqMUoEYJ5HZfelRi53YOz27VNiuZE7THeNqDdR5Ks5wrFj95j2FMlcBFZSoBHJNRwXDBSpbaTj5iapRJciaIxqSgG6RuhI+6KKgkm278uGyfXk//WopqJDkefg8Zpwb0ORVVXzTg2Ca67HgqqWQ9SLIAPcVVRs1JkY4qXE1hUdi35u/bgcjipFlKtuyOOBVHeQRz06YpUbnrU8hoqvQ10n3A/wnv605WDqBIVK56etZe8Z4OKmRtwbn+lQ4mqkaAA42Ngjv6D0qSKcEHfj6j/PWs4yMjfLnHSnx78HbgDqfep5SuY0kfcxX7pB6mpIWwxVj171k/aWHyk8jvUjTlQmSOeePShRHz2NZ5PlwCMUqnA7/AE71lGddpOctjvQl78p3Z9jmjlK9qaokx0J57ineaSuG4J/lWP8Aa2OMOCF644psl5Jn92wx0o5Rqq0bPmAOAp475pZZm/hXrxxWJ9uIOPzNPa8Z0GCD35NHIHtTTaZu1AuApGXBHfPrWH553E7yM/jQZSDklcnqfWjkY1UOgE5JAJHqKe9xt/jwB6Vz8l5grtbOOvGM077ZuJ3Hj0o5GL23mbK3SIfv0yW9Lt8ig4GTisJ7nhQNoA9KY90egIA9BTUGS69uptPqCmMNnDHt0NVJNRKf6sA+vvWRJKCc8571G1wAPSrVMxliUt2aT37t1yCO9I14GUjkZ64rKaYk9eKaZcjrV+zOd4pGo93leCenTPeomu34GTgehrOMvI5pGl7jrmqVMh4s0DcMWJyQT700zDPWs5rhQSSfrzTTcDH09aapkPF2NBpRjFRNKPrmqRuQVOO3BxzUL3Ixnj2JNUqZjPF3NEzY43Co/tGQM1nSXS5wD/8AWqFrsEgHnqatUmc8sX5moZyD6H1pDNxlsD3rH+14IVuMimm7G4kgewBqlRZm8UbRmGM5HvTTP6Ecd+1YhuyCw3gA9s4pr3oAwGGapUTP62bhnAXkgEevaoxcdecGsUXXHy9R2Jpy3OEJHJ9KPY2F9aubAmBzzx0PtTvN+UEHj35rHF6qoTuU56knrQb3GDjKkjjrR7Jh9ZRrlgTjJ4NNV/l6d8dayTfjJJYHcMj2pv29cYBBOeCOOKPZMTxKNdZBn72QO/rUvmbSQT/+usM3eCSCoyeOamhuiWJOQF4OP1odItYhGx9r247E+lWYrjPWsaCZSw5BGO9X4nB/z0rKcLHTSrvuacbZFTxsCBjr79Kz45fy9anSTjisJRPTpVjZgcbfQjnP9KsStlVIPPcisdJ2CgbulTR3LgjJyOlZOB2xqI1XmYOoUZyM8ipxKWIBXAxxWf5m9VJ2g54qxDNEAOuc4+lS4miloX1ck4PbtTwQxyf1qqGDYIzg8nmpEcEEHFFi1MsLKYgxGCD2NK05I749PWqxPykkimGQccHIHWiwnULLuCcjjHv0piyEk84z7VA8q7Cc9KFLFc55POMUyXMmOS454FFQhztzn/61FAuZHCByAMfrS+dtBZvu5qkkuVGPTkGhmPIByDx9K7+Q+WVd9DQ+0LilWcNxWcpZMcn8alSTAw2B6cUnApYiXUvCQdz+VPWTHofeqAkGcDg+/FSK+TnOSOKlxNlXLqSe/FSrKR0zn2rP3lcc/hTxIR9KlwNo4gvCYk88GlE7gkg/KeMVREnvS+ae3SlyGn1jzLjycZJpqzHgFs4qqXDjk0isvajlE67ve5fWb86QOTzVQNg9ad5uOSevpS5TRV+5bVueuBQZsCqTSZPJpvm5HWjkB4mxc8zI4PXtSeZhcdBVEynJwMGozOeOvPHTrVKBk8UXzIPXmkMwwOaz2n6AMN3pUZmHXPtin7MyeLNNp89xTTPgEZ5rI+2Jtzu46ZPWoZLw/Md/ygYOR0NWqLMZY02TcL3OfpUb3IHXj61im6IIAxzx7VE95hQHb/61WqPYwljGzaa5z3OPWozPnLDBHT2rFe+wHG7OOxFRPeh8gA5IzjNWqDMZYs2/tIxzjA6nNNN0cn5h/nvXPtdtjO4jsRQJ3bDsxGB0zV+w0uYyxTN37VnkZOe1Ma+yMr0FYPnuSwOQDyT3xTTKWAXO70J4qvYpEvESZsteHGDgkg5Heo/tqn+MEsOgrILHI7dz1pHYcHIIPP1q/ZIh1ZGp9sOW+Y/lx9Ki+1lsEdO+elZ+SM/MB7+tJnjoe2TTVNIlzky3JdHJwc5/So3uGYryPT61EcE88H1FJyMZ6ev17VaihXfckaRt4A3eo5pokYE9d2fWo8DdzxxknPSnEkgkDnOM45oQrCliSRuOT1B5/Gk3ZA9B3pDknAByOhoOSuCM84IximA9WJXuAKXf8mAAD6j0qMZXkqV9x1pS2e2MUrahYfztGMjHQe1Mzn7pOM5wKb2xxn0z1pSRkjPHYCgLEgz5ZI6k4B700dCzAAHpk/pQpx65A/WkAOMjOO/1oYrChuqgDHXmpI3YZXOWznioTktgc8dKcpJHQfXHpRYe2xp28hwrDPToa1IZGYA96wY3G0DIzg/h7VowSkKu3PI6Z6muerE6qVS2psxOxAx09qsxknmspZOVOQQOeDV23mLngZH0rklGx6VGpc0Izx1zirEZGPeqcbkCp0bNYtHp0p2Li9cDHPY1Oh+bgn3HrVJXIIIHT1qUSse/NZtM64zvoXRMFAUA4BzxU/mhEIHrxWeGYgYxk85p0LfOS/PFS0Vc0EuGY7cdgelKuW6EkdeD0qKInkgcmnRu25uBuXvUsdyTaFcEDIznFPdgoOD83sKYFB2sx+bPT0zUcrNv/dHAHU/1osK4snDbm3KMfhRUcrIE++M9RRVbAtTzyJlVTycdevP1oWctgMM8+tZodtgyx4P+NNWRsrk5ySOfpXr+zufEOrymo8xwQMYPA54NAm4HOB1NZiyPuiO4jcfyojkbnn7q5/Wn7PS5Ht2av2nGAO9PFwE55+tYm4naSc8d/rSxytlfQ8YodJXKWIdzdFwAMk4HoaclyMDB5PY1jeYyggHoM1MGzwQMA1Hs0aRrs1fPwSc8UomHZvxJ6VmAZUN0O0n8c0Kx+UdBg/p0qfZo09vI0hcAKNv60on5HNZUjkOqdR7/AEpc5Ofaj2asHt5bmqs+RnNO+0KCM9PrWBJK6Y2nvTRcSFjyACccVXsbi+tNK5vfa1JIBBzTDdjH8/8A61YAuJAGORnp0piuzEAs3QHrTVBEPFyNtrxeck8YzzjFQteAY5X6k9BWMCckkkkg96b0C/7pq1RSIdeTNU3qkMFYk9jnNV3vCx47deeaoqSXZSeBzSOf3n0q1TS1Ic5NlmS7lb+IcHrjpULykktzjAGM0bQc8dvWmuPnbr2qopEXuK0g2DqT0+lG4gqVxnJxz/OmueSD04NNYYbqepoQJDzIw5bORkDmmBiQTn6gnrSE4wR3OKkKhenb/wCvRuOw3op7nrxSo3IyAd3XtSfd3svBBoj5I9qa1DoAJwPQDnHNJjIzgfWlTkrnuf8AGmMdrJjHIzzQA8cEFeQPxprA57Y70YDMoPdqU8SAe1FxiYwTjpinZzgk85pBymT68e3NIcBcgdqPUQ4HByec88DpSN2z19RSsNjcfrSZ5xgcGi9wAff+XtQzZGPQYpyjOT3yv40gG5ipJxTQCZ5I6DqDnkUMe4yMd6UcNj/ax+FC/MRmh6AIBhsn0oyCQD+NA42j1OKVfugkk8kYpeoxD8qYxwexoz7jJPSnKAI1GO2c00/dQ9yKBCqRnhuPX0pEbtnGD6UBcSADvQ7FQDkknuaGFgAGTkHJ4XtSgYAxjA6ZqPccg+vFPx989cYxQmNjtx3LkA5GDkVetiSw5PAxxxVNvlIA9OtXLHkIcY3Ag/hUT2HT30NOLkkk89PbHbirtvIMDAwOnWqVuuYjyRznirP3SSpIzk4rkkrnfSk0ky40h4xjPaiOZxknOPpio7cZCg/nU+0FwD0rB6HbFtlmKXIHpVhHOOapIAPlHQVOOtZvc7aU2kWhIcY/Gng8Hv61VU1LETkmpaOqM7l2GbacMcfQcVKrkgHJ2t196oyMQfqKTccA596jl6mnMaUjgMpDEletVZpuSV9fpVcueee2aH4ApqIcxKW3KSc9BxRVXG5uaKfLYXPc/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42083=[""].join("\n");
var outline_f41_6_42083=null;
var title_f41_6_42084="Mitral flow velocities";
var content_f41_6_42084=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75687&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Mitral flow inflow velocities",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 302px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Sherif F Nagueh.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42084=[""].join("\n");
var outline_f41_6_42084=null;
var title_f41_6_42085="Hydrocodone and ibuprofen: Patient drug information";
var content_f41_6_42085=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Hydrocodone and ibuprofen: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/2/8233?source=see_link\">",
"     see \"Hydrocodone and ibuprofen: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F180184\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ibudone&reg;;",
"     </li>",
"     <li>",
"      Reprexain&trade;;",
"     </li>",
"     <li>",
"      Vicoprofen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F180185\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Vicoprofen&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10029763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700782",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of very bad and sometimes deadly heart and blood vessel side effects like heart attack and stroke. The risk may be greater if you have heart disease or risks for heart disease. The risk may be greater with long-term use. Do not use this drug right before or after bypass heart surgery.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700792",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may raise the chance of ulcers or bleeding from the stomach or bowel. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10029765\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10029764\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702260",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to hydrocodone, ibuprofen, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701061",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are more than 24 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10029769\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697693",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may be habit-forming with long-term use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697173",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have asthma, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697164",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a bowel block, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697135",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a history of a drug or drinking problem, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697235",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had an ulcer or bleeding from your stomach or bowel, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before you use other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10029770\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10029772\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699023",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness or passing out.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698619",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in strength on 1 side is greater than the other, trouble speaking or thinking, change in balance, or blurred eyesight.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699058",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in thinking clearly and with logic.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699000",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Poor pain control.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699050",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad swelling or pain of hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698607",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Black, tarry, or bloody stools.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698609",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Blood in the urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10029767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3927405",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug with other strong pain drugs or if you are using a pain patch without talking to your doctor first.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695904",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with food to stop an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698543",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a pain diary.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10029768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10029773\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10029774\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10741 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42085=[""].join("\n");
var outline_f41_6_42085=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180184\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F180185\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029763\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029765\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029764\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029769\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029770\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029772\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029767\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029768\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029773\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10029774\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?8/2/8233?source=related_link\">",
"      Hydrocodone and ibuprofen: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_6_42086="Vascular anatomy lacunes";
var content_f41_6_42086=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F73027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F73027&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 489px\">",
"   <div class=\"ttl\">",
"    Vascular anatomy of lacunar strokes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 469px; height: 506px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Anatomic location of lentriculostriate, thalamoperforant and paramedian pontine branches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from Kistler, JP, et al, Cerebrovascular diseases, Harrison's Principles of Internal Medicine, 13th ed, McGraw-Hill, New York 1994. Copyright 1994 McGraw-Hill Companies, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42086=[""].join("\n");
var outline_f41_6_42086=null;
var title_f41_6_42087="Endoscopic diagnosis and management of biliary parasitosis";
var content_f41_6_42087=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Endoscopic diagnosis and management of biliary parasitosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42087/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42087/contributors\">",
"     D Nageshwar Reddy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42087/contributors\">",
"     Amitabh Monga, MBBS, MD, MRCP (UK), FAMS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42087/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42087/contributors\">",
"     Douglas A Howell, MD, FASGE, FACG",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42087/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42087/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/6/42087/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 9, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Parasitic infections of the biliary tract are a major concern in the tropical and subtropical countries with significant morbidity and mortality. Clinicians in other parts of the world should also be aware of these infections in view of increasing travel and migration.",
"   </p>",
"   <p>",
"    Infestations of the hepatic and extrahepatic biliary tree occur most commonly with Ascaris lumbricoides, Clonorchis sinensis, Opisthorchis felineus, and Fasciola hepatica. Other hepatobiliary parasites include O. Viverrini, Fasciola gigantica, and Dicrocoelium dendriticum.",
"   </p>",
"   <p>",
"    Helminthic infestation affects the liver and the biliary tract either during transit of worms or because these organs serve as natural habitats. Worms in the bile ducts may produce features of recurrent pyogenic cholangitis or acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/1\">",
"     1",
"    </a>",
"    ], liver cysts and abscesses may occur due to ascariasis or liver flukes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/2\">",
"     2",
"    </a>",
"    ], and hepatic Echinococcal cysts can rupture into the biliary tract, producing cholangitis. Endoscopic retrograde cholangiopancreatography (ERCP) has now become the main diagnostic and therapeutic tool in these patients.",
"   </p>",
"   <p>",
"    This topic will review the endoscopic diagnosis and management of biliary parasitosis. Detailed discussions of the various parasites and a discussion of recurrent pyogenic cholangitis can be found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20407?source=see_link\">",
"     \"Epidemiology and control of echinococcosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27561?source=see_link\">",
"     \"Treatment of echinococcosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10648?source=see_link\">",
"     \"Liver flukes: Clonorchiasis and opisthorchiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31735?source=see_link\">",
"     \"Liver flukes: Fascioliasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14472?source=see_link\">",
"     \"Recurrent pyogenic cholangitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ASCARIS LUMBRICOIDES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The roundworm, Ascaris lumbricoides, is globally one of the most highly prevalent helminthic parasites in humans, infecting an estimated one billion people. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    .) Fortunately, it only infrequently produces symptomatic disease. Ascaris lumbricoides organisms normally reside in the jejunum but are actively motile and can invade the papilla, thus migrating into the bile duct and causing biliary obstruction with a variety of hepatobiliary complications. The following disease associations were observed in a series from Kashmir, India of 500 patients with hepatobiliary and pancreatic disease due to Ascaris [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Biliary colic &ndash; 56 percent",
"     </li>",
"     <li>",
"      Acute cholangitis &ndash; 24 percent",
"     </li>",
"     <li>",
"      Acute cholecystitis &ndash; 13 percent",
"     </li>",
"     <li>",
"      Acute pancreatitis &ndash; 6 percent",
"     </li>",
"     <li>",
"      Hepatic abscess &ndash; &lt;1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, ascariasis has also been reported as the cause of post-cholecystectomy syndrome (ie, persistence of symptoms following cholecystectomy) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/4\">",
"     4",
"    </a>",
"    ]. Identification of parasite DNA in biliary stones has suggested that C. Sinensis and A. Lumbricoides may also be related to biliary stone formation. The diagnosis should be suspected in patients from an endemic area who have biliary symptomatology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/3\">",
"     3",
"    </a>",
"    ]. In these settings, identification of the egg or the adult worm from bile or feces is strongly suggestive of the diagnosis, which can be confirmed by ultrasound or ERCP.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Radiographic imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two ultrasound findings are strongly suggestive of biliary ascariasis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long, linear, parallel echogenic structures without acoustic shadowing",
"     </li>",
"     <li>",
"      \"Four lines sign\" &ndash; Non-shadowing echogenic strips with a central anechoic tube representing the parasite's digestive tract, indicative of the worm and its intestines [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/5\">",
"       5",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    MR cholangiogram may show intraductal worms as a linear low intensity filling defect in the bile ducts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;ERCP is a highly sensitive method to demonstrate the worm in the biliary and pancreatic ducts. Worms can be seen in the duodenum and very often across the ampulla of Vater during endoscopy (",
"    <a class=\"graphic graphic_picture graphicRef58130 \" href=\"mobipreview.htm?5/36/5696\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/6\">",
"     6",
"    </a>",
"    ]. Cholangiographic findings of the Ascaris worm during ERCP include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Long, smooth, linear filling defects with tapering ends (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef68876 \" href=\"mobipreview.htm?21/8/21647\">",
"       image 1",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Parallel, smooth filling defects, curves, and loops crossing the hepatic ducts transversely",
"     </li>",
"     <li>",
"      Dilatation of bile ducts (usually the common bile duct).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the availability of choledochoscopes (eg, the SpyGlass direct visualization system, Boston Scientific, Natick, MA, USA), the worm can also be visualized directly within the bile duct (",
"    <a class=\"graphic graphic_picture graphicRef64053 \" href=\"mobipreview.htm?23/62/24559\">",
"     picture 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21897?source=see_link\">",
"     \"Cholangioscopy and pancreatoscopy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The extraction of the worm is easiest if it is protruding out of the papilla where a grasping forceps can be used to hold it, while both worm and endoscope are withdrawn from the patient (",
"    <a class=\"graphic graphic_picture graphicRef58130 \" href=\"mobipreview.htm?5/36/5696\">",
"     picture 1",
"    </a>",
"    ). Worms that are entirely within the bile duct can sometimes be stimulated to migrate out of the papilla after contrast injection, or they can be extracted by using a basket or occlusion balloon. As an alternative, the worm can be grasped gently within a Dormia basket, pulled into the duodenum, and then removed with a grasping forceps [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/7\">",
"     7",
"    </a>",
"    ]. The worm should be extracted completely since remnants can lead to stone formation.",
"   </p>",
"   <p>",
"    A polypectomy snare should",
"    <strong>",
"     not",
"    </strong>",
"    be used since it tends to cut the worm. The use of endoscopic sphincterotomy for the removal of worms is debatable. It has been postulated that the widened opening facilitates further entry of worms into the biliary tree. One study including more than 300 patients suggested that pancreato-biliary ascariasis was more common in patients with prior cholecystectomy or sphincterotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/8\">",
"     8",
"    </a>",
"    ]. However, in another study, a wide sphincterotomy was required for worm removal in 73 of 77 patients (95 percent) with pancreaticobiliary ascariasis. There were no major complications reported during or following the procedure, and recurrence after sphincterotomy did not occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/9\">",
"     9",
"    </a>",
"    ]. Similarly, a third study did not report any recurrence of biliary ascariasis in patients after a papillotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/10\">",
"     10",
"    </a>",
"    ]. We have used papillary balloon dilation to facilitate extraction in some patients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/19/37175?source=see_link\">",
"     \"Endoscopic balloon dilatation for removal of bile duct stones\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Extraction of the worm is usually associated with rapid relief of symptoms and is successful in more than 80 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/7,8,11\">",
"     7,8,11",
"    </a>",
"    ]. However, infection may be associated with calculi or strictures, which can usually be dealt with endoscopically [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/12\">",
"     12",
"    </a>",
"    ]. Patients should be treated with anthelminthic therapy to eradicate remaining worms. A single oral dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    (400 mg) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    (500 mg) is usually successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16520?source=see_link\">",
"     \"Ascariasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23221?source=see_link\">",
"     \"Anthelminthic therapies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ECHINOCOCCUS GRANULOSUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The definitive hosts for Echinococcus granulosus are canines (dogs, wolves, and foxes) in which the adult worm resides in the intestines. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20407?source=see_link\">",
"     \"Epidemiology and control of echinococcosis\"",
"    </a>",
"    .) The parasite forms a hydatid cyst in humans and other species, which serve as intermediate hosts. The most common site of cystic hydatid disease is the liver.",
"   </p>",
"   <p>",
"    The most patients are infected as children and most are asymptomatic. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    .) However, in approximately one-fourth of the cases the hepatic hydatid cyst ruptures into the biliary tree (because of higher pressure in the cyst, often up to 80 cm H",
"    <sub>",
"     2",
"    </sub>",
"    O), often producing obstructive jaundice [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/14\">",
"     14",
"    </a>",
"    ]. In a series of 16 patients, one study found biliary rupture of the cyst in eight patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/10\">",
"     10",
"    </a>",
"    ]. Less commonly, cysts can rupture into the peritoneal cavity or other organs, potentially leading to anaphylaxis and multiorgan failure.",
"   </p>",
"   <p>",
"    There are two types of communications with the biliary tree: frank intrabiliary rupture and simple communication. Patients with simple communications may be asymptomatic, with the communications identified only during surgery. By contrast, patients with frank intrabiliary ruptures are usually symptomatic. The contents of the cyst (the scolices and daughter cysts) drain into the biliary ducts and cause intermittent or complete obstruction of bile duct, resulting in obstructive jaundice, cholangitis, and sometimes cholangitic abscesses.",
"   </p>",
"   <p>",
"    Most of these patients present with jaundice, which can be progressive or fluctuating. The only physical sign may be tender hepatomegaly. Intrabiliary rupture should be suspected when an ultrasound reveals a cystic space occupying lesion in the liver and a dilated common bile duct in a patient from an endemic area.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is usually established by radiologic tests and serology. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28025?source=see_link\">",
"     \"Clinical manifestations and diagnosis of echinococcosis\"",
"    </a>",
"    .) ERCP is indicated when the results of these tests are uncertain, and in patients who have recurrent biliary colic, especially if associated with icterus or cholangitis (see below). One study reported that biliary complications of hydatid cysts were detected by ERCP in 60 percent of cases compared with 25 percent by computed tomography (CT) or ultrasound.",
"   </p>",
"   <p>",
"    Cholangiography often reveals minor communications, particularly with peripheral ducts, which are of unclear clinical significance. 99mTc&ndash;labeled albumin aggregate injection into cysts can assist in the detection of leakage into the systemic circulation. Duodenoscopy sometimes shows whitish, glistening membranes lying in the duodenum, or impacted in the papilla of Vater (",
"    <a class=\"graphic graphic_picture graphicRef75827 \" href=\"mobipreview.htm?22/26/22945\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Three patterns of intraductal filling defects on ERCP have been described:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Filiform, linear, wavy material in the common bile duct due to laminated hydatid membranes or ill-defined, irregular leaf-like filling defects due to fragmented membranes",
"     </li>",
"     <li>",
"      Round or oval lucent filling defects, floating in the common bile duct due to daughter cysts",
"     </li>",
"     <li>",
"      Brown, thick, amorphous debris",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of hydatid disease usually involves anthelminthic therapy combined with either surgical resection of the cyst or percutaneous aspiration and instillation of scolicidal agents. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27561?source=see_link\">",
"     \"Treatment of echinococcosis\"",
"    </a>",
"    .)&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     Albendazole",
"    </a>",
"    is highly effective and should be started prior to endoscopic or surgical therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23221?source=see_link\">",
"     \"Anthelminthic therapies\"",
"    </a>",
"    .) Endoscopic therapy should be reserved for patients with suspected biliary complications occurring before or after surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Preoperative ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sphincterotomy is often needed in patients with obstructive jaundice or cholangitis. The cysts and membranes can then be removed with the help of a basket or an occlusion balloon [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/18\">",
"     18",
"    </a>",
"    ]. Saline irrigation of the bile duct may be necessary to flush out the hydatid sand and small daughter cysts. Life-threatening episodes of acute cholangitis can be managed by initially placing a nasobiliary drain (NBD), followed by extraction of hydatid cysts and membranes with or without sphincterotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/19\">",
"     19",
"    </a>",
"    ]. The drained bile (through NBD) can be examined for hydatid hooklets or membranes.",
"   </p>",
"   <p>",
"    Sterilization of the remaining daughter cysts and germinal layers is required to complete treatment. This has usually been accomplished during surgery when the cyst is completely removed after instillation of a cysticidal agent (such as hypertonic saline, iodophor, or ethanol), which is left to dwell in the cyst cavity for 30 minutes prior to excision. It can also be achieved endoscopically if a catheter can be passed into the communicating cyst, permitting irrigation of the main cyst with hypertonic saline (30 percent). However, the safety and efficacy of this approach has not been well studied. It should not be attempted in settings in which the cysts communicate with other parts of the biliary tree or branches. There have been only a handful of case reports of successful non-surgical treatment of complicated hydatid disease with ERCP and medical therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Post-operative ERCP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complications can also develop following surgery for hydatid disease. Early complications include the development of jaundice (which is often due to echinococcal remnants) or an external biliary fistula, occurring in up to 2 percent of patients typically within two to four weeks of surgery. Endoscopic biliary stenting for approximately four to six weeks is usually sufficient to achieve fistula closure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/21\">",
"     21",
"    </a>",
"    ]. Sphincterotomy may also be effective [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Late complications, including sphincter of Oddi stenosis and sclerosing cholangitis, are most commonly seen in patients in whom formalin was used to sterilize the cysts during surgery; minor or major communications with the bile duct permit the formalin to enter the biliary system, causing inflammatory changes. Most of these complications can be treated with ERCP [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/11,23\">",
"     11,23",
"    </a>",
"    ]. Patients who develop sphincter of Oddi stenosis can be treated with sphincterotomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/24\">",
"     24",
"    </a>",
"    ]. A biliary endoprosthesis or balloon dilation may be required in patients who develop a bile duct stricture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Endoscopic treatment methods have also been successful in addressing other complications of biliary hydatidosis such as clearing the biliary tree, closing fistulas and biliary leaks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLONORCHIS SINENSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clonorchis sinensis, also known as Chinese liver fluke, is a trematode commonly found in the Far East, mainly in China, Japan, Korea, Taiwan, and Vietnam. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10648?source=see_link\">",
"     \"Liver flukes: Clonorchiasis and opisthorchiasis\"",
"    </a>",
"    .) It lives in the biliary tract of humans and other fish-eating animals, where it can cause obstructive jaundice. Infection is acquired from eating raw fresh water fish (carp and salmon group). Complications include intrahepatic stones, recurrent bile duct stones, cholangitis, cirrhosis, pancreatitis, and cholangiocarcinoma. Opisthorchis felineus and Opisthorchis viverrini are closely related, have similar life cycles and pathophysiology, and produce similar clinical manifestations. The geographic distribution of these parasites varies. While O. viverrini is endemic in Laos and Thailand, O. felineus is endemic in Eastern Europe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Pathogenesis of biliary injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;The metacercariae (the infective stage) attach to the common bile duct, migrate along the epithelial lining of the duct, and stay in the intrahepatic ducts where they mature into adult worms, which are flat, elongated and 10 to 23 mm in length. As a general rule, they seek the smaller branches of the left lobe of liver, attain maturity in about one-month and begin to pass eggs. The migration of the immature worm causes trauma to the bile duct epithelium leading to ulceration and desquamation. Adenomatous hyperplasia and goblet cell metaplasia may develop as a result of epithelial injury, which can lead to fibrous tissue formation, resulting in extensive thickening of the bile duct (referred to as encapsulating fibrosis of the duct).",
"   </p>",
"   <p>",
"    Single exposure to the parasite is of little clinical significance. However, repeated exposures may provoke a diffuse involvement of the biliary tree, including the large bile ducts and gallbladder. The average infection involves 20 to 200 adult worms; in heavy infections 20,000 flukes may be present in the liver. Dilated subcapsular bile ducts, adenomatous hyperplasia of the bile duct epithelium with or without periductal fibrosis, and an eosinophilic infiltration may be seen in early infections. Cirrhosis may develop in late infection and in patients with repeated infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of infected patients are asymptomatic. Symptomatic patients usually present with cholangitis, intrahepatic calculi, or cholangiohepatitis. Chronic infection is also associated with the development of cholangiocarcinoma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=see_link\">",
"     \"Epidemiology, pathogenesis, and classification of cholangiocarcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanical effect of the worm blocks bile flow, predisposing to cholangitis, which causes death of the worm. Paroxysms of colicky upper abdominal pain due to cholangitis may be confused with calculous biliary disease. However, calculous disease may coexist since the eggs can act as a nidus for stone formation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Characteristics on cholangiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many cholangiographic findings have been described (depending upon the stage of infection), including elongated filling defects (from a few millimeters to 10 mm in length) and intrahepatic biliary dilatation, which is predominantly peripheral. The defects are of variable size and shape and occur mostly within the smaller tertiary or quaternary intrahepatic bile ducts. Findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A mulberry-like appearance: multiple saccular or cystic dilatations of the intrahepatic bile ducts",
"     </li>",
"     <li>",
"      An arrowhead sign: rapid tapering of the intrahepatic bile ducts to the periphery",
"     </li>",
"     <li>",
"      A decrease in the number of intrahepatic radicles due to portal and periportal fibrosis",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Duct wall irregularities are due to adenomatous hyperplasia, and vary from small indentations to hemispherical filling defects. When these indentations or defects occur in series, they can give rise to a scalloped appearance. The individual Clonorchis worms may be visible as filamentous, wavy, and elliptical shaped filling defects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Flukes within the bile ducts may be difficult to visualize on ultrasound. On CT, they appear as nonshadowing echogenic",
"    <span class=\"nowrap\">",
"     foci/casts",
"    </span>",
"    within bile ducts. Flukes within the gallbladder move in reaction to a light blow above the gallbladder with the transducer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urgent biliary decompression is required for patients with acute cholangitis. Aspirated bile may show adult worms and ova. Endoscopic biopsies are indicated when cholangiocarcinoma is suspected. Surgical intervention may be required in patients who have developed abscesses, extensive fibrosis, or biliary lithiasis.",
"   </p>",
"   <p>",
"    The drug of choice is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    (75",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses). Although it is virtually 100 percent effective, biliary ductal abnormalities may persist even after successful drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     FASCIOLA HEPATICA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fasciola hepatica, also known as the sheep liver fluke, is more frequent in sheep raising areas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31735?source=see_link\">",
"     \"Liver flukes: Fascioliasis\"",
"    </a>",
"    .) Human infection usually occurs after eating raw vegetables that are infested with metacercariae (the infective form). Humans are an accidental final host in the life cycle of the parasite. The diagnosis should be suspected when eosinophilia and right upper quadrant pain are seen in a patient with history of ingesting watercress (water plants).",
"   </p>",
"   <p>",
"    The fasciola infection can be divided into two phases:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Acute (hepatic) phase",
"     </li>",
"     <li>",
"      The chronic (biliary) phase",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    During the acute phase, immature worms penetrate the duodenal wall, migrate across peritoneal cavity, and enter the biliary passages through the capsule and parenchyma of liver. The larvae in the bile ducts elicit inflammatory reactions due to toxic metabolites and mechanical effects, leading to necrosis and adenomatous changes of the epithelium, and biliary fibrosis. These changes ultimately evolve into cystic dilatation, total or partial obstruction of bile ducts, and periportal cirrhosis.",
"   </p>",
"   <p>",
"    The chronic phase of fascioliasis develops following infection of bile duct",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gallbladder with the adult worm, which has a life span of approximately 9 to 13 years. This phase develops three to four months after the contaminated meal. Patients typically present with jaundice, fever, right upper quadrant pain, and rarely with acalculous cholecystitis, severe hemobilia, and acute pancreatitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/28\">",
"     28",
"    </a>",
"    ]. Similar to Clonorchis infection, eggs or the dead parasites can act as a nidus for calculous formation, potentially leading to intra or extrahepatic biliary lithiasis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Role of ERCP/endoscopic ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flukes may appear as small, radiolucent linear, elliptical, or crescent-like shadows, with jagged, irregular margins in the gallbladder or dilated bile ducts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/10,29\">",
"     10,29",
"    </a>",
"    ]. Biliary fascioliasis has also been diagnosed on endoscopic ultrasonography, which showed a dilated common bile duct with a floating, linear structure within [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/30\">",
"     30",
"    </a>",
"    ]. The worms can be extracted after creation of a small sphincterotomy. Adequate drainage should be achieved in patients with acute cholangitis.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/54/25447?source=see_link\">",
"     Chloroquine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/42/12965?source=see_link\">",
"     mebendazole",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"     albendazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"     praziquantel",
"    </a>",
"    have been used with variable success. Bithionol, a dichlorophenol, is recommended in a dose of 30 to 50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    on alternate days for 10 to 15 doses. It is available through the Centers for Disease Control and Prevention in the United States. Chronic infection is more difficult to treat than acute disease. A case report suggested that washing the biliary system with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"     povidone iodine",
"    </a>",
"    during ERCP may be effective for resistant cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/31\">",
"     31",
"    </a>",
"    ]. Some of the ductal changes are reversible following successful treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42087/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24496355\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infestations of the hepatic and extrahepatic biliary tree occur most commonly by Ascaris lumbricoides, Clonorchis sinensis, Opisthorchis felineus, and Fasciola hepatica. Other hepatobiliary parasites include O. Viverrini, Fasciola gigantica, and Dicrocoelium dendriticum. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Ascaris lumbricoides organisms normally reside in the jejunum but are actively motile and can invade the papilla, thus migrating into the bile duct, causing biliary obstruction. Endoscopic retrograde cholangiopancreatography (ERCP) is a highly sensitive method to demonstrate the worm in the biliary and pancreatic ducts. Worms can be seen in the duodenum and very often across the ampulla of Vater during endoscopy (",
"      <a class=\"graphic graphic_picture graphicRef58130 \" href=\"mobipreview.htm?5/36/5696\">",
"       picture 1",
"      </a>",
"      ). Extraction of the worm is usually associated with rapid relief of symptoms and is successful in more than 80 percent of patients. Patients should be treated with anthelminthic therapy to eradicate remaining worms. A single oral dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"       albendazole",
"      </a>",
"      (400 mg) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/42/12965?source=see_link\">",
"       mebendazole",
"      </a>",
"      (500 mg) is usually successful. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Ascaris lumbricoides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The definitive hosts for Echinococcus granulosus are canines (dogs, wolves, and foxes). In humans, who serve as intermediate hosts, the parasite forms a hydatid cyst. The most common site of cystic hydatid disease is the liver. The diagnosis is usually established by radiologic tests and serology. ERCP is indicated when the results of these tests are uncertain and in patients who have recurrent biliary colic, especially if associated with icterus or cholangitis.",
"      <br/>",
"      <br/>",
"      Treatment of hydatid disease usually involves anthelminthic therapy combined with either surgical resection of the cyst or percutaneous aspiration and instillation of scolicidal agents.&nbsp;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/6/24678?source=see_link\">",
"       Albendazole",
"      </a>",
"      is highly effective and should be started prior to endoscopic or surgical therapy. Endoscopic therapy should be reserved for patients with suspected biliary complications occurring before or after surgery. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Echinococcus granulosus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clonorchis sinensis lives in the biliary tract of humans and other fish-eating animals, where it can cause obstructive jaundice. Infection is acquired from eating raw fresh water fish (carp and salmon group). Complications include intrahepatic stones, recurrent bile duct stones, cholangitis, cirrhosis, pancreatitis, and cholangiocarcinoma. Many types of cholangiographic findings have been described (depending upon the stage of infection), including elongated filling defects (from a few millimeters to 10 mm in length) and intrahepatic biliary dilatation, which is predominantly peripheral. The defects are of variable size and shape and occur mostly within the smaller tertiary or quaternary intrahepatic bile ducts.",
"      <br/>",
"      <br/>",
"      Urgent biliary decompression is required for patients with acute cholangitis. Aspirated bile may show adult worms and ova. Endoscopic biopsies are indicated when cholangiocarcinoma is suspected. Surgical intervention may be required in patients who have developed abscesses, extensive fibrosis, or biliary lithiasis. The drug of choice is",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/16/25860?source=see_link\">",
"       praziquantel",
"      </a>",
"      (75",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in three divided doses). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clonorchis sinensis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fasciola hepatica, also known as the sheep liver fluke, is more frequent in sheep raising areas. During the acute phase of infection, immature worms penetrate the duodenal wall, migrate across the peritoneal cavity, and enter the biliary passages through the capsule and parenchyma of liver. The larvae in the bile ducts elicit inflammatory reactions, leading to necrosis and adenomatous changes of the epithelium, and biliary fibrosis. These changes ultimately evolve into cystic dilatation, total or partial obstruction of bile ducts, and periportal cirrhosis. The chronic phase of fascioliasis develops following infection of bile duct",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      gallbladder with the adult worm.",
"      <br/>",
"      <br/>",
"      Patients typically present with jaundice, fever, right upper quadrant pain, and rarely with acalculous cholecystitis, severe hemobilia, and acute pancreatitis. On ERCP, the flukes may appear as small, radiolucent linear, elliptical, or crescent-like shadows, with jagged, irregular margins in the gallbladder or dilated bile ducts. Biliary fascioliasis has also been diagnosed on endoscopic ultrasonography, which showed a dilated common bile duct with a floating, linear structure within. The worms can be extracted after creation of a small sphincterotomy. Adequate drainage should be achieved in patients with acute cholangitis. Bithionol, a dichlorophenol, is recommended in a dose of 30 to 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      on alternate days for 10 to 15 doses. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Fasciola hepatica'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/1\">",
"      Yellin AE, Donovan AJ. Biliary lithiasis and helminthiasis. Am J Surg 1981; 142:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/2\">",
"      Schulman A. Non-western patterns of biliary stones and the role of ascariasis. Radiology 1987; 162:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/3\">",
"      Khuroo MS, Zargar SA, Mahajan R. Hepatobiliary and pancreatic ascariasis in India. Lancet 1990; 335:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/4\">",
"      Wani NA, Shah OJ, Naqash SH. Postoperative biliary ascariasis: presentation and management--experience. World J Surg 2000; 24:1143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/5\">",
"      Khuroo MS, Zargar SA, Mahajan R, et al. Sonographic appearances in biliary ascariasis. Gastroenterology 1987; 93:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/6\">",
"      Mijandrusi��-Sinci�� B, Stimac D, Kezele B, et al. Acute pancreatitis caused by Ascaris lumbricoides: a case report. Gastrointest Endosc 2008; 67:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/7\">",
"      Beckingham IJ, Cullis SN, Krige JE, et al. Management of hepatobiliary and pancreatic Ascaris infestation in adults after failed medical treatment. Br J Surg 1998; 85:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/8\">",
"      Sandouk F, Haffar S, Zada MM, et al. Pancreatic-biliary ascariasis: experience of 300 cases. Am J Gastroenterol 1997; 92:2264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/9\">",
"      Alam S, Mustafa G, Ahmad N, Khan M. Presentation and endoscopic management of biliary ascariasis. Southeast Asian J Trop Med Public Health 2007; 38:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/10\">",
"      Bekta�� M, D&ouml;kmeci A, Cinar K, et al. Endoscopic management of biliary parasitic diseases. Dig Dis Sci 2010; 55:1472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/11\">",
"      Magistrelli P, Masetti R, Coppola R, et al. Value of ERCP in the diagnosis and management of pre- and postoperative biliary complications in hydatid disease of the liver. Gastrointest Radiol 1989; 14:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/12\">",
"      al-Karawi M, Sanai FM, Yasawy MI, Mohammed AE. Biliary strictures and cholangitis secondary to ascariasis: endoscopic management. Gastrointest Endosc 1999; 50:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/13\">",
"      Albonico M, Smith PG, Hall A, et al. A randomized controlled trial comparing mebendazole and albendazole against Ascaris, Trichuris and hookworm infections. Trans R Soc Trop Med Hyg 1994; 88:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/14\">",
"      Dadoukis J, Gamvros O, Aletras H. Intrabiliary rupture of the hydatid cyst of the liver. World J Surg 1984; 8:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/15\">",
"      Iscan M, D&uuml;ren M. Endoscopic sphincterotomy in the management of postoperative complications of hepatic hydatid disease. Endoscopy 1991; 23:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/16\">",
"      Spiliadis C, Georgopoulos S, Dailianas A, et al. The use of ERCP in the study of patients with hepatic echinococcosis before and after surgical intervention. Gastrointest Endosc 1996; 43:575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/17\">",
"      Dumas R, Le Gall P, Hastier P, et al. The role of endoscopic retrograde cholangiopancreatography in the management of hepatic hydatid disease. Endoscopy 1999; 31:242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/18\">",
"      Tarcin O. Rupture of hydatid cyst into the biliary tract. Gastrointest Endosc 2006; 63:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/19\">",
"      Al Karawi MA, Mohamed AR, Yasawy I, Haleem A. Non-surgical endoscopic trans-papillary treatment of ruptured echinococcus liver cyst obstructing the biliary tree. Endoscopy 1987; 19:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/20\">",
"      Khoshbaten M, Farhang S, Hajavi N. Endoscopic retrograde cholangiography for intrabiliary rupture of hydatid cyst. Dig Endosc 2009; 21:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/21\">",
"      de Aretxabala X, Perez OL. The use of endoprostheses in biliary fistula of hydatid cyst. Gastrointest Endosc 1999; 49:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/22\">",
"      Tekant Y, Bilge O, Acarli K, et al. Endoscopic sphincterotomy in the treatment of postoperative biliary fistulas of hepatic hydatid disease. Surg Endosc 1996; 10:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/23\">",
"      Bilsel Y, Bulut T, Yamaner S, et al. ERCP in the diagnosis and management of complications after surgery for hepatic echinococcosis. Gastrointest Endosc 2003; 57:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/24\">",
"      Rodriguez AN, S&aacute;nchez del R&iacute;o AL, Alguacil LV, et al. Effectiveness of endoscopic sphincterotomy in complicated hepatic hydatid disease. Gastrointest Endosc 1998; 48:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/25\">",
"      Yilmaz U, Sakin B, Boyacioglu S, et al. Management of postoperative biliary strictures secondary to hepatic hydatid disease by endoscopic stenting. Hepatogastroenterology 1998; 45:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/26\">",
"      Eickhoff A, Schilling D, Benz CA, Riemann JF. Endoscopic stenting for postoperative biliary strictures due to hepatic hydatid disease: effectiveness and long-term outcome. J Clin Gastroenterol 2003; 37:74.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/27\">",
"      Leung JW, Sung JY, Banez VP, et al. Endoscopic cholangiopancreatography in hepatic clonorchiasis--a follow-up study. Gastrointest Endosc 1990; 36:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/28\">",
"      Badalov NL, Anklesaria A, Torok A, et al. Fasciola hepatica causing acute pancreatitis complicated by biliary sepsis. Gastrointest Endosc 2009; 70:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/29\">",
"      Cheung J, Enns R, Romney M, et al. Biliary fascioliasis. Gastrointest Endosc 2005; 61:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/30\">",
"      Gandhi V, Jain P, Rathod V, Nagral S. Endoscopic ultrasound in biliary fasciolosis. Indian J Gastroenterol 2010; 29:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/31\">",
"      Dowidar N, El Sayad M, Osman M, Salem A. Endoscopic therapy of fascioliasis resistant to oral therapy. Gastrointest Endosc 1999; 50:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42087/abstract/32\">",
"      Dias LM, Silva R, Viana HL, et al. Biliary fascioliasis: diagnosis, treatment and follow-up by ERCP. Gastrointest Endosc 1996; 43:616.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 630 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-E320E62127-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42087=[""].join("\n");
var outline_f41_6_42087=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24496355\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ASCARIS LUMBRICOIDES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Radiographic imaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ECHINOCOCCUS GRANULOSUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Preoperative ERCP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Post-operative ERCP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLONORCHIS SINENSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Pathogenesis of biliary injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Characteristics on cholangiography",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      FASCIOLA HEPATICA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Role of ERCP/endoscopic ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24496355\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/630\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/630|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?21/8/21647\" title=\"diagnostic image 1\">",
"      Biliary ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/630|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/36/5696\" title=\"picture 1\">",
"      Ascaris lumbricoides Endosc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?23/62/24559\" title=\"picture 2\">",
"      Ascaris lumbricoides in the common bile duct",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?22/26/22945\" title=\"picture 3\">",
"      Hydatid membranes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/43/23221?source=related_link\">",
"      Anthelminthic therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/8/16520?source=related_link\">",
"      Ascariasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/24/21897?source=related_link\">",
"      Cholangioscopy and pancreatoscopy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/23/28025?source=related_link\">",
"      Clinical manifestations and diagnosis of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/19/37175?source=related_link\">",
"      Endoscopic balloon dilatation for removal of bile duct stones",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/59/20407?source=related_link\">",
"      Epidemiology and control of echinococcosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43881?source=related_link\">",
"      Epidemiology, pathogenesis, and classification of cholangiocarcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/25/10648?source=related_link\">",
"      Liver flukes: Clonorchiasis and opisthorchiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/63/31735?source=related_link\">",
"      Liver flukes: Fascioliasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/8/14472?source=related_link\">",
"      Recurrent pyogenic cholangitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/58/27561?source=related_link\">",
"      Treatment of echinococcosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_6_42088="Normal assortment";
var content_f41_6_42088=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F52882%7EPC%2F81597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F52882%7EPC%2F81597&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 628px\">",
"   <div class=\"ttl\">",
"    Normal assortment",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 608px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal chromosomal crossover and assortment during meiosis. Maternal (M) and Paternal (P) chromosomes exchange homologous segments during metaphase, resulting in new haplotypes (in red). Following disjunction (separation of two chromosomal copies), one copy of each chromosome assorts into individual gametes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Non-disjunction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 467px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Consequence of non-disjunction of chromosome 20, with two copies of chr20 in one gamete, and none in the other. Either monosomy (left) or trisomy (right) can result, depending on which of the two abnormal gametes contributes to embryo formation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42088=[""].join("\n");
var outline_f41_6_42088=null;
var title_f41_6_42089="Nonablative skin resurfacing for skin rejuvenation";
var content_f41_6_42089=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nonablative skin resurfacing for skin rejuvenation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42089/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42089/contributors\">",
"     Macrene Alexiades-Armenakas, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42089/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42089/contributors\">",
"     Jeffrey S Dover, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42089/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42089/contributors\">",
"     Abena O Ofori, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/6/42089/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H22567951\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over time, chronic sun exposure and chronological aging contribute to changes in the skin, such as dyschromia, rhytides (wrinkles), telangiectasias, textural alterations, and skin laxity (",
"    <a class=\"graphic graphic_table graphicRef85936 \" href=\"mobipreview.htm?24/38/25197\">",
"     table 1",
"    </a>",
"    ). Although ablative laser resurfacing and surgical procedures are effective for improving features of cutaneous aging, concern regarding potential adverse effects and required recovery times deter many patients from proceeding with these procedures.",
"   </p>",
"   <p>",
"    Nonablative lasers and light sources are therapeutic options for skin rejuvenation that demonstrate low risks for serious adverse effects and nonexistent or abbreviated recovery periods. Certain nonablative procedures are highly effective for the treatment of the dyschromia (eg, intense pulsed light [IPL] and fractional lasers) and vascular changes (eg, vascular lasers and IPL) seen in photoaged skin.",
"   </p>",
"   <p>",
"    Significant improvements in rhytides and skin laxity require the induction of dermal collagen remodeling and are relatively more difficult to achieve with nonablative technology. Infrared lasers, radiofrequency devices, and fractional lasers are typically used for these indications. Since the degree of improvement achieved is often modest, patients with mild to moderate rhytides or skin laxity are better candidates for nonablative procedures than individuals with more severe manifestations of these features.",
"   </p>",
"   <p>",
"    The modalities of nonablative skin resurfacing utilized for skin rejuvenation, including vascular lasers, IPL, infrared lasers and light sources, radiofrequency, photodynamic therapy, and nonablative fractional lasers, will be reviewed here. The basic principles of laser and light therapy for cutaneous lesions and ablative laser skin resurfacing are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22360?source=see_link\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link\">",
"     \"Ablative laser resurfacing for skin rejuvenation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3628651\">",
"    <span class=\"h1\">",
"     BACKGROUND",
"    </span>",
"    &nbsp;&mdash;&nbsp;Restoration of a youthful appearance to the skin is dependent upon the ability to remove or improve features characteristic of photodamage (cutaneous damage induced by ultraviolet light) and chronological aging, such as irregular skin pigmentation, telangiectasias, and cutaneous erythema. Chronic exposure to ultraviolet light also promotes damage to the dermis, which manifests clinically as rhytides and skin laxity and histologically as disorganized collagen fibrils and abnormal elastotic material [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/1\">",
"     1",
"    </a>",
"    ]. Because collagen is the major structural component of the skin, treatments that successfully restore collagen to a condition that resembles collagen in youthful skin are beneficial for the reversal of these features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23400?source=see_link\">",
"     \"Photoaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Nonablative skin resurfacing techniques arose from the desire to achieve clinically significant cosmetic improvements in aging skin with procedures that had lower risks and shorter recovery times than ablative laser or surgical treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/2\">",
"     2",
"    </a>",
"    ]. Ablative resurfacing with continuous wave carbon dioxide (CO",
"    <sub>",
"     2",
"    </sub>",
"    ) lasers, which was introduced in the 1980s, was associated with a high rate of side effects including scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link&amp;anchor=H8009623#H8009623\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Overview'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although subsequent advances in ablative laser technology led to the availability of short-pulse, high peak-power CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers; rapidly scanned, focused-beam CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers; and normal-mode erbium:yttrium aluminum garnet (Er:YAG) lasers, all of which were less prone to severe adverse effects than continuous wave CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers, recovery periods remained relatively long (several days to three weeks) and a small but significant complication risk persisted. Most nonablative skin resurfacing modalities (eg, vascular lasers, intense pulsed light [IPL], infrared lasers and light sources, and radiofrequency devices) function through the utilization of optical energy or radiofrequency to selectively heat and injure components of the dermis without inducing significant epidermal damage or tissue ablation. This results in the ability to improve signs of cutaneous aging with minimal collateral damage, which in turn manifests as rapid recovery times, relatively insignificant posttreatment erythema, and a low risk for complications.",
"   </p>",
"   <p>",
"    However, these favorable characteristics of nonablative modalities are tempered by the generally lower degree of improvement in rhytides attained after nonablative treatments when treatment outcomes are compared to the results achieved with ablative laser resurfacing. In addition, multiple treatment sessions are often required to achieve results that are less significant than those achieved with a single session with an ablative laser. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link\">",
"     \"Ablative laser resurfacing for skin rejuvenation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Fractional resurfacing is a unique form of laser therapy that was developed in the early 21",
"    <sup>",
"     st",
"    </sup>",
"    century that represents a midpoint between traditional nonablative skin resurfacing and ablative skin resurfacing in regards to the efficacy of treatment and side effects. Fractional lasers deliver microscopic columns of light to the epidermis and dermis in regularly spaced arrays, thereby treating only a select fraction of the skin (",
"    <a class=\"graphic graphic_figure graphicRef53757 \" href=\"mobipreview.htm?38/15/39153\">",
"     figure 1",
"    </a>",
"    ). Rapid healing occurs after treatment due to the retention of reservoirs of viable tissue within treated areas. Fractional nonablative lasers are more effective than vascular lasers and IPL for rhytides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, posttreatment recovery periods are shorter than those that follow treatment with traditional ablative or fractional ablative lasers. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22360?source=see_link&amp;anchor=H31999193#H31999193\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Fractionated lasers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link&amp;anchor=H832338#H832338\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Traditional ablative lasers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link&amp;anchor=H7559191#H7559191\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Ablative fractional lasers'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22567974\">",
"    <span class=\"h1\">",
"     NONABLATIVE SYSTEMS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5986921\">",
"    <span class=\"h2\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of nonablative lasers, light sources, and other devices have been utilized to rejuvenate skin. The classes of technologies employed for this purpose include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <strong>",
"       Vascular lasers",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Infrared lasers and infrared broadband light sources",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Intense pulsed light (IPL)",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Radiofrequency devices",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Photodynamic therapy",
"      </strong>",
"     </li>",
"     <li>",
"      <strong>",
"       Nonablative fractional lasers",
"      </strong>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The value of these modalities for specific features of cutaneous aging varies. Light from vascular lasers, although highly absorbed by hemoglobin and useful for reducing telangiectasias and erythema, has relatively shallow penetration into the dermis and demonstrates limited ability to induce the dermal collagen remodeling necessary to improve rhytides or skin laxity (",
"    <a class=\"graphic graphic_figure graphicRef60561 \" href=\"mobipreview.htm?43/30/44516\">",
"     figure 2B",
"    </a>",
"    ). IPL devices, noncoherent light sources that emit wavelengths of light that are strongly absorbed by melanin and hemoglobin, are highly effective for treating dyschromia and vascular changes in aging skin, but may be less valuable for inducing clinically significant effects on collagen in the dermis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/47/17146?source=see_link&amp;anchor=H113212014#H113212014\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Yellow and green light lasers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22360?source=see_link&amp;anchor=H31999201#H31999201\">",
"     \"Principles of laser and intense pulsed light for cutaneous lesions\", section on 'Intense pulsed light'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Certain lasers and light sources that emit light in the infrared range are much better suited for rhytides since the longer wavelengths penetrate more deeply into the dermis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Energy emitted from radiofrequency devices can also be utilized to target the dermis, resulting in improvements in rhytides and skin laxity. (See",
"    <a class=\"local\" href=\"#H3581168\">",
"     'Preoperative counseling and treatment selection'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The light sources utilized for nonablative skin resurfacing are reviewed in greater detail below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22567981\">",
"    <span class=\"h2\">",
"     Vascular lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Vascular lasers emit wavelengths of light that are highly absorbed by their target chromophore, hemoglobin (",
"    <a class=\"graphic graphic_figure graphicRef74419 \" href=\"mobipreview.htm?21/34/22048\">",
"     figure 2A",
"    </a>",
"    ). These lasers, including the 585 nm and 595 nm pulsed dye lasers (PDLs) and the 532 nm potassium titanyl phosphate (KTP) laser, are efficacious for the treatment of the telangiectasias and erythema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Long-pulsed PDLs used with a compression handpiece have also been effective for the treatment of lentigines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/47/17146?source=see_link&amp;anchor=H113212014#H113212014\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Yellow and green light lasers'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    After clinical and histologic benefits in collagen remodeling were observed after PDL treatment of erythematous hypertrophic scars, striae distensae, and acne scars, studies were employed to determine the efficacy of these lasers for rhytides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/2\">",
"     2",
"    </a>",
"    ]. Although small, uncontrolled studies demonstrated clinical and histopathologic improvements in facial rhytides following treatments with 585 nm PDLs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/11-13\">",
"     11-13",
"    </a>",
"    ] and long-pulsed 595 nm PDLs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/14\">",
"     14",
"    </a>",
"    ], the efficacy of PDL for this indication is limited and modest in comparison to other treatments. Thus, vascular lasers are typically not used for the treatment of rhytides.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22567988\">",
"    <span class=\"h2\">",
"     Intense pulsed light",
"    </span>",
"    &nbsp;&mdash;&nbsp;The broad range of wavelengths emitted from IPL devices (500 to 1200 nm) account for the ability of these devices to effectively target both melanin and hemoglobin in the skin (",
"    <a class=\"graphic graphic_figure graphicRef74419 \" href=\"mobipreview.htm?21/34/22048\">",
"     figure 2A",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/15\">",
"     15",
"    </a>",
"    ]. This correlates with the utility of IPL for improving the dyspigmentation and vascularity that often characterize photoaged skin (",
"    <a class=\"graphic graphic_picture graphicRef86711 \" href=\"mobipreview.htm?13/1/13331\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9370?source=see_link&amp;anchor=H1325109#H1325109\">",
"     \"Laser and light therapy for cutaneous hyperpigmentation\", section on 'Intense pulsed light'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/47/17146?source=see_link&amp;anchor=H3923257#H3923257\">",
"     \"Laser and light therapy for cutaneous vascular lesions\", section on 'Intense pulsed light'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although histologic evaluation has demonstrated IPL-induced dermal remodeling that is characterized by increases in extracellular matrix proteins and neocollagenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/18\">",
"     18",
"    </a>",
"    ], studies conflict on the clinical efficacy of this modality for rhytides. Small, split-face randomized trials comparing treatment with IPL alone to IPL in combination with other rejuvenating procedures have documented variable amounts of improvement in fine rhytides after IPL monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. In addition, partial improvement after IPL has been detected in several uncontrolled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, other randomized trials have not found IPL to be effective for rhytides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/5,16\">",
"     5,16",
"    </a>",
"    ]. As an example, in a randomized split-face trial in which 32 women with mild to moderate rhytides received three once-monthly treatments with filtered IPL (530 to 750 nm, 7.5 to 8.5",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     ,",
"    </span>",
"    2.5 ms pulses, 10 ms interpulse delay) to one side of the face and no treatment to the other side, greater improvements in telangiectasias, pigmentation, and skin texture were detected in sites treated with IPL, but there was not a significant difference in the effect on rhytides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/16\">",
"     16",
"    </a>",
"    ]. Variability in the treatment methods across studies (eg, fluence, pulse durations, and filtered wavelengths) may account for the inconsistent findings on the efficacy of IPL for this indication. Of note, the trials above that found that IPL was not effective for rhytides filtered out the longer, more deeply penetrating wavelengths of IPL (750 to 1200 nm), a factor that is likely to have compromised treatment efficacy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/5,16\">",
"     5,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of a topical photosensitizer in conjunction with IPL (photodynamic therapy) may enhance the level of improvement in features of photoaging attained with IPL devices [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/19,24\">",
"     19,24",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H22568009\">",
"     'Photodynamic therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22567995\">",
"    <span class=\"h2\">",
"     Infrared lasers and light devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the depth of penetration of visible light into the skin rises with increasing laser wavelength (",
"    <a class=\"graphic graphic_figure graphicRef60561 \" href=\"mobipreview.htm?43/30/44516\">",
"     figure 2B",
"    </a>",
"    ), this principle does not consistently apply to light in the infrared range (",
"    <a class=\"graphic graphic_figure graphicRef70045 \" href=\"mobipreview.htm?15/8/15502\">",
"     figure 3",
"    </a>",
"    ). Strong absorption of infrared light by water can significantly limit the depth of penetration, as occurs with the ablative 2940 nm Er:YAG and 10,600 nm CO",
"    <sub>",
"     2",
"    </sub>",
"    lasers (",
"    <a class=\"graphic graphic_figure graphicRef74419 graphicRef60561 \" href=\"mobipreview.htm?41/55/42871\">",
"     figure 2A-B",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link&amp;anchor=H214349#H214349\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast, infrared devices with wavelengths between 1000 and 1800 nm penetrate deeply and exert nonablative effects in the reticular dermis. These devices exert these effects by eliminating shorter wavelengths that absorb strongly in melanosomes and hemoglobin, yet including infrared wavelengths that are less strongly absorbed by sebaceous glands than by water and collagen (",
"    <a class=\"graphic graphic_figure graphicRef74419 \" href=\"mobipreview.htm?21/34/22048\">",
"     figure 2A",
"    </a>",
"    ). As light emitted from these devices is absorbed by water and collagen fibrils in the dermis, the dermis is heated, leading to collagen contraction, new collagen formation, and improvements in rhytides and skin laxity. Since infrared wavelengths are poorly absorbed by hemoglobin and melanin, these devices are not useful for the treatment of pigmentary or vascular changes (",
"    <a class=\"graphic graphic_figure graphicRef74419 \" href=\"mobipreview.htm?21/34/22048\">",
"     figure 2A",
"    </a>",
"    ). Technology to cool the skin surface, such as a cryogen spray, is essential to prevent heat-related damage to the epidermis during treatment with infrared devices.",
"   </p>",
"   <p>",
"    The first infrared device utilized for nonablative skin resurfacing was a 1320 nm neodymium:yttrium aluminum garnet (Nd:YAG) laser (CoolTouch, ICN Photonics, Costa Mesa, CA) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. This was followed by the development of a 1450 nm diode laser and a 1540 nm erbium:glass laser. In a randomized split-face trial in which nine patients were given three treatments with a 1450 nm diode laser and cryogen spray on one side of the face (23.3 to 28.6",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    and the cryogen spray alone on the contralateral side, periorbital or perioral wrinkle scores were significantly reduced from baseline on the laser-treated side, but not on the control side [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/25\">",
"     25",
"    </a>",
"    ]. Moreover, in another split-face randomized trial and several uncontrolled studies, treatment with nonablative infrared lasers has yielded mild to moderate clinical improvements in rhytides and findings of increased dermal thickness and neocollagenesis on histopathological examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/3,4,25-28\">",
"     3,4,25-28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the infrared lasers, an infrared broadband device that emits wavelengths spanning 1100 to 1800 nm has demonstrated efficacy for skin tightening [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. In an uncontrolled study of 25 patients with laxity of the brow, cheek, neck,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lower face, one to three treatments (20 to 30",
"    <span class=\"nowrap\">",
"     J/cm",
"     <sup>",
"      2",
"     </sup>",
"     )",
"    </span>",
"    resulted in eyebrow lifting in 18 of 24 patients, and improvement of cheek or neck flaccidity in 18 of 22 patients. Changes consistent with skin contraction were noted immediately after treatment in most patients. Other studies of this device have also documented beneficial effects on skin laxity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/32,33\">",
"     32,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike treatment with nonablative infrared lasers which is typically painful and requires topical anesthesia, treatment with the infrared broadband device is associated with minimal discomfort [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/34\">",
"     34",
"    </a>",
"    ]. Altering the method of delivery of broadband infrared light may reduce patient discomfort even further and may allow for more aggressive treatment. In a small, uncontrolled study, a treatment protocol in which the handpiece of an 1100 to 1800 nm broadband infrared device was kept in continuous motion allowed for painless treatment and facilitated the use of higher fluences and more passes. Treatment was also effective; all 22 women had improvement in skin laxity (mean percent improvement in laxity score of 14 &plusmn; 11 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/35\">",
"     35",
"    </a>",
"    ]. Further study is necessary to determine the efficacy of the mobile protocol in comparison to other treatment methods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568002\">",
"    <span class=\"h2\">",
"     Radiofrequency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonablative radiofrequency devices target the dermis and are effective for the treatment of rhytides and skin laxity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/36\">",
"     36",
"    </a>",
"    ]. These devices generate electrical current or unipolar incoherent electromagnetic radiation that is utilized to heat the dermis. The depth of heating varies with the type of delivery. Treatment results in collagen contraction that manifests as immediate skin tightening as well as the induction of subsequent collagen remodeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Radiofrequency can be administered via monopolar, bipolar, and unipolar devices. Similar to nonablative infrared light sources, interventions to cool the skin surface and prevent heat-related damage to the epidermis (eg, cooling module, capacitive coupling gel) are utilized with these devices.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1458868\">",
"    <span class=\"h3\">",
"     Monopolar",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prototype radiofrequency device was a monopolar device",
"    <span class=\"nowrap\">",
"     (ThermaCool/Thermage,",
"    </span>",
"    Solta Medical, Hayward, CA). This device transmits current through the skin, and tissue resistance to the current flow results in a uniform volumetric heating effect in the dermis. A grounding pad is required.",
"   </p>",
"   <p>",
"    Initial reports of the efficacy of monopolar radiofrequency for skin tightening demonstrated inconsistent results [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/38\">",
"     38",
"    </a>",
"    ]. Subsequent technological advances (eg, increase in tip size) and technique modifications (eg, increase in the number of passes with lower energy settings) have augmented the consistency and extent of improvement and have made treatment more tolerable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/39-41\">",
"     39-41",
"    </a>",
"    ]. In one study, the ultrastructural changes in collagen fibers detected in skin treated with five lower energy passes were similar to those observed after a single, more painful pass [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical efficacy of multiple low energy passes with a monopolar radiofrequency device was evident in an uncontrolled prospective study in which 66 patients with moderate facial laxity were treated with up to five passes on the lower face and neck [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/41\">",
"     41",
"    </a>",
"    ]. Six months after treatment, improvement in facial skin laxity was detected in 92 percent of patients. Among the study participants, 28 percent achieved 50 to 75 percent (very good) improvement, 33 percent achieved 26 to 50 percent (good) improvement, 31 percent achieved less than 25 percent (minimal) improvement, and 8 percent had no improvement. Although high rates of improvement were reported in preceding studies that utilized higher energies and fewer passes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/42,43\">",
"     42,43",
"    </a>",
"    ], the degree of clinical improvement that occurred was less extensive than seen in the protocol with multiple low energy passes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1458875\">",
"    <span class=\"h3\">",
"     Bipolar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike monopolar radiofrequency devices, bipolar radiofrequency devices transmit current between two electrodes on the handpiece tip. Bipolar systems allow for better control of energy distribution, but may penetrate the skin less deeply [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/44,45\">",
"     44,45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Combination devices that consist of bipolar radiofrequency plus diode lasers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/46-48\">",
"     46-48",
"    </a>",
"    ], IPL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/49,50\">",
"     49,50",
"    </a>",
"    ], or broadband infrared light have been developed. The goal of these combination devices is a synergistic effect in which the light energy emitted from the optical device selectively heats the target tissue, thereby lowering its resistance to radiofrequency (also referred to as electro-optical synergy technology or selective radiophotothermolysis) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/47,50\">",
"     47,50",
"    </a>",
"    ]. Because less optical and radiofrequency energy is required to achieve the desired results, the risk for side effects associated with optical modalities (eg, dyspigmentation and scarring) and radiofrequency devices (eg, pain, blistering, burns) may be lower [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/46,47,51\">",
"     46,47,51",
"    </a>",
"    ]. Uncontrolled studies have demonstrated efficacy of these combination devices for rhytides and abnormalities in skin texture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/46,47,49,52,53\">",
"     46,47,49,52,53",
"    </a>",
"    ]. For bipolar radiofrequency combined with IPL, improvements in skin erythema, telangiectasia, and hyperpigmentation have also been detected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In line with the positive effects on photoaging demonstrated with dual devices, treatment regimens that include three or more nonablative modalities have been administered in attempts to concurrently improve multiple aspects of photoaging. As an example, one to five treatments with both a",
"    <span class=\"nowrap\">",
"     radiofrequency/diode",
"    </span>",
"    laser device and a",
"    <span class=\"nowrap\">",
"     radiofrequency/IPL",
"    </span>",
"    device effectively improved multiple signs of aging, including rhytides, skin laxity, and other features of photodamage in an uncontrolled study of 28 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/54\">",
"     54",
"    </a>",
"    ]. In a separate small, split-face randomized trial, four treatment sessions with radiofrequency, IPL, infrared light, and a diode laser also led to improvement in multiple features of aging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1458882\">",
"    <span class=\"h3\">",
"     Unipolar",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unipolar delivery of radiofrequency energy as electromagnetic radiation is estimated to penetrate more deeply into targeted tissue than other methods of radiofrequency delivery (up to 20 mm for unipolar versus 2 to 8 mm for bipolar) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/56\">",
"     56",
"    </a>",
"    ]. However, the relevance of this feature on clinical outcome is uncertain.",
"   </p>",
"   <p>",
"    The efficacy of unipolar radiofrequency electromagnetic radiation was compared to bipolar radiofrequency current in a randomized split-face trial of 10 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/56\">",
"     56",
"    </a>",
"    ]. The trial was performed with a novel device that had interchangeable unipolar and bipolar handpieces. In addition, a painless, mobile delivery technique was utilized for both treatments, rather than the stationary technique typically used for the delivery of bipolar radiofrequency. A non-statistically significant trend towards mild improvement in rhytides and skin laxity was detected with both handpieces. A higher number of passes may have been necessary to achieve statistically significant results. Further studies are necessary to evaluate the efficacy of unipolar radiofrequency for skin rejuvenation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H87171147\">",
"    <span class=\"h3\">",
"     Fractional",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fractional bipolar radiofrequency devices have been developed for skin rejuvenation. Similar to fractional lasers, these devices deliver energy in a matrix array that results in heating of a select portion of the epidermis and dermis. Fractional bipolar radiofrequency devices have demonstrated efficacy for the treatment of rhytides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. However, this particular technology induces ablation, coagulation,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    necrosis of the epidermis and is not considered a nonablative modality. The term &ldquo;sublative rejuvenation&rdquo; has been used to refer to this mode of treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568009\">",
"    <span class=\"h2\">",
"     Photodynamic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Photodynamic therapy (PDT), which consists of the application of a topical photosensitizer (eg, 5-aminolevulinic acid [5-ALA]) followed by irradiation from a light source is effective for skin rejuvenation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of light sources have been utilized in PDT skin rejuvenation. Regimens with 5-ALA and IPL have been the most extensively studied, and this particular combination of treatment has been referred to as &ldquo;photodynamic photorejuvenation&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/24\">",
"     24",
"    </a>",
"    ]. A randomized, split-face trial that compared five sessions of IPL alone (515 to 1200 nm, 23 to 28",
"    <span class=\"nowrap\">",
"     J/cm2,",
"    </span>",
"    pulse duration 2.4 to 4 ms) to three sessions of PDT with 5-ALA and IPL followed by two sessions of IPL alone found greater improvements in erythema, dyspigmentation, and fine rhytides on the sides of the face treated with PDT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other light sources that have demonstrated efficacy in PDT for photodamaged skin include long-pulsed PDL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/61\">",
"     61",
"    </a>",
"    ] and blue light [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/62\">",
"     62",
"    </a>",
"    ]. Red light PDT is associated with increased risk for vesiculation, crusting, and dyspigmentation, and is not considered to be nonablative therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3581065\">",
"    <span class=\"h2\">",
"     Fractional lasers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fractional nonablative lasers utilized for skin rejuvenation are infrared lasers. Three major features differentiate these lasers from traditional infrared devices. First, as the name implies, fractional nonablative resurfacing treats a fraction of the skin surface by thermally altering microscopic columns of skin, which are known as &ldquo;microthermal zones&rdquo; (",
"    <a class=\"graphic graphic_figure graphicRef53757 \" href=\"mobipreview.htm?38/15/39153\">",
"     figure 1",
"    </a>",
"    ). The intervening areas of untreated skin serve to repopulate the columns of thermally injured tissue. Second, in contrast to standard nonablative treatments, for which thermal injury is confined to the dermis, in nonablative fractional resurfacing, the microscopic columns of thermal injury span the epidermis and superficial dermis. However, depending on the level of energy utilized, the stratum corneum can remain relatively spared, leaving epidermal barrier function intact [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/64\">",
"     64",
"    </a>",
"    ]. This feature allows for the categorization of certain fractional laser treatments as nonablative therapy. Lastly, fractional nonablative resurfacing requires a recovery period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/65\">",
"     65",
"    </a>",
"    ]. Mild erythema and edema that persist for two to three days after treatment are the norm.",
"   </p>",
"   <p>",
"    In general, fractional nonablative lasers achieve mild to moderate improvements in dyspigmentation and rhytides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. Multiple treatment sessions are typically required to achieve satisfactory results. In our experience, dyspigmentation tends to improve more quickly than rhytides, though we tend to achieve better results in dyspigmentation with IPL. For patients who desire improvements in skin laxity, radiofrequency devices and infrared light sources are better options.",
"   </p>",
"   <p>",
"    The prototype fractional nonablative device was the 1550 nm Fraxel&reg; laser [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Examples of published studies demonstrating the efficacy of fractional nonablative resurfacing for skin rejuvenation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the first published study exploring the effect of fractional photothermolysis on the skin, four treatments with an adjustable prototype nonablative fractional device (1480 to 1550 nm, 6 to 12 mJ per MTZ) were administered to one side of the face [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/66\">",
"       66",
"      </a>",
"      ]. Three months after treatment, improvement in wrinkles or skin texture assessed by investigators as moderate or better was present in 34 and 47 percent of patients, respectively. Posttreatment wrinkle scores were improved over baseline by 18 percent.",
"     </li>",
"     <li>",
"      In an uncontrolled study of 50 patients with mild to moderate cutaneous photodamage, dyspigmentation, rhytides, and skin surface irregularities on the face, neck, or chest who were given three treatments with a 1550 nm erbium-doped fiber fractionated laser, statistically significant clinical improvement was present up to nine months after treatment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/65\">",
"       65",
"      </a>",
"      ]. At nine months, at least 51 percent improvement in photodamage was achieved in 73 percent of treated areas of facial skin and 55 percent of treated areas in nonfacial sites.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important advantage of fractional nonablative resurfacing is that it may be safely applied to nonfacial sites, such as the neck chest, limbs, hands, and feet. Treatment of these anatomic sites with other nonablative and ablative modalities has been associated with elevated risks for side effects and complications. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link&amp;anchor=H1693104#H1693104\">",
"     \"Ablative laser resurfacing for skin rejuvenation\", section on 'Nonfacial sites'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patient-administered fractional nonablative laser therapy may be a future treatment option. Two small uncontrolled studies found that at-home treatment of periorbital wrinkles with a 1410 nm nonablative fractional laser was well-tolerated and associated with clinical improvement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/69\">",
"     69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the studies that have demonstrated the benefits of fractional nonablative laser therapy for signs of photoaging, the results of an uncontrolled study of 20 patients suggest that this treatment may improve the appearance of facial pores [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/70\">",
"     70",
"    </a>",
"    ]. Two weeks after the last of six facial treatments with a 1440 nm fractional laser, assessments of facial skin with an automated imaging system revealed a significant reduction in the percentage of the skin surface with pores. In addition, both study investigators and patients noted subjective improvement. Given the short follow-up period, a transient posttreatment effect cannot be ruled out. Larger controlled studies with longer patient follow-up are necessary to confirm the efficacy of fractional nonablative laser therapy for this indication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568025\">",
"    <span class=\"h1\">",
"     PATIENT EVALUATION AND MANAGEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3581168\">",
"    <span class=\"h2\">",
"     Preoperative counseling and treatment selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A careful evaluation to ensure that the patient is an appropriate candidate for nonablative skin resurfacing is essential prior to proceeding with treatment. A discussion to determine the specific concerns of the patient (preferably with the use of a mirror) as well as a clinical examination to determine the type and severity of physical features should be performed. A scale created and utilized by the author during patient assessment is provided (",
"    <a class=\"graphic graphic_table graphicRef85936 \" href=\"mobipreview.htm?24/38/25197\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In general, nonablative resurfacing is appropriate for patients with features of cutaneous aging who desire rapid recovery and a low risk for complications. Since the degree of improvement attained can be modest (particularly for rhytides and skin laxity), patients should also be given clear expectations for the results of treatment. Patients who desire a greater degree of improvement than is likely to occur with nonablative techniques may achieve more satisfactory results with ablative laser resurfacing or surgical procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link\">",
"     \"Ablative laser resurfacing for skin rejuvenation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A basic scheme for the selection of nonablative therapies for particular indications is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Mild to advanced erythema",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       telangiectasias",
"      </strong>",
"      &minus;",
"      <strong>",
"      </strong>",
"      Vascular laser or IPL",
"     </li>",
"     <li>",
"      <strong>",
"       Mild to advanced dyschromia",
"      </strong>",
"      &minus; IPL or fractional nonablative laser",
"     </li>",
"     <li>",
"      <strong>",
"       Mild to moderate rhytides",
"      </strong>",
"      &minus; Fractional nonablative laser, infrared laser, or broadband infrared light source",
"     </li>",
"     <li>",
"      <strong>",
"       Mild to moderate skin laxity",
"      </strong>",
"      &minus; Infrared laser or light source, radiofrequency devices",
"     </li>",
"     <li>",
"      <strong>",
"       Combination of features of photoaging (mild to moderate rhytides, dyschromia, vascular changes, solar elastosis, rough skin texture)",
"      </strong>",
"      &minus; Fractional nonablative laser, IPL combined with infrared or radiofrequency devices, photodynamic therapy (PDT)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonablative skin resurfacing techniques are not favorable choices for patients with advanced rhytides or skin laxity (",
"    <a class=\"graphic graphic_table graphicRef85936 \" href=\"mobipreview.htm?24/38/25197\">",
"     table 1",
"    </a>",
"    ), since satisfactory improvement is unlikely to be attained. However, these treatments are sometimes utilized for patients with such features who are adverse to more aggressive interventions and understand the therapeutic limitations of nonablative therapy.",
"   </p>",
"   <p>",
"    The preferences of the patient regarding the time required to recover from a procedure also influences treatment selection. Unlike other nonablative resurfacing procedures, a recovery period of two to four days is typically necessary after fractional nonablative resurfacing [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once it is determined that the patient is an appropriate candidate for nonablative skin resurfacing, informed consent for the procedure to be performed should be attained and documented. Important concepts to review include the predicted number of treatments required, expected outcomes, anticipated recovery time, adverse effects, and alternatives to treatment. Although nonablative modalities are less likely to induce dyspigmentation than ablative resurfacing techniques, dark-skinned and tanned patients should be advised of the possibility of posttreatment skin dyspigmentation. (See",
"    <a class=\"local\" href=\"#H3581222\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7958395\">",
"    <span class=\"h2\">",
"     Contraindications and preoperative measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to therapy should be assessed prior to administering treatment. Although data on the risk for adverse effects from nonablative skin resurfacing during or following oral",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/62/1000?source=see_link\">",
"     isotretinoin",
"    </a>",
"    therapy are lacking, due to concern for impaired wound healing, we defer treatment when patients have received isotretinoin in the preceding six months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/71\">",
"     71",
"    </a>",
"    ]. For patients receiving fractional nonablative therapy, we extend the waiting period to one year.",
"   </p>",
"   <p>",
"    We typically avoid nonablative skin resurfacing procedures in women who are pregnant or breastfeeding due to increased risk for posttreatment hyperpigmentation. The impact of nonablative treatments on pregnancy is unknown, and we avoid treatment of pregnant women. In addition, treatment with radiofrequency devices is contraindicated in patients with pacemakers, defibrillators, and facial implants in the treatment area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/44\">",
"     44",
"    </a>",
"    ]. Prophylactic antibiotic and antiviral therapy is not routinely indicated for nonablative procedures since the epidermis is not compromised.",
"   </p>",
"   <p>",
"    Treatment of a small, inconspicuous area (test spot) prior to proceeding with the intended treatment is recommended in patients who are considered to be at increased risk for adverse effects, such as darkly pigmented (skin phototype IV to VI (",
"    <a class=\"graphic graphic_table graphicRef60541 \" href=\"mobipreview.htm?15/37/15963\">",
"     table 2",
"    </a>",
"    )) or tanned individuals, or patients with a history of keloidal scarring. Treatment with IPL should be avoided in tanned patients; patients may follow up for treatment when the skin returns to normal pigmentation. To reduce the risk for side effects from IPL in patients with naturally dark skin, longer pulse durations and conservative energy settings are indicated.",
"   </p>",
"   <p>",
"    Scarring is a rare occurrence in patients treated with nonablative modalities. Treatment should be approached with caution in patients with histories of keloids, since scarring may be particularly disfiguring in these individuals. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1847?source=see_link\">",
"     \"Keloids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568039\">",
"    <span class=\"h2\">",
"     Anesthesia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for anesthesia varies with the type of nonablative treatment. Anesthesia typically is not required for treatment with vascular lasers or IPL; the mild discomfort that occurs with these interventions is usually well-tolerated. The application of a cold pack immediately after treatment can help to alleviate any residual mild discomfort.",
"   </p>",
"   <p>",
"    In contrast, topical anesthesia is generally necessary prior to treatment with infrared lasers. A topical anesthetic agent, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/32/6660?source=see_link\">",
"     prilocaine",
"    </a>",
"    cream",
"    <strong>",
"    </strong>",
"    (EMLA) or 4 to 5% lidocaine (LMX, LMX-5) is usually applied for one hour prior to the procedure. Cold packs are applied immediately after treatment to reduce residual discomfort; however, true pain should not be present after treatment. Treatment with the 1100 to 1800 nm infrared broadband light source does not require anesthesia.",
"   </p>",
"   <p>",
"    Current treatment protocols for monopolar radiofrequency and the mobile delivery method of",
"    <span class=\"nowrap\">",
"     unipolar/bipolar",
"    </span>",
"    radiofrequency are painless and do not require anesthesia. The use of combination",
"    <span class=\"nowrap\">",
"     radiofrequency/diode",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     radiofrequency/IPL",
"    </span>",
"    devices usually requires pretreatment with topical anesthetics. Discomfort is relatively mild with a",
"    <span class=\"nowrap\">",
"     radiofrequency/infrared",
"    </span>",
"    light handpiece, and anesthesia is not required. &nbsp;",
"   </p>",
"   <p>",
"    Topical anesthesia and cold air cooling are utilized to minimize pain during treatment with fractional nonablative devices. Some fractional nonablative devices deliver painless treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568046\">",
"    <span class=\"h2\">",
"     Techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment parameters and protocols differ among the nonablative technologies. &nbsp;General principles for treatment are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Vascular lasers",
"      </strong>",
"      &minus; Operated with subpurpuric fluences and pulse durations with minimally overlapping passes; multiple treatments administered every three to four weeks are typically required",
"     </li>",
"     <li>",
"      <strong>",
"       Intense pulsed light (IPL)",
"      </strong>",
"      &minus; Devices and techniques vary significantly; cold aqueous gel must be applied prior to treatment; one or more passes administered pretreatment session; multiple treatments administered at monthly intervals",
"     </li>",
"     <li>",
"      <strong>",
"       Infrared lasers",
"      </strong>",
"      &minus; Operated initially at recommended moderate fluence, with gradual increase to the highest tolerated fluence with multiple passes to maximize efficacy; utilized in conjunction with cryogen spray delivered several milliseconds prior to laser pulsing to protect the epidermis; multiple treatments are given at two to four week intervals; erythema and minimal edema are the desired treatment endpoints",
"     </li>",
"     <li>",
"      <strong>",
"       Radiofrequency devices",
"      </strong>",
"      &minus; Technique varies according to device; a grounding pad is necessary for monopolar devices; coupling fluid or aqueous gel is applied to the treatment tip; one to three treatments given at monthly intervals; regimens with low fluences and multiple passes are increasingly utilized",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22568053\">",
"    <span class=\"h2\">",
"     Post-operative management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike ablative laser resurfacing, specific postoperative measures to promote healing usually are not necessary after nonablative resurfacing treatments. The minimal erythema and edema that occur after treatment with non-fractional light sources typically resolve within several hours; only occasionally do these symptoms persist into the following day. For patients with more persistent erythema, a mild potency topical corticosteroid (group VI) can be utilized for three days (",
"    <a class=\"graphic graphic_table graphicRef62402 \" href=\"mobipreview.htm?38/56/39809\">",
"     table 3",
"    </a>",
"    ). The vast majority of patients can apply makeup and return to normal activities immediately after treatment.",
"   </p>",
"   <p>",
"    The recovery from nonablative fractional resurfacing is variable; edema may persist for 24 hours to seven days, and posttreatment erythema typically resolves in two to four days. Additional posttreatment side effects include xerosis and pruritus, which typically appear three to four days after treatment and dissipate quickly. On average, patients require two to four days to recover from treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/67\">",
"     67",
"    </a>",
"    ]. Posttreatment management involves gentle cleansing of the skin and the application of a non-irritating emollient to maintain skin moisture. Some clinicians, including ourselves, utilize specialized emollients that contain ingredients that may promote healing and reduce redness.",
"   </p>",
"   <p>",
"    Sun exposure may increase risk for posttreatment hyperpigmentation. Daily use of sunscreen on the treated areas is recommended for at least four weeks after nonablative skin resurfacing. Continued use of sunscreen beyond this period is advised, since it may reduce additional photodamage to the skin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23400?source=see_link\">",
"     \"Photoaging\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3581222\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rarely, blistering, transient hyperpigmentation, and pinpoint scarring have followed treatment with infrared lasers. In our experience, blistering appears to occur with increased frequency in patients with a history of flushing and rosacea, and may be prevented by premedication with H1 antihistamines administered one hour prior to treatment. In the event of vesiculation, we advise patients to apply a bland, petrolatum-based ointment (eg, Aquaphor Healing Ointment) twice daily until healed. Vesicles heal without scarring in the vast majority of cases.",
"   </p>",
"   <p>",
"    Complications after nonablative fractional resurfacing are rare. Blistering that heals without scarring, prolonged erythema that eventually subsides, petechiae (particularly in thin-skinned areas), postinflammatory hyperpigmentation, and acneiform eruptions may occur [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/67\">",
"     67",
"    </a>",
"    ]. Scarring is an extremely rare event that usually develops in the setting of overaggressive treatment. Hyperpigmentation due to fractional nonablative resurfacing or other nonablative modalities may improve with sun protection, topical",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/59/36788?source=see_link\">",
"     hydroquinone",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    superficial chemical peels.",
"   </p>",
"   <p>",
"    Treatment with radiofrequency devices is associated with minimal postoperative erythema that typically resolves within hours. Infrequent complications of radiofrequency treatment include burns and scarring [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42089/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    The potential complications of resurfacing with vascular lasers and IPL include pigmentary alteration, blistering, ulceration, and scarring. To minimize the risk for burns from IPL, gel should be applied adequately, excessive fluence settings should be avoided, and the laser should be placed in proper contact with the skin. Burns are most likely to occur in sites of bony prominences and areas of the face with little fat such as the brow or temple.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2782331\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic sun exposure and chronological aging can lead to the development of multiple changes in the appearance of skin, such as dyschromia, telangiectasias, rhytides, skin roughness, and skin laxity. A variety of skin resurfacing procedures are useful for improving these features. (See",
"      <a class=\"local\" href=\"#H3628651\">",
"       'Background'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nonablative skin resurfacing for skin rejuvenation involves the use of devices that improve the physical characteristics of aging by heating specific targets in the skin. Unlike ablative skin resurfacing, tissue ablation does not occur and minimal or no damage is inflicted upon the epidermis. (See",
"      <a class=\"local\" href=\"#H5986921\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=see_link\">",
"       \"Ablative laser resurfacing for skin rejuvenation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Examples of nonablative treatment modalities include vascular lasers, intense pulsed light (IPL), infrared lasers, infrared light sources, radiofrequency devices, and photodynamic therapy. Vascular lasers (pulsed dye lasers and potassium titanyl phosphate [KTP] lasers) are most effective for the treatment of cutaneous erythema and telangiectasias. IPL is most beneficial for the treatment of vascular changes and dyspigmentation. (See",
"      <a class=\"local\" href=\"#H5986921\">",
"       'Overview'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22567981\">",
"       'Vascular lasers'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22567988\">",
"       'Intense pulsed light'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Improvement in rhytides (wrinkles) and skin laxity require the induction of changes in collagen in the dermis, such as collagen contraction and remodeling. Although all nonablative skin resurfacing modalities have demonstrated some ability to alter collagen, the most effective modalities for this indication include infrared lasers, infrared light sources, radiofrequency devices, and nonablative fractional lasers. (See",
"      <a class=\"local\" href=\"#H22567995\">",
"       'Infrared lasers and light devices'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H22568002\">",
"       'Radiofrequency'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3581065\">",
"       'Fractional lasers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Not all patients with aging skin are good candidates for nonablative skin resurfacing. The best candidates are individuals with dyspigmentation, vascular changes,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      mild to moderate rhytides or skin laxity. Patients with severe rhytides or severe skin laxity are often better served by other rejuvenating procedures. (See",
"      <a class=\"local\" href=\"#H3581168\">",
"       'Preoperative counseling and treatment selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With the exception of fractional nonablative skin resurfacing, recovery periods are not necessary after nonablative resurfacing procedures. Fractional nonablative resurfacing most frequently requires a recovery period of two to four days. (See",
"      <a class=\"local\" href=\"#H22568053\">",
"       'Post-operative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Serious adverse events are uncommon after nonablative skin resurfacing. Careful patient selection and proper treatment administration further minimize these risks. (See",
"      <a class=\"local\" href=\"#H7958395\">",
"       'Contraindications and preoperative measures'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3581222\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/1\">",
"      Kim KH, Geronemus RG. Nonablative laser and light therapies for skin rejuvenation. Arch Facial Plast Surg 2004; 6:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/2\">",
"      Alexiades-Armenakas MR, Dover JS, Arndt KA. The spectrum of laser skin resurfacing: nonablative, fractional, and ablative laser resurfacing. J Am Acad Dermatol 2008; 58:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/3\">",
"      Goldberg DJ. Full-face nonablative dermal remodeling with a 1320 nm Nd:YAG laser. Dermatol Surg 2000; 26:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/4\">",
"      Goldberg DJ. Non-ablative subsurface remodeling: clinical and histologic evaluation of a 1320-nm Nd:YAG laser. J Cutan Laser Ther 1999; 1:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/5\">",
"      J&oslash;rgensen GF, Hedelund L, Haedersdal M. Long-pulsed dye laser versus intense pulsed light for photodamaged skin: a randomized split-face trial with blinded response evaluation. Lasers Surg Med 2008; 40:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/6\">",
"      Nymann P, Hedelund L, Haedersdal M. Long-pulsed dye laser vs. intense pulsed light for the treatment of facial telangiectasias: a randomized controlled trial. J Eur Acad Dermatol Venereol 2010; 24:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/7\">",
"      Seirafi H, Fateh S, Farnaghi F, et al. Efficacy and safety of long-pulse pulsed dye laser delivered with compression versus cryotherapy for treatment of solar lentigines. Indian J Dermatol 2011; 56:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/8\">",
"      Galeckas KJ, Collins M, Ross EV, Uebelhoer NS. Split-face treatment of facial dyschromia: pulsed dye laser with a compression handpiece versus intense pulsed light. Dermatol Surg 2008; 34:672.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/9\">",
"      Kono T, Chan HH, Groff WF, et al. Long-pulse pulsed dye laser delivered with compression for treatment of facial lentigines. Dermatol Surg 2007; 33:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/10\">",
"      Kono T, Groff WF, Sakurai H, et al. Comparison study of intense pulsed light versus a long-pulse pulsed dye laser in the treatment of facial skin rejuvenation. Ann Plast Surg 2007; 59:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/11\">",
"      Goldberg D, Tan M, Dale Sarradet M, Gordon M. Nonablative dermal remodeling with a 585-nm, 350-microsec, flashlamp pulsed dye laser: clinical and ultrastructural analysis. Dermatol Surg 2003; 29:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/12\">",
"      Bjerring P, Clement M, Heickendorff L, et al. Selective non-ablative wrinkle reduction by laser. J Cutan Laser Ther 2000; 2:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/13\">",
"      Zelickson BD, Kilmer SL, Bernstein E, et al. Pulsed dye laser therapy for sun damaged skin. Lasers Surg Med 1999; 25:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/14\">",
"      Rostan E, Bowes LE, Iyer S, Fitzpatrick RE. A double-blind, side-by-side comparison study of low fluence long pulse dye laser to coolant treatment for wrinkling of the cheeks. J Cosmet Laser Ther 2001; 3:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/15\">",
"      Babilas P, Schreml S, Szeimies RM, Landthaler M. Intense pulsed light (IPL): a review. Lasers Surg Med 2010; 42:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/16\">",
"      Hedelund L, Due E, Bjerring P, et al. Skin rejuvenation using intense pulsed light: a randomized controlled split-face trial with blinded response evaluation. Arch Dermatol 2006; 142:985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/17\">",
"      Weiss RA, Weiss MA, Beasley KL. Rejuvenation of photoaged skin: 5 years results with intense pulsed light of the face, neck, and chest. Dermatol Surg 2002; 28:1115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/18\">",
"      Goldberg DJ. New collagen formation after dermal remodeling with an intense pulsed light source. J Cutan Laser Ther 2000; 2:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/19\">",
"      Dover JS, Bhatia AC, Stewart B, Arndt KA. Topical 5-aminolevulinic acid combined with intense pulsed light in the treatment of photoaging. Arch Dermatol 2005; 141:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/20\">",
"      Carruthers J, Carruthers A. The effect of full-face broadband light treatments alone and in combination with bilateral crow's feet Botulinum toxin type A chemodenervation. Dermatol Surg 2004; 30:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/21\">",
"      Goldberg DJ, Cutler KB. Nonablative treatment of rhytids with intense pulsed light. Lasers Surg Med 2000; 26:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/22\">",
"      Bitter PH. Noninvasive rejuvenation of photodamaged skin using serial, full-face intense pulsed light treatments. Dermatol Surg 2000; 26:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/23\">",
"      Sadick NS, Weiss R, Kilmer S, Bitter P. Photorejuvenation with intense pulsed light: results of a multi-center study. J Drugs Dermatol 2004; 3:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/24\">",
"      Ruiz-Rodriguez R, Sanz-S&aacute;nchez T, C&oacute;rdoba S. Photodynamic photorejuvenation. Dermatol Surg 2002; 28:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/25\">",
"      Paithankar DY, Clifford JM, Saleh BA, et al. Subsurface skin renewal by treatment with a 1450-nm laser in combination with dynamic cooling. J Biomed Opt 2003; 8:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/26\">",
"      Lupton JR, Williams CM, Alster TS. Nonablative laser skin resurfacing using a 1540 nm erbium glass laser: a clinical and histologic analysis. Dermatol Surg 2002; 28:833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/27\">",
"      Fournier N, Dahan S, Barneon G, et al. Nonablative remodeling: clinical, histologic, ultrasound imaging, and profilometric evaluation of a 1540 nm Er:glass laser. Dermatol Surg 2001; 27:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/28\">",
"      Dahan S, Lagarde JM, Turlier V, et al. Treatment of neck lines and forehead rhytids with a nonablative 1540-nm Er:glass laser: a controlled clinical study combined with the measurement of the thickness and the mechanical properties of the skin. Dermatol Surg 2004; 30:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/29\">",
"      Ruiz-Esparza J. Near [corrected] painless, nonablative, immediate skin contraction induced by low-fluence irradiation with new infrared device: a report of 25 patients. Dermatol Surg 2006; 32:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/30\">",
"      Carniol PJ, Dzopa N, Fernandes N, et al. Facial skin tightening with an 1100-1800 nm infrared device. J Cosmet Laser Ther 2008; 10:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/31\">",
"      Chan HH, Yu CS, Shek S, et al. A prospective, split face, single-blinded study looking at the use of an infrared device with contact cooling in the treatment of skin laxity in Asians. Lasers Surg Med 2008; 40:146.",
"     </a>",
"    </li>",
"    <li>",
"     Lee M-W C. Comparison of radiofrequency vs. 1100-1800 nm infrared light for skin laxity. Amer Soc Derm Surg Abst, Atlanta, GA, October 27, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/33\">",
"      Goldberg DJ, Hussain M, Fazeli A, Berlin AL. Treatment of skin laxity of the lower face and neck in older individuals with a broad-spectrum infrared light device. J Cosmet Laser Ther 2007; 9:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/34\">",
"      Bunin LS, Carniol PJ. Cervical facial skin tightening with an infrared device. Facial Plast Surg Clin North Am 2007; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/35\">",
"      Alexiades-Armenakas M. Assessment of the mobile delivery of infrared light (1100-1800 nm) for the treatment of facial and neck skin laxity. J Drugs Dermatol 2009; 8:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/36\">",
"      Fitzpatrick R, Geronemus R, Goldberg D, et al. Multicenter study of noninvasive radiofrequency for periorbital tissue tightening. Lasers Surg Med 2003; 33:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/37\">",
"      el-Domyati M, el-Ammawi TS, Medhat W, et al. Radiofrequency facial rejuvenation: evidence-based effect. J Am Acad Dermatol 2011; 64:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/38\">",
"      Hsu TS, Kaminer MS. The use of nonablative radiofrequency technology to tighten the lower face and neck. Semin Cutan Med Surg 2003; 22:115.",
"     </a>",
"    </li>",
"    <li>",
"     Dover JS, Zelickson B, Atkin D, et al. A multi-specialty review and ratification of standardized treatment guidelines for optimizing tissue tightening and contouring with a non-invasive monopolar radiofrequency device. Amer Soc Derm Surg Abstracts October 28, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/40\">",
"      Kist D, Burns AJ, Sanner R, et al. Ultrastructural evaluation of multiple pass low energy versus single pass high energy radio-frequency treatment. Lasers Surg Med 2006; 38:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/41\">",
"      Bogle MA, Ubelhoer N, Weiss RA, et al. Evaluation of the multiple pass, low fluence algorithm for radiofrequency tightening of the lower face. Lasers Surg Med 2007; 39:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/42\">",
"      Alster TS, Tanzi E. Improvement of neck and cheek laxity with a nonablative radiofrequency device: a lifting experience. Dermatol Surg 2004; 30:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/43\">",
"      Nahm WK, Su TT, Rotunda AM, Moy RL. Objective changes in brow position, superior palpebral crease, peak angle of the eyebrow, and jowl surface area after volumetric radiofrequency treatments to half of the face. Dermatol Surg 2004; 30:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/44\">",
"      Paasch U, Bodendorf MO, Grunewald S, Simon JC. Skin rejuvenation by radiofrequency therapy: methods, effects and risks. J Dtsch Dermatol Ges 2009; 7:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/45\">",
"      Gold MH, Goldman MP, Rao J, et al. Treatment of wrinkles and elastosis using vacuum-assisted bipolar radiofrequency heating of the dermis. Dermatol Surg 2007; 33:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/46\">",
"      Sadick NS, Trelles MA. Nonablative wrinkle treatment of the face and neck using a combined diode laser and radiofrequency technology. Dermatol Surg 2005; 31:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/47\">",
"      Hammes S, Greve B, Raulin C. Electro-optical synergy (ELOS) technology for nonablative skin rejuvenation: a preliminary prospective study. J Eur Acad Dermatol Venereol 2006; 20:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/48\">",
"      Kulick M. Evaluation of a combined laser-radio frequency device (Polaris WR) for the nonablative treatment of facial wrinkles. J Cosmet Laser Ther 2005; 7:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/49\">",
"      Sadick NS, Alexiades-Armenakas M, Bitter P Jr, et al. Enhanced full-face skin rejuvenation using synchronous intense pulsed optical and conducted bipolar radiofrequency energy (ELOS): introducing selective radiophotothermolysis. J Drugs Dermatol 2005; 4:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/50\">",
"      Bitter P Jr, Stephen Mulholland R. Report of a new technique for enhanced non-invasive skin rejuvenation using a dual mode pulsed light and radio-frequency energy source: selective radio-thermolysis. J Cosmet Dermatol 2002; 1:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/51\">",
"      Sadick NS. Combination radiofrequency and light energies: electro-optical synergy technology in esthetic medicine. Dermatol Surg 2005; 31:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/52\">",
"      Doshi SN, Alster TS. Combination radiofrequency and diode laser for treatment of facial rhytides and skin laxity. J Cosmet Laser Ther 2005; 7:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/53\">",
"      Choi YJ, Lee JY, Ahn JY, et al. The safety and efficacy of a combined diode laser and bipolar radiofrequency compared with combined infrared light and bipolar radiofrequency for skin rejuvenation. Indian J Dermatol Venereol Leprol 2012; 78:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/54\">",
"      Alexiades-Armenakas M. Rhytides, laxity, and photoaging treated with a combination of radiofrequency, diode laser, and pulsed light and assessed with a comprehensive grading scale. J Drugs Dermatol 2006; 5:731.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/55\">",
"      Kim JE, Chang S, Won CH, et al. Combination treatment using bipolar radiofrequency-based intense pulsed light, infrared light and diode laser enhanced clinical effectiveness and histological dermal remodeling in Asian photoaged skin. Dermatol Surg 2012; 38:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/56\">",
"      Alexiades-Armenakas M, Dover JS, Arndt KA. Unipolar versus bipolar radiofrequency treatment of rhytides and laxity using a mobile painless delivery method. Lasers Surg Med 2008; 40:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/57\">",
"      Hruza G, Taub AF, Collier SL, Mulholland SR. Skin rejuvenation and wrinkle reduction using a fractional radiofrequency system. J Drugs Dermatol 2009; 8:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/58\">",
"      Brightman L, Goldman MP, Taub AF. Sublative rejuvenation: experience with a new fractional radiofrequency system for skin rejuvenation and repair. J Drugs Dermatol 2009; 8:s9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/59\">",
"      Lee HS, Lee DH, Won CH, et al. Fractional rejuvenation using a novel bipolar radiofrequency system in Asian skin. Dermatol Surg 2011; 37:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/60\">",
"      Alexiades-Armenakas MR, Geronemus RG. Laser-mediated photodynamic therapy of actinic keratoses. Arch Dermatol 2003; 139:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/61\">",
"      Alam M, Dover JS. Treatment of photoaging with topical aminolevulinic acid and light. Skin Therapy Lett 2004; 9:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/62\">",
"      Touma D, Yaar M, Whitehead S, et al. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004; 140:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/63\">",
"      Alexiades-Armenakas M. Laser-mediated photodynamic therapy. Clin Dermatol 2006; 24:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/64\">",
"      Laubach HJ, Tannous Z, Anderson RR, Manstein D. Skin responses to fractional photothermolysis. Lasers Surg Med 2006; 38:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/65\">",
"      Wanner M, Tanzi EL, Alster TS. Fractional photothermolysis: treatment of facial and nonfacial cutaneous photodamage with a 1,550-nm erbium-doped fiber laser. Dermatol Surg 2007; 33:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/66\">",
"      Manstein D, Herron GS, Sink RK, et al. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med 2004; 34:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/67\">",
"      Narurkar VA. Nonablative fractional laser resurfacing. Dermatol Clin 2009; 27:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/68\">",
"      Geraghty LN, Biesman B. Clinical evaluation of a single-wavelength fractional laser and a novel multi-wavelength fractional laser in the treatment of photodamaged skin. Lasers Surg Med 2009; 41:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/69\">",
"      Leyden J, Stephens TJ, Herndon JH Jr. Multicenter clinical trial of a home-use nonablative fractional laser device for wrinkle reduction. J Am Acad Dermatol 2012; 67:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/70\">",
"      Saedi N, Petrell K, Arndt K, Dover J. Evaluating facial pores and skin texture after low-energy nonablative fractional 1440-nm laser treatments. J Am Acad Dermatol 2013; 68:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42089/abstract/71\">",
"      Rubenstein R, Roenigk HH Jr, Stegman SJ, Hanke CW. Atypical keloids after dermabrasion of patients taking isotretinoin. J Am Acad Dermatol 1986; 15:280.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13645 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.167.4.114-2B3BC00349-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42089=[""].join("\n");
var outline_f41_6_42089=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H2782331\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22567951\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3628651\">",
"      BACKGROUND",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22567974\">",
"      NONABLATIVE SYSTEMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5986921\">",
"      Overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22567981\">",
"      Vascular lasers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22567988\">",
"      Intense pulsed light",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22567995\">",
"      Infrared lasers and light devices",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22568002\">",
"      Radiofrequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1458868\">",
"      - Monopolar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1458875\">",
"      - Bipolar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1458882\">",
"      - Unipolar",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H87171147\">",
"      - Fractional",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22568009\">",
"      Photodynamic therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3581065\">",
"      Fractional lasers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22568025\">",
"      PATIENT EVALUATION AND MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3581168\">",
"      Preoperative counseling and treatment selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7958395\">",
"      Contraindications and preoperative measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22568039\">",
"      Anesthesia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22568046\">",
"      Techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22568053\">",
"      Post-operative management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3581222\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2782331\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/13645\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13645|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/15/39153\" title=\"figure 1\">",
"      Fractionated photothermolysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/34/22048\" title=\"figure 2A\">",
"      Chromophore absorption spectrum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?43/30/44516\" title=\"figure 2B\">",
"      Laser penetration into skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?15/8/15502\" title=\"figure 3\">",
"      Electromagnetic spectrum",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13645|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/1/13331\" title=\"picture 1\">",
"      Treatment of lentigines with intense pulsed light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/13645|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?24/38/25197\" title=\"table 1\">",
"      Grading scale for aging skin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/37/15963\" title=\"table 2\">",
"      Fitzpatrick skin phototypes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/56/39809\" title=\"table 3\">",
"      Topical corticosteroids",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/36/1610?source=related_link\">",
"      Ablative laser resurfacing for skin rejuvenation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/51/1847?source=related_link\">",
"      Keloids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/9/9370?source=related_link\">",
"      Laser and light therapy for cutaneous hyperpigmentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/47/17146?source=related_link\">",
"      Laser and light therapy for cutaneous vascular lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/54/23400?source=related_link\">",
"      Photoaging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/53/22360?source=related_link\">",
"      Principles of laser and intense pulsed light for cutaneous lesions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_6_42090="Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults";
var content_f41_6_42090=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of rheumatoid arthritis resistant to initial DMARD therapy in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42090/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42090/contributors\">",
"     Peter H Schur, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42090/contributors\">",
"     Stanley Cohen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42090/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42090/contributors\">",
"     James R O'Dell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?41/6/42090/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?41/6/42090/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?41/6/42090/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of rheumatoid arthritis (RA) is directed toward the control of synovitis and the prevention of joint injury. In patients whose condition is resistant to an initial course of treatment with disease-modifying antirheumatic drugs (DMARDs), such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , timely adjustments in the treatment regimens are required to achieve effective disease control and to prevent damage to the joints. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H6422708#H6422708\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Tight control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H111269724#H111269724\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Early use of DMARDs'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Support for an early aggressive approach to treatment is based upon the observations that joint damage, which may ultimately result in disability, begins early in the course of disease and that the longer that disease activity persists, the less likely the patient is to respond to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/1\">",
"     1",
"    </a>",
"    ]. Improved outcomes have resulted from the use of potent and well-tolerated nonbiologic (traditional) and biologic DMARDs used alone and in combination to induce and maintain tight control of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/2-10\">",
"     2-10",
"    </a>",
"    ]. These medications and strategies have the potential to control synovitis and to slow or even stop radiographic progression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/2,9,11,12\">",
"     2,9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The treatment of active RA resistant to initial DMARD therapies in adults will be reviewed here. The details of many of the clinical trials upon which this approach is based, the general principles of the management of RA, the initial treatment of RA, and the approach to RA patients with severe structural damage are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7385?source=see_link\">",
"     \"Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H21#H21\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Monitoring and reevaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37861?source=see_link\">",
"     \"Evaluation and medical management of end-stage rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=see_link\">",
"     \"Total joint replacement for severe rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22353727\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES AND APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2892723\">",
"    <span class=\"h2\">",
"     Principles of management",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several general principles that are important in the management of all patients with RA. Briefly, these include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Achievement and maintenance of tight control of disease activity, defined as remission or a state of low disease activity, without compromising safety",
"     </li>",
"     <li>",
"      Treatment of all patients diagnosed with RA with DMARD therapy",
"     </li>",
"     <li>",
"      Use of antiinflammatory therapies, including nonsteroidal antiinflammatory drugs (NSAIDs) and glucocorticoids, to help control symptoms until DMARDs take effect",
"     </li>",
"     <li>",
"      Evaluation and ongoing care by an expert in the treatment of RA, typically a rheumatologist",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These principles are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to determine whether joint symptoms in patients with persistently symptomatic RA are due to active inflammatory arthritis or are the result of structural damage that is unlikely to respond to antiinflammatory drugs and to nonbiologic or biologic DMARDs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H344392649#H344392649\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Assessment of disease activity'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5187547\">",
"    <span class=\"h2\">",
"     Definition of resistance to initial DMARDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Resistance to initial DMARD therapy is defined as one of the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Failure to achieve remission or low disease activity within three to six months of initiating",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) or other DMARD therapy in maximally tolerated doses within the usual therapeutic range (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361200#H7361200\">",
"       \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Remission'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link\">",
"       \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      A requirement, in addition to DMARDs, for chronic glucocorticoid therapy in a dose of greater than about 5 to 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or equivalent to achieve or maintain remission or low disease activity after three to six months of treatment with DMARDs",
"     </li>",
"     <li>",
"      A requirement for multiple courses with glucocorticoids, in excess of doses used for chronic therapy, for the treatment of recurrent disease flares in patients whose medication doses have been increased to the maximally tolerated or acceptable level",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Resistance or an inadequate response to subsequent DMARD therapy may be defined similarly, depending upon the treatment goals in an individual patient. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H6422708#H6422708\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Tight control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H2541292#H2541292\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Other considerations in RA management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186961554\">",
"    <span class=\"h2\">",
"     Nonpharmacologic and preventive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of nonpharmacologic measures and other medical interventions are important in the comprehensive management of RA, in addition to antiinflammatory and antirheumatic drug therapies. These interventions, including patient education, vaccinations, and others, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=see_link\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109283721\">",
"    <span class=\"h2\">",
"     Approach to drug therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients resistant to initial therapy with DMARDs, we either add additional DMARDs or switch the patient to a different DMARD or DMARD combination, while also treating the active inflammation with antiinflammatory drug therapy. The choice of DMARD therapy in patients resistant to initial DMARD treatment depends largely upon the responses to the specific medications that have been used previously. It is also influenced by patient preferences, especially for oral versus parenteral administration; by regulatory or insurance limitations on drug choice; by comorbidities; and by cost to the patient. A choice among these agents is dependent upon the initial DMARD therapy and upon disease activity. (See",
"    <a class=\"local\" href=\"#H2897438\">",
"     'Resistant to initial DMARD'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H2897446\">",
"     'Resistant to TNF inhibitor'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H109285125\">",
"     'Symptomatic drug therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Briefly, we generally take the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients treated for mildly active disease who have not responded adequately to initial therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (HCQ) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ) within three to six months, we add an alternative DMARD, usually",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX), or we administer &ldquo;triple therapy&rdquo; with HCQ, SSZ, and MTX. (See",
"      <a class=\"local\" href=\"#H109285579\">",
"       'Resistant to HCQ and/or SSZ'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients who have not achieved treatment goals after three to six months of MTX, we generally treat with MTX plus a tumor necrosis factor (TNF) inhibitor, particularly in patients with high levels of disease activity or with adverse prognostic features.",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       Abatacept",
"      </a>",
"      may be used as an alternative to a TNF inhibitor. (See",
"      <a class=\"local\" href=\"#H12087126\">",
"       'Resistant to MTX'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H12087392\">",
"       'Choice of therapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H7011196\">",
"       'MTX plus TNF inhibitor'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      &ldquo;Triple therapy&rdquo; is an acceptable alternative to MTX plus a TNF inhibitor. In patients who do not achieve a satisfactory response with this combination within three to six months, we discontinue SSZ and HCQ and continue to administer MTX while adding a TNF inhibitor. (See",
"      <a class=\"local\" href=\"#H12087126\">",
"       'Resistant to MTX'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H12087392\">",
"       'Choice of therapy'",
"      </a>",
"      below and",
"      <a class=\"local\" href=\"#H7013148\">",
"       'DMARD triple therapy'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients who do not respond adequately to therapy with MTX plus an initial TNF inhibitor within three to six months, we generally switch to a different TNF inhibitor and continue therapy with MTX. An alternative approach is switching to another biologic agent with a different mechanism of action in this setting rather than a second TNF inhibitor, particularly in patients who discontinue the initial TNF inhibitor due to an adverse reaction. (See",
"      <a class=\"local\" href=\"#H8152910\">",
"       'Resistant to one TNF inhibitor'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      In patients who do not respond adequately to the therapies above, including MTX and trials of one or two TNF inhibitors, we use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , or the kinase inhibitor",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"       tofacitinib",
"      </a>",
"      in place of the TNF inhibitor. (See",
"      <a class=\"local\" href=\"#H8152313\">",
"       'Resistant to two TNF inhibitors'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Importantly, we do NOT recommend combinations of biologic DMARDs, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    and a TNF inhibitor, or the combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    with either a TNF inhibitor or anakinra. Similarly, a biologic agent should not be combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    . These regimens are associated with an increased frequency of severe adverse effects, particularly serious infections, compared with combinations of a nonbiologic and biologic DMARD. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link\">",
"     \"General principles of management of rheumatoid arthritis in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3026408\">",
"    <span class=\"h1\">",
"     PRETREATMENT INTERVENTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of important precautions should be taken before using DMARDs, including laboratory assessment (complete blood count, serum creatinine, aminotransferases, and other studies as indicated), evaluation of comorbidities, vaccinations, and screening for hepatitis C, hepatitis B, and latent tuberculosis infection. Precautions relevant to the use of each new agent being prescribed should be reviewed before initiating such therapy to confirm that all appropriate measures have been performed. A chest radiograph should be obtained prior to initiating treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    . These issues are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=see_link&amp;anchor=H11#H11\">",
"     \"Nonpharmacologic and preventive therapies of rheumatoid arthritis\", section on 'Vaccinations'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=see_link\">",
"     \"Hepatitis B virus reactivation associated with immunosuppression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=see_link\">",
"     \"Diagnosis of latent tuberculosis infection in HIV-negative adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link&amp;anchor=H3#H3\">",
"     \"Major side effects of low-dose methotrexate\", section on 'Pulmonary toxicity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H111270327#H111270327\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2897438\">",
"    <span class=\"h1\">",
"     RESISTANT TO INITIAL DMARD",
"    </span>",
"    &nbsp;&mdash;&nbsp;The approach to patients resistant to initial DMARD therapy depends upon the treatment the patient has already been given. In patients with only mildly active disease when DMARDs were initiated,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) may have been started, and the patient may not have received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX). The next step at this point is starting MTX, either in place of or in addition to these agents. In patients who have already been treated with MTX, combination therapy of MTX with a biologic DMARD or additional nonbiologic DMARDs is the next step. (See",
"    <a class=\"local\" href=\"#H109285579\">",
"     'Resistant to HCQ and/or SSZ'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12087126\">",
"     'Resistant to MTX'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H12087392\">",
"     'Choice of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109285579\">",
"    <span class=\"h2\">",
"     Resistant to HCQ and/or SSZ",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients resistant to three to six months of therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ)for initially mildly active disease, we suggest adding an alternative DMARD, usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX); the approach in these patients is generally similar to that for patients with moderately to severely active disease presenting for initial DMARD therapy. An acceptable alternative would be treatment with a combination of HCQ, SSZ, and MTX, termed &ldquo;triple therapy.&rdquo; A therapeutic trial of greater than three months is generally used in patients with partial responses showing progressive improvement, particularly in those in this group with low levels of disease activity and with limited functional impairment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link&amp;anchor=H14#H14\">",
"     \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Monitoring and reevaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H3981583#H3981583\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Initial therapy with methotrexate'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We prefer MTX over alternative nonbiologic and biologic DMARDs in such patients for several reasons. MTX typically serves as the &ldquo;anchor&rdquo; drug for the most commonly used DMARD combinations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Randomized head-to-head trials have found that MTX has a faster onset of action, has comparable or greater efficacy, has better long-term tolerance, and improves survival, compared with other nonbiologic DMARD monotherapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. Direct comparisons of MTX with TNF inhibitor monotherapy have also shown comparable benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Additionally, those patients with an inadequate response to MTX can be quickly identified and subsequently treated prior to the development of irreversible injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/18-23\">",
"     18-23",
"    </a>",
"    ]. There is also some evidence that risk may be greater with biologic agents, and, frequently, there are regulatory or cost barriers to the use of biologic therapies in patients who have not been treated with MTX. Treatment with MTX is reviewed in detail separately, and the efficacy of such &ldquo;triple therapy&rdquo; with this DMARD combination is discussed in further detail below. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H3981583#H3981583\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Initial therapy with methotrexate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H207103444#H207103444\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'MTX versus other DMARDs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H207103451#H207103451\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'MTX versus initial combination therapy'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7011759\">",
"     'Efficacy of MTX/TNF inhibitor versus triple therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087126\">",
"    <span class=\"h2\">",
"     Resistant to MTX",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients resistant to MTX after three to six months of treatment at optimal doses, we suggest either the combination of continued MTX plus a tumor necrosis factor (TNF) inhibitor or the use of DMARD &ldquo;triple therapy&rdquo; with MTX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ), rather than monotherapy with another nonbiologic or biologic DMARD. In patients with partial responses showing progressive improvement, we may continue therapy with MTX for greater than three months before switching to one of these approaches, particularly in those with low to moderate levels of disease activity and with limited functional impairment. (See",
"    <a class=\"local\" href=\"#H12087392\">",
"     'Choice of therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7011196\">",
"     'MTX plus TNF inhibitor'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7013148\">",
"     'DMARD triple therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    , the T-cell costimulation blocker, is an alternative to TNF inhibitors for use in combination with MTX in patients with an inadequate response to MTX, but its use in this setting is supported by a smaller body of evidence than that for TNF inhibitor use. It can be administered intravenously or subcutaneously. Usual practice since TNF inhibitors came into clinical use beginning in the late 1990s has been to add a TNF inhibitor to MTX in patients with an inadequate response to MTX.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    have each generally been used in practice only following inadequate responses to both MTX and TNF inhibitors, although both of these biologic agents are available for use in the US for patients who have not responded adequately to MTX alone; their respective efficacy in such patients is supported by evidence from randomized trials, which are described separately. (See",
"    <a class=\"local\" href=\"#H7014295\">",
"     'MTX plus abatacept'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=see_link&amp;anchor=H5#H5\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Tocilizumab'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H1503703\">",
"     'Dosing and efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    A further alternative for patients resistant to or unable to take MTX is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    (LEF), an orally administered immunosuppressive agent, which may be used as monotherapy or in combination with either MTX or a TNF inhibitor. (See",
"    <a class=\"local\" href=\"#H12087392\">",
"     'Choice of therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7013910\">",
"     'Leflunomide'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H3982784#H3982784\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Alternatives to MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12087392\">",
"    <span class=\"h3\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of treatment options are reasonable in patients with an inadequate response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) therapy. The choice of drug combinations in such patients depends upon a combination of factors, including the level of disease activity, patient preference for route of administration, the presence of adverse prognostic features, and regulatory and cost barriers to drug access. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H344394776#H344394776\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We prefer combination therapy with MTX plus a TNF inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      ), particularly in patients with high levels of disease activity or with adverse prognostic features. It may have a faster onset of action compared with DMARD triple therapy. However, it requires subcutaneous injections or intravenous infusions, and regulatory or cost considerations may limit access. (See",
"      <a class=\"local\" href=\"#H7011196\">",
"       'MTX plus TNF inhibitor'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      We prefer triple therapy with MTX,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ), and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (HCQ) in patients for whom drug cost, regulatory restrictions on the use of biologic DMARDs, or preference for an oral agent that is not a biologic is an important factor. In addition, concern regarding the risk of serious infections, the uncertain long-term increased risk of malignancy, and other possible adverse effects may influence clinician or patient preference for nonbiologic agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/24-26\">",
"       24-26",
"      </a>",
"      ]. In those who do not achieve a satisfactory response with nonbiologic triple therapy within three to six months, we discontinue SSZ and HCQ and administer a TNF inhibitor with MTX. Some experts continue one or both of these medications, usually HCQ, when adding a TNF inhibitor, but this practice has not been formally evaluated or compared with other approaches. (See",
"      <a class=\"local\" href=\"#H7013148\">",
"       'DMARD triple therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       Abatacept",
"      </a>",
"      may be used as an alternative to a TNF inhibitor in patients in whom MTX plus a TNF inhibitor would otherwise be appropriate, particularly in patients unable to use a TNF inhibitor and in patients with a high level of disease activity. It may have a faster onset of action than triple therapy or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      (LEF). We generally prefer a TNF inhibitor over abatacept because the data supporting the use of abatacept are more limited than those available for the TNF inhibitors, although they suggest comparable benefit. (See",
"      <a class=\"local\" href=\"#H7014295\">",
"       'MTX plus abatacept'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      LEF may be of particular benefit for patients in whom regulatory or cost considerations preclude use of a biologic agent, despite failure of MTX to adequately control disease activity. It can be used in place of MTX in those patients who do not tolerate MTX, or it can be used in combination with MTX instead of adding a biologic agent, with appropriate monitoring of liver function tests. It is also an option for patients who prefer not to use a parenterally administered drug. (See",
"      <a class=\"local\" href=\"#H7013910\">",
"       'Leflunomide'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7011196\">",
"    <span class=\"h3\">",
"     MTX plus TNF inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients resistant to MTX, particularly those with high levels of disease activity or with adverse prognostic features, we prefer combination therapy with MTX plus a TNF inhibitor. We usually use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (50 mg administered subcutaneously once weekly) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (40 mg administered subcutaneously every two weeks) as the initial TNF inhibitor in combination with continued MTX therapy, after appropriate pretreatment measures have been performed. An alternative TNF inhibitor in patients who prefer therapy by intravenous infusions is",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (usually 3 to 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight weeks after an initial loading schedule at zero, two, and six weeks). Other alternative TNF inhibitors include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H186961554\">",
"     'Nonpharmacologic and preventive therapies'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H3026408\">",
"     'Pretreatment interventions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients with an inadequate response to MTX, the use of combination therapy with the addition of a TNF inhibitor is supported by multiple randomized trials and meta-analyses that demonstrate the superiority of this approach compared with adding placebo while continuing the MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/24,27-30\">",
"     24,27-30",
"    </a>",
"    ]. The American College of Rheumatology (ACR) 20 percent response (ACR20), ACR50, and ACR70 are composite measures reflecting at least 20, 50, and 70 percent improvement in several defined measurements of disease activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/31\">",
"     31",
"    </a>",
"    ]. Trials of MTX plus a TNF inhibitor in patients who have not responded adequately to MTX alone typically result in ACR20, ACR50, and ACR70 response rates of about 60, 40, and 20 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/28\">",
"     28",
"    </a>",
"    ]. Indirect comparisons of the biologic agents in meta-analyses of randomized trials involving patients with an inadequate response to MTX have shown a statistically nonsignificant trend suggesting that TNF inhibitors may be more likely to result in an ACR50 response compared with other biologic agents (odds ratio [OR] 1.30, 95% CI 0.91-1.86) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361109#H7361109\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'ACR response criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meta-analyses and randomized trials have also shown that combination therapy of MTX with a biologic agent, such as a TNF inhibitor, is superior to biologic or traditional DMARD monotherapy in patients who are na&iuml;ve to DMARDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/19,24,29,33,34\">",
"     19,24,29,33,34",
"    </a>",
"    ]. However, in patients who have had an inadequate response to MTX, most randomized trials have continued MTX while adding either a biologic or a placebo. A small number of randomized trials and retrospective studies have evaluated the relative benefits of adding a biologic agent to MTX compared with biologic monotherapy; results range from showing small, statistically nonsignificant advantages for combination therapy to demonstrating substantial added benefit that is both statistically and clinically significant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/35-42\">",
"     35-42",
"    </a>",
"    ]. Trials of biologic DMARDs and data supporting their use in patients with active RA are described in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7385?source=see_link\">",
"     \"Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10410?source=see_link\">",
"     \"Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The evidence comparing the efficacy and safety of MTX plus a TNF inhibitor in this setting with those of nonbiologic DMARD triple therapy and with those of MTX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    are described in detail below. (See",
"    <a class=\"local\" href=\"#H7011759\">",
"     'Efficacy of MTX/TNF inhibitor versus triple therapy'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7012229\">",
"     'Efficacy of MTX/TNF inhibitor versus MTX/abatacept'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is no convincing evidence that any one of the TNF inhibitors has greater efficacy than the others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/43\">",
"     43",
"    </a>",
"    ]. The choice of TNF inhibitor depends upon regulatory or insurance restrictions on drug choice, upon safety issues, and upon patient preference for route",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    frequency of injection.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     Etanercept",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    might be safer than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25,27,44\">",
"     25,27,44",
"    </a>",
"    ]. However, comparisons between these agents are largely indirect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25,27\">",
"     25,27",
"    </a>",
"    ]; additionally, a case control study suggesting greater safety with etanercept, compared with infliximab or adalimumab, only addressed the risk of reactivation of latent tuberculosis in patients who had not received adequate chemoprophylaxis prior to therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/44\">",
"     44",
"    </a>",
"    ]. Indirect comparisons of randomized trial results in a network meta-analysis suggested that patients receiving etanercept, adalimumab, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    had statistically significantly lower rates of withdrawal from trials due to adverse effects compared with infliximab (OR 0.63, 95% CI 0.41-0.95; OR 0.50, 95% CI 0.32-0.78; and OR 0.55, 95% CI 0.30-0.99) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    TNF inhibitor therapy is generally well-tolerated, but these medications pose increased risk of reactivation of latent tuberculosis and of new infection with other granulomatous diseases (eg, histoplasmosis and coccidiomycosis) or with varicella zoster. Adverse effects include injection-site reactions, infusion reactions, mildly reduced neutrophil counts and cytopenias, serious common and opportunistic infections, reactivation of hepatitis B, autoimmune phenomena including multiple sclerosis, and hepatotoxicity. There is no proof of increased risk of malignancy with these agents in analyses of short-term randomized trial data, and results of a large population-based long-term study of patients with RA are encouraging [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. However, further long-term studies are required. TNF inhibitors should not be administered to patients with active infections, and they are relatively contraindicated in patients with multiple sclerosis or congestive heart failure. The adverse effects of TNF inhibitor therapy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7011759\">",
"    <span class=\"h4\">",
"     Efficacy of MTX/TNF inhibitor versus triple therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have compared the combination of MTX plus a TNF inhibitor with DMARD triple therapy combining MTX plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/47-49\">",
"     47-49",
"    </a>",
"    ]; the trials found only small or no differences in clinical efficacy using composite measures of disease activity (ACR20 responses of approximately 35 to 50 percent after one or two years). Radiographic outcomes only slightly favored TNF inhibitor use, but these differences did achieve statistical significance. Limitations in trial design and the use of different TNF inhibitors in the published reports preclude adequate direct comparisons of the regimens in the two trials. Both trials included a step-up design, in which patients were randomly assigned (either before or after initial treatment with MTX) to receive one of the two treatment options following an inadequate response to MTX:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Swefot trial",
"      </strong>",
"      &mdash; The Swedish Pharmacotherapy (Swefot) trial compared the efficacy of MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      with that of triple therapy using MTX, SSZ, and HCQ [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/47,48\">",
"       47,48",
"      </a>",
"      ]. This randomized but non-blinded trial involved 258 patients with RA of less than one year in duration who had not achieved low disease activity within three to four months of starting treatment with MTX alone (20 mg once weekly). Differences between the groups were not significant at six or nine months, but, by one year (nine months after randomization and one year after initiating DMARD therapy with MTX alone), there was a significantly higher proportion of good responders (by the European League Against Rheumatism [EULAR] response criteria) among the group receiving infliximab (39 versus 25 percent, risk ratio [RR] 1.59, 95% CI 1.10-2.30). However, by two years, this difference was reduced, and the trend toward a higher frequency of good responders in the infliximab group was no longer statistically significant (38 versus 31 percent, RR 1.31, 95% CI 0.93-1.85). A similar proportion of each group achieved an ACR20 response at two years (40 versus 33 percent). Interpretation of these results is hampered by the open design of this trial and by the switching of patients to alternate therapies within the trial.",
"      <br/>",
"      <br/>",
"      Radiographic outcomes at two years favored the infliximab group, but the treatment differences were of uncertain clinical significance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/48\">",
"       48",
"      </a>",
"      ]. At 24 months, the mean increases in the van der Heijde-modified Sharp score (score range 0 to 448, reflecting radiographic detection of joint damage) were statistically significantly lower in the patients receiving infliximab compared with those receiving conventional DMARD triple therapy (4 versus 7.23, for a treatment difference of 3.23, 95% CI 0.14-6.32). However, this difference between treatments was less than 5, which is considered the minimum clinically important difference using this scoring system [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       TEAR trial",
"      </strong>",
"      &mdash; The Treatment of Early Aggressive Rheumatoid Arthritis (TEAR) trial, which included 755 patients with poor prognosis early RA, compared the efficacy of therapy for active RA in four groups over two years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/49\">",
"       49",
"      </a>",
"      ]. Previous receipt of a biologic agent was an exclusion criterion; patients were randomly assigned in this double-blind trial to receive one of the following: immediate treatment with MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ; immediate treatment with DMARD triple therapy (MTX plus SSZ and HCQ); step-up from MTX to MTX plus etanercept at week 24, if the Disease Activity Score 28 using erythrocyte sedimentation rate (DAS28-ESR) was &ge;3.2 (moderate or greater disease activity); and step-up from MTX to triple therapy at week 24, if the DAS28-ESR was &ge;3.2.",
"      <br/>",
"      <br/>",
"      Clinical outcomes (DAS28 scores) were comparable at 24 weeks in the two immediate combination therapy groups, which together showed a significantly greater reduction in disease activity compared with the two step-up groups (DAS28-ESR decrease of 4.2 versus 3.6) at this time point (prior to stepping up to combination therapy). Patients on MTX alone who had not reached the target of low disease activity at 24 weeks stepped up either to MTX plus etanercept or to triple therapy at that time. Clinical outcomes, measured by the DAS28-ESR scores, were comparable during weeks 48 to 102 in patients receiving MTX plus etanercept or receiving triple therapy, regardless of whether they were initially assigned to immediate or step-up therapy. Similar proportions of all four groups achieved an ACR20 at two years (approximately 45 to 50 percent). At two years, the immediate combination groups did not differ clinically or radiographically from the step-up combination groups. However, radiographic outcomes at week 102 slightly but statistically significantly favored those who received MTX plus etanercept (increased van der Heijde-modified Sharp score of 0.64 versus 1.69 on a scale of 0 to 448). There was no difference in the frequency of overall adverse effects or of serious adverse effects between the treatment groups.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7012229\">",
"    <span class=\"h4\">",
"     Efficacy of MTX/TNF inhibitor versus MTX/abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two randomized trials have compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    with a TNF inhibitor for use in combination with continued MTX therapy in patients with an inadequate response to MTX, suggesting comparable benefit and safety of the two regimens, with 60 to 70 percent of patients achieving an ACR20 response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       ATTEST trial",
"      </strong>",
"      &mdash; In the &ldquo;",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       Abatacept",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      versus placebo, a Trial for Tolerability, Efficacy, and Safety in Treating rheumatoid arthritis&rdquo; (ATTEST) trial, 431 patients with active RA and with an inadequate response to MTX were randomly assigned to receive abatacept (500, 750, or 1000 mg in patients weighing &lt;60 kg, 60 to 100 kg, or &gt;100 kg, respectively, by intravenous infusion on days 1, 15, and 29, then every four weeks), infliximab (3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      by intravenous infusion on days 1, 15, 43, and 85, then every eight weeks), or placebo infusions, while continuing background MTX [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/51\">",
"       51",
"      </a>",
"      ]. After six months, use of either abatacept or infliximab resulted in significantly greater benefit compared with placebo (ACR20 responses of 67 and 59 percent versus 42 percent, respectively). After one year of treatment, the frequency of ACR20 responses with abatacept plus MTX was statistically significantly greater than with infliximab plus MTX (72 versus 56 percent). An increase in the dose or frequency of infliximab, which may occur in clinical practice in infliximab-inadequate responders, was not allowed in the trial, but the patients receiving abatacept had numerically fewer serious adverse events (10 versus 18 percent) and serious infections (2 versus 9 percent), compared with those receiving the trial dose of infliximab.",
"     </li>",
"     <li>",
"      <strong>",
"       AMPLE trial",
"      </strong>",
"      &mdash; A preliminary report of the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       Abatacept",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       Adalimumab",
"      </a>",
"      Comparison in Biologic-Na&iuml;ve RA Subjects with Background",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      (AMPLE) trial, involving 646 patients with active RA and with an inadequate response to MTX, found comparable clinical and radiographic responses to MTX plus abatacept (125 mg administered subcutaneously weekly) and to MTX plus adalimumab (40 mg administered subcutaneously every two weeks) at one year (ACR20 of 65 and 63 percent, respectively, and increased modified total Sharp scores of 0.58 and 0.38 on a scale of 0 to 448, respectively) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/52\">",
"       52",
"      </a>",
"      ]. Rates of adverse effects, including infections, were similar between the two groups. (See",
"      <a class=\"local\" href=\"#H7011759\">",
"       'Efficacy of MTX/TNF inhibitor versus triple therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7013148\">",
"    <span class=\"h3\">",
"     DMARD triple therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients resistant to MTX as the sole DMARD, for whom drug cost, regulatory restrictions on the use of biologic DMARDs, or preference for an oral agent that is not a biologic is an important factor, we prefer triple therapy with MTX,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    (SSZ), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"     hydroxychloroquine",
"    </a>",
"    (HCQ). Drug dosing is as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      MTX is continued at the maximum tolerated dose achieved with initial therapy up to 25 mg once weekly. The use of MTX in RA and the adverse effects of MTX are described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link\">",
"       \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=see_link\">",
"       \"Major side effects of low-dose methotrexate\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link\">",
"       \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      SSZ is gradually increased from 500 mg once daily to 1000 mg twice daily. The use of SSZ in RA and the adverse effects of SSZ are described in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=see_link\">",
"       \"Sulfasalazine in the treatment of rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link&amp;anchor=H10#H10\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Patients with mild activity and poor prognostic signs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      HCQ is used at a dose of 400 mg daily in most patients but does not exceed 6.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      calculated on the basis of lean body weight. The use of HCQ in rheumatic disease, including RA, as well as the dosing, adverse effects, and monitoring of HCQ, is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=see_link\">",
"       \"Antimalarial drugs in the treatment of rheumatic disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link&amp;anchor=H20660556#H20660556\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Patients who lack poor prognostic features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment with the triple therapy regimen is usually well-tolerated, with adverse effects comparable to MTX alone, and the available evidence indicates that switching to a regimen containing a biologic agent in patients who do not first respond adequately to a three- to six-month trial of triple therapy results in similar patient outcomes compared with having started a biologic agent sooner. The evidence describing the efficacy of triple therapy in patients who have had an inadequate response to MTX and comparing triple therapy with the combination of MTX plus a TNF inhibitor are described above; the efficacy and safety of DMARD triple therapy compared with other nonbiologic DMARDs used singly or in combination are described separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/98?source=see_link\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7385?source=see_link\">",
"     \"Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H7011759\">",
"     'Efficacy of MTX/TNF inhibitor versus triple therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7013515\">",
"    <span class=\"h3\">",
"     Alternatives to MTX/TNF inhibitor and to triple therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some patients resistant to initial DMARD therapy with MTX, the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    as an alternative biologic to a TNF inhibitor or the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    , an orally administered nonbiologic DMARD, in place of or in addition to MTX may be appropriate. We suggest the combination of MTX plus abatacept in patients in whom MTX plus a TNF inhibitor would otherwise be appropriate, particularly in patients who are unable to use a TNF inhibitor and who have a high level of disease activity. We suggest either switching to leflunomide (LEF) or adding LEF to ongoing MTX as therapeutic options for patients in whom regulatory or cost considerations preclude use of a biologic agent, despite failure of MTX to adequately control disease activity. (See",
"    <a class=\"local\" href=\"#H12087392\">",
"     'Choice of therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7014295\">",
"     'MTX plus abatacept'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H7013910\">",
"     'Leflunomide'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7014295\">",
"    <span class=\"h4\">",
"     MTX plus abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     Abatacept",
"    </a>",
"    may be used as an alternative to a TNF inhibitor. In patients for whom MTX plus abatacept is the choice of therapy following an inadequate response to MTX, abatacept can be administered intravenously (IV) every four weeks (750 mg per dose for patients 60 to 100 kg, adjusted for lower or higher weight to 500 or 1000 mg, respectively) after the three initial doses given at two-week intervals, or it can be administered subcutaneously (SC) (125 mg once weekly, with or without an intravenous loading dose given on the first week before starting SC dosing the following week). The decision regarding route of administration can be based upon patient preference. We generally use abatacept in combination with continued MTX therapy, after appropriate pretreatment measures have been performed, but it may also be administered as monotherapy or in combination with other nonbiologic DMARDs. It should not be used in combination with other biologic DMARDs, such as TNF inhibitors or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"     anakinra",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Meta-analyses of multiple randomized trials have documented the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    compared with placebo for use either alone or in combination with nonbiologic DMARDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25,53,54\">",
"     25,53,54",
"    </a>",
"    ]. In a systematic review and in indirect comparisons of randomized trial results from a network meta-analysis of biologic agents in patients with an inadequate response to MTX, the combination of abatacept with MTX was significantly more effective compared with MTX alone (ACR50 at 24 weeks of 32 versus 12 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/53\">",
"     53",
"    </a>",
"    ]. Abatacept was comparable to other biologic agents, including several TNF inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    . Evidence describing the benefits of abatacept compared with placebo in patients who have had an inadequate response to a TNF inhibitor is further reviewed below. (See",
"    <a class=\"local\" href=\"#H8152313\">",
"     'Resistant to two TNF inhibitors'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H1503703\">",
"     'Dosing and efficacy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Only a few trials have directly compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    with another active DMARD. These include two randomized trials described above, which have suggested comparable benefit of abatacept to TNF inhibitor therapy when either is used in combination with continued MTX in patients with an inadequate response to MTX therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7012229\">",
"     'Efficacy of MTX/TNF inhibitor versus MTX/abatacept'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The efficacy and safety of subcutaneous and intravenous administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    were comparable in a randomized trial involving 1457 patients with a previously inadequate response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/55\">",
"     55",
"    </a>",
"    ]. The efficacy of abatacept SC (125 mg SC on days one and eight, then weekly, plus an IV loading dose on day one of approximately 10",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    was comparable to abatacept IV (approximately 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV on days 1, 15, and 29, then every four weeks) in achieving an ACR20 response after six months of treatment (both 76 percent). The onset and magnitude of the responses, disease activity, improvements in physical function, and adverse effects were also comparable. Injection site reactions were mostly mild and were as frequent in patients receiving the active SC drug as in those receiving SC placebo (2.5 to 2.6 percent).",
"   </p>",
"   <p>",
"    Potential adverse effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    include infusion reactions, which may occur within an hour after beginning the intravenous administration of the drug and which may be characterized by headache, dizziness, and hypertension; anaphylactoid reactions are rare. Abatacept also appears to increase the risk of serious infections, including pneumonia, pyelonephritis, cellulitis, and diverticulitis. A definite association with tuberculosis has not been shown. The overall safety of abatacept appears comparable to or, possibly, slightly better than that of the TNF inhibitors, although there are few direct comparisons. An indirect comparison of biologic agents in data from a 2011 meta-analysis of randomized trials and extension studies showed a statistically nonsignificant trend for abatacept compared with the other agents toward fewer serious adverse events (OR 0.65, 95% CI 0.42-1.01) and serious infections (OR 0.57, 95% CI 0.30-1.08), while other biologics generally showed similar risks compared with each other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25\">",
"     25",
"    </a>",
"    ]. Additional evidence supporting the use and safety of abatacept in RA is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7013910\">",
"    <span class=\"h4\">",
"     Leflunomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with an inadequate response to MTX, some, but not all, experts advocate either switching to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    (LEF) or adding LEF to ongoing MTX therapy. The use of LEF alone, without MTX, is preferred in the absence of clinical improvement from prior treatment with the maximally tolerated dose of MTX within the usual therapeutic range, as well as in patients in whom there is a greater degree of concern for the possible increased risk of side effects with the combination of LEF and MTX. Although both drugs are potentially hepatotoxic, the rationale for combined therapy is based upon their differing mechanisms of action. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=see_link&amp;anchor=H3#H3\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\", section on 'Mechanism of action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients in whom LEF is used in place of MTX, the usual dose is 20 mg daily. Reduced dosing with either LEF (10 instead of 20 mg daily) or MTX (eg, 15 mg instead of 20 to 25 mg weekly) should be used initially if the drugs are used in combination; the dose is then increased incrementally no more frequently than monthly to usual maximal doses if it is required clinically and if there is no evidence of toxicity. Some experts continue to use a loading dose of LEF (100 mg daily for the first three days of therapy) in patients given LEF monotherapy, but other experts avoid the use of a loading dose because of increased risk of frequent bowel movements and of diarrhea with this approach. The use of LEF in patients with RA is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of LEF was superior to placebo and was comparable to MTX in a systematic review of six randomized trials including comparisons of LEF with placebo",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    MTX, suggesting approximately twice the likelihood compared with placebo of achieving an ACR20 response at 6 or 12 months for either LEF or MTX [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/56\">",
"     56",
"    </a>",
"    ]. In one trial involving 482 patients, for example, an ACR20 at one year was achieved in a similar proportion of patients on LEF or on MTX, and this rate was significantly higher than that seen with placebo (52 and 46 percent versus 26 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/57\">",
"     57",
"    </a>",
"    ]. However, these trials have been criticized for using lower maximum doses of MTX (up to 15",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    than those that have subsequently been commonly employed (up to 25",
"    <span class=\"nowrap\">",
"     mg/week)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. LEF had comparable efficacy to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    at 12 months of therapy in patients with an inadequate response to MTX (ACR50 of 40 versus 42 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/59\">",
"     59",
"    </a>",
"    ]; however, LEF has not been compared directly with other agents in such patients. LEF has not been directly compared with the TNF inhibitors, but the superiority of TNF inhibitors is suggested by the comparability of LEF to sometimes suboptimal doses of MTX and to SSZ; by the more rapid effects and greater overall benefit of TNF inhibitors when they have been directly compared with MTX or SSZ; and by clinical experience. The trial data that support the efficacy of LEF in the treatment of RA, including its use together with MTX, and the adverse effects of LEF are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H207103444#H207103444\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'MTX versus other DMARDs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7385?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults\", section on 'MTX-leflunomide'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=see_link\">",
"     \"Leflunomide in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"     leflunomide",
"    </a>",
"    and MTX is effective in patients who have not responded adequately to MTX alone. As an example, in a randomized trial of 263 patients, LEF or placebo was added to existing MTX therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/60\">",
"     60",
"    </a>",
"    ]. At 24 weeks, the proportion of patients who met ACR20 criteria for improvement was significantly higher with LEF compared with placebo (46 versus 20 percent). The combination was well-tolerated. The rate of discontinuation and the incidence of adverse events, which were predominantly mild or moderate, were similar in the two groups. Diarrhea and elevation of serum aminotransferases were the only adverse effects seen significantly more often with LEF plus MTX than with placebo plus MTX. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/98?source=see_link&amp;anchor=H11#H11\">",
"     \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\", section on 'Leflunomide and MTX'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients on both LEF and MTX may require closer monitoring (eg, monthly aminotransferase testing) for hepatotoxicity, given the increased risk of hepatotoxicity in some but not most studies, including reports of fatal liver failure [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/61-63\">",
"     61-63",
"    </a>",
"    ]. Other adverse effects of LEF include diarrhea, alopecia, myelosuppression, hypertension, and rash.",
"   </p>",
"   <p>",
"    In patients with an inadequate response to initial treatment with LEF alone, a TNF inhibitor may be added to LEF. An analysis of patients with RA in a large population database from Switzerland indicated that the addition of a TNF inhibitor was beneficial in patients with persistent disease activity on LEF alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/64\">",
"     64",
"    </a>",
"    ]. However, randomized trials to prospectively evaluate the efficacy and safety of LEF used together with a biologic DMARD have not been performed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7385?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults\", section on 'Leflunomide-TNF inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2897506\">",
"    <span class=\"h1\">",
"     REEVALUATION AND MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease activity and the response to therapy should be regularly reassessed, along with monitoring for drug toxicities, every four to eight weeks following a change in the treatment regimen until the patient is stable and until disease is under control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/9,65-67\">",
"     9,65-67",
"    </a>",
"    ]. Subsequently, assessments should not be less frequent than every three months. More frequent laboratory monitoring may be required depending upon the medications being used and following increases in dosing; more frequent clinical assessments may be required in patients experiencing a flare of disease or in those undergoing changes in therapy. Well-controlled patients who are seen less frequently may require laboratory monitoring beyond that performed at scheduled visits and should be counseled, as should all patients, to contact their treating clinician if the arthritis flares. Laboratory testing for the monitoring of disease activity and for the monitoring and prevention of drug toxicity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H111270327#H111270327\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Pretreatment evaluation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H111270903#H111270903\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Assessment and monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We periodically reevaluate disease activity using a quantitative composite measure at each assessment (eg, the Clinical Disease Activity Index [CDAI] or the Disease Activity Score [DAS] with 28 joint count [DAS28]). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H6422708#H6422708\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Tight control'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H344392649#H344392649\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Assessment of disease activity'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who fail to achieve remission or low disease activity within three to six months of initiating therapy or who require more than 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or equivalent glucocorticoid to maintain a state of remission should generally receive a more potent DMARD or combination of DMARDs. A therapeutic trial of greater than three months is generally used in patients with partial responses showing progressive improvement, particularly in those with low to moderate levels of disease activity and with limited functional impairment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2897446\">",
"    <span class=\"h1\">",
"     RESISTANT TO TNF INHIBITOR",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8152910\">",
"    <span class=\"h2\">",
"     Resistant to one TNF inhibitor",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond adequately to therapy with an initial TNF inhibitor within three months, we suggest switching to a different TNF inhibitor and continuing therapy with MTX. In such patients, we usually use one of the three more established TNF inhibitors (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ), rather than one of the newer agents with which there is less experience (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    ). An inadequate response to one anti-TNF agent does not predict resistance to other agents in this class, although inefficacy and discontinuation rates increase with successive switches. (See",
"    <a class=\"local\" href=\"#H5187547\">",
"     'Definition of resistance to initial DMARDs'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Some experts advocate switching to another class of biologic in patients who have experienced a serious adverse event (as defined by the US Food and Drug Administration [FDA]) with an initial TNF inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/68\">",
"     68",
"    </a>",
"    ]. The FDA definition of a serious adverse event includes an adverse event associated with the use of a medical product that resulted in a life-threatening event, in hospitalization, prolongation of a hospitalization, in disability or permanent damage, in a congenital anomaly or birth defect in a child of a parent using the medication, or in an adverse event requiring intervention to prevent permanent impairment or damage.",
"   </p>",
"   <p>",
"    Limited randomized trials, several large registry-based studies, and case series have demonstrated the benefit of switching from one biologic DMARD to another, if inefficacy or toxicity limits the use of a given agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/69-79\">",
"     69-79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best data illustrating that switching to a second TNF inhibitor after discontinuation of a first is effective are from a randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    as the second agent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/70\">",
"     70",
"    </a>",
"    ]. There is more limited clinical experience with golimumab than with several of the other TNF inhibitors, and its role relative to other TNF inhibitors in RA treatment remains to be better defined. In this trial, 461 patients with active RA despite prior use of at least one TNF inhibitor were randomly assigned to golimumab or placebo while continuing stable doses of baseline nonbiologic DMARDs (MTX, SSZ,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    HCQ), glucocorticoids, and nonsteroidal antiinflammatory drugs. The prior TNF inhibitor could have been discontinued due either to ineffectiveness (58 percent) or to other factors unrelated to effectiveness, including intolerance or inaccessibility (53 percent); some discontinued the first TNF inhibitor for multiple reasons. Among those who had discontinued the first TNF inhibitor due to lack of effectiveness, patients in the combined golimumab group (who received either 50 or 100 mg every four weeks) were significantly more likely to achieve an ACR20 or higher response at week 14 (39 versus 18 percent). Patients who discontinued the first drug for reasons other than ineffectiveness were also more likely to achieve at least an ACR20 response with golimumab (34 versus 20 percent). There was no increase in serious adverse events in patients on golimumab compared with those on placebo. The results of this trial are consistent with findings from observational studies of other TNF inhibitors.",
"   </p>",
"   <p>",
"    The relative benefits of switching to a second or a third TNF inhibitor (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    ) were examined in a prospective observational study of 373 patients in the South Swedish Arthritis Treatment Group register [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/73\">",
"     73",
"    </a>",
"    ]. After three months of treatment, patients receiving their first compared with their second anti-TNF agent and patients receiving their second compared with their third anti-TNF agent were more likely to achieve an ACR20 (61 versus 51 versus 35 percent, respectively) or ACR50 response (37 versus 27 versus 18 percent, respectively). European League Against Rheumatism (EULAR) overall response rates in the three groups were 76 versus 71 versus 58 percent.",
"   </p>",
"   <p>",
"    No direct comparisons have been performed of different biologic agents in patients who have had an inadequate response to a TNF inhibitor; indirect comparisons based upon data from the small number of available trials have not shown significant differences in benefit between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/24/35206?source=see_link\">",
"     golimumab",
"    </a>",
"    and biologic DMARDs from other classes with which there are much less experience in this setting, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/32,80\">",
"     32,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8152313\">",
"    <span class=\"h2\">",
"     Resistant to two TNF inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who do not respond adequately to three- to six-month trials of the therapies above, including trials of MTX and trials of two TNF inhibitors, or who are unable to take a TNF inhibitor, we suggest the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , biologic agents which may all be effective in patients who have not responded adequately to MTX plus a TNF inhibitor.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     Tofacitinib",
"    </a>",
"    , the orally administered kinase inhibitor available for use in the US, is also an alternative in this setting, although there is very limited experience with this agent, and its role will be better defined over time with wider use and further study.",
"   </p>",
"   <p>",
"    Because the likelihood of a response decreases with second switches of TNF inhibitors, a change to a biologic DMARD other than a TNF inhibitor is suggested after the failure of two such agents. There are no randomized trials that have evaluated this hypothesis. (See",
"    <a class=\"local\" href=\"#H8152910\">",
"     'Resistant to one TNF inhibitor'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In patients who discontinue the second TNF inhibitor, analyses of data from a large national patient registry in Great Britain suggested that discontinuation was primarily due to the same reason for which the first drug was stopped (inefficacy or toxicity) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7014677\">",
"    <span class=\"h3\">",
"     Choice of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The choice between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    depends upon several factors, which vary in importance in different patients. These factors include patient preference; regulatory, insurance, and cost limitations; comorbidities; and clinician experience. They have not been directly compared, but abatacept, tocilizumab, and rituximab appear comparable in indirect comparisons of randomized trial data in a meta-analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/80\">",
"     80",
"    </a>",
"    ]. We generally take the following approach:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We usually use",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      as the first choice in this group of patients in the seropositive subset. In seronegative patients, we prefer abatacept or tocilizumab. In patients who experience adverse effects from these agents, the immunosuppressive or immunomodulatory actions of abatacept or tocilizumab are more rapidly reversed than those of rituximab, whose effects may last for several months or longer. Additionally, rituximab use may be very rarely associated with devastating illness due to reactivation of the polyomavirus JC (JC virus), progressive multifocal leukoencephalopathy (PML). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"       \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=see_link\">",
"       \"Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In older patients with more comorbidities, we prefer",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      . There is more limited experience with tocilizumab than with abatacept or rituximab, and some concerns remain regarding potential toxicity. Indirect comparisons suggest that abatacept may have fewer adverse effects than the other biologic agents used in RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       Rituximab",
"      </a>",
"      may be preferred in patients in whom monthly drug administration may be problematic, as a treatment course of two IV infusions is administered no more frequently than every six months. Patients with rheumatoid factor or with anti-citrullinated peptide antibodies may have a greater response to the drug than seronegative patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/81,82\">",
"       81,82",
"      </a>",
"      ]. Otherwise, the efficacy and safety of rituximab in patients with RA appear similar to those of other biologic agents [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25,83\">",
"       25,83",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The relative role of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"       tofacitinib",
"      </a>",
"      in patients who have had an inadequate response to other DMARDs is unclear. A potential advantage of this medication is that it is administered orally, but data regarding the risk of adverse events and outcomes with this drug compared with other antirheumatic medications are more limited compared with what is known regarding other available agents.",
"     </li>",
"     <li>",
"      We prefer these agents over",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      , as they all appear more effective than anakinra, based upon their comparability to biologic DMARDs that have been shown superior to anakinra in indirect comparisons [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/27\">",
"       27",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H266402509\">",
"       'Resistant to standard therapies'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1503703\">",
"    <span class=\"h3\">",
"     Dosing and efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing, efficacy, and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    are described below:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110291223\">",
"    <span class=\"h4\">",
"     Abatacept",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dosing and administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    in patients with RA are described elsewhere in this topic review, and the use of abatacept in patients with RA in general, evidence supporting such use, and the adverse effects of abatacept are also reviewed in detail separately. (See",
"    <a class=\"local\" href=\"#H7014295\">",
"     'MTX plus abatacept'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H7012229\">",
"     'Efficacy of MTX/TNF inhibitor versus MTX/abatacept'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=see_link&amp;anchor=H5#H5\">",
"     \"T cell targeted therapies for rheumatoid arthritis\", section on 'Abatacept'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A randomized trial and larger open-label study have described the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    compared with placebo in patients who have had an inadequate response to a TNF inhibitor [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/75,84\">",
"     75,84",
"    </a>",
"    ]. In the randomized trial, involving 391 patients, patients receiving abatacept were significantly more likely compared with placebo-treated patients to achieve at least 20 percent improvement in the level of disease activity after 24 weeks of therapy (ACR20 of 50 versus 20 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/75\">",
"     75",
"    </a>",
"    ]. The rate of serious infections was the same in both groups (2.3 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110291231\">",
"    <span class=\"h4\">",
"     Tocilizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    , a humanized anti-human interleukin (IL)-6 receptor antibody, is administered intravenously every four weeks (at an initial dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per infusion, which may be increased to 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per infusion, based upon the clinical response, to a maximum of 800",
"    <span class=\"nowrap\">",
"     mg/infusion).",
"    </span>",
"    The efficacy and safety of tocilizumab in RA have been characterized in meta-analyses of randomized trials of the drug as monotherapy or together with MTX compared with placebo. This evidence is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=see_link&amp;anchor=H5#H5\">",
"     \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Tocilizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     Tocilizumab",
"    </a>",
"    has been effective in patients with RA who have not responded adequately to TNF inhibitors. In a randomized trial involving 499 patients with an inadequate response to TNF inhibitor therapy, the use of tocilizumab (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    administered intravenously every four weeks, respectively), together with continued treatment with MTX, significantly improved treatment outcomes at six months compared with placebo plus MTX (ACR20 of 50 and 30 percent versus 10 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/77\">",
"     77",
"    </a>",
"    ]. Substantial improvement was noted within four weeks and may be maintained for at least several years in long-term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/79\">",
"     79",
"    </a>",
"    ]. The rates of serious adverse events, serious infections, and adverse events leading to drug discontinuation were similar in all three groups; adverse events that were numerically more common in patients on tocilizumab included infections (49 and 47 percent versus 41 percent), gastrointestinal symptoms (37 and 33 percent versus 19 percent), and rash (22 and 31 percent versus 14 percent).",
"   </p>",
"   <p>",
"    A dose adjustment or drug discontinuation may be required in patients with significant liver enzyme (aminotransferase) elevations, neutropenia, or thrombocytopenia. Other adverse effects include serious infections, including mycobacterial and other opportunistic infections. The risk of adverse effects is greater in patients on concomitant immunosuppressive therapy. Hyperlipidemia may occur and should be managed according to available guidelines. Intestinal perforations have been reported, especially in older patients and in those with a history of diverticulitis, which is a contraindication to the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    . (See",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     \"Tocilizumab: Drug information\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in primary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110291285\">",
"    <span class=\"h4\">",
"     Rituximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a monoclonal anti-CD20 antibody that depletes B cells. It is administered intravenously (1000",
"    <span class=\"nowrap\">",
"     mg/dose)",
"    </span>",
"    on days 1 and 15 of therapy, usually 30 minutes following intravenous administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    (100 mg), which can reduce the incidence and severity of infusion reactions. Subsequent courses are usually given every 6 to 12 months if clinically indicated, based upon disease activity. Similarly, we generally wait six months after administration of rituximab before switching to an alternative medication for lack of efficacy or for adverse effects because of the duration of its biologic effects. Rituximab is given in combination with ongoing MTX treatment.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    plus continued therapy with MTX in patients with an inadequate response to a TNF inhibitor was shown in comparison with placebo plus continued MTX in a randomized trial involving 520 patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/76\">",
"     76",
"    </a>",
"    ]. At six months, significantly more patients receiving rituximab showed at least 20 percent improvement in clinical activity compared with placebo treated patients (ACR20 of 51 versus 18 percent). Additional evidence suggests benefit with retreatment six months after an initial course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/85\">",
"     85",
"    </a>",
"    ]. Additionally, a registry-based study suggested that, when the reason for stopping a TNF inhibitor was lack of effect rather than an adverse event, rituximab resulted in a greater decrease in disease activity compared with treatment with another TNF inhibitor (DAS28 decrease of -1.34 versus -0.93) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/74\">",
"     74",
"    </a>",
"    ]. The use of rituximab in the treatment of RA, additional evidence supporting such use, and the adverse effects of rituximab are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=see_link&amp;anchor=H2#H2\">",
"     \"Rituximab and other B cell targeted therapies for rheumatoid arthritis\", section on 'Rituximab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H110291293\">",
"    <span class=\"h4\">",
"     Tofacitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     Tofacitinib",
"    </a>",
"    is an orally administered Janus kinase (JAK kinase) inhibitor that decreases signalling by a number of cytokine and growth factor receptors. It is taken in a dose of 5 mg twice daily. Tofacitinib can be used as monotherapy or combined with MTX or other nonbiologic DMARDs in patients with moderately to severely active RA who have had an inadequate response or intolerance to MTX, but it should not be taken in combination with biologic agents or with other potent immunosuppressants, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . The evidence supporting the use of tofacitinib in patients with RA is reviewed here briefly and is discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/22/16746?source=see_link&amp;anchor=H5878192#H5878192\">",
"     \"Cytokine networks in rheumatic diseases: Implications for therapy\", section on 'JAK inhibition'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy and safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    in rheumatoid arthritis have been evaluated in several trials in patients with an inadequate response to MTX or another traditional or biologic DMARD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/86,87\">",
"     86,87",
"    </a>",
"    ]. In a randomized trial involving 611 patients with an inadequate response to at least one nonbiologic or biologic DMARD, tofacitinib monotherapy (5 mg twice daily) resulted significantly more often in reductions in signs and symptoms of active RA after three months of treatment, compared with placebo (ACR20 of 60 versus 27 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/86\">",
"     86",
"    </a>",
"    ]. In a randomized trial involving 717 patients, tofacitinib (5 mg twice daily) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (40 mg administered subcutaneously every two weeks) showed similarly significant benefit compared with placebo after six months in patients with active RA who had had an inadequate response to MTX and who continued MTX cotherapy (ACR20 of 52 and 47 percent versus 28 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative safety of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    appeared similar to that of biologic DMARDs, including increased risk of infections and liver function test abnormalities; additional concerns that require attention in clinical use include neutropenia, hyperlipidemia, and, possibly, increased serum creatinine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/86-90\">",
"     86-90",
"    </a>",
"    ]. Gastrointestinal perforations have also been reported. The need for concurrent MTX therapy with use of tofacitinib is uncertain and requires further study.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H266402509\">",
"    <span class=\"h2\">",
"     Resistant to standard therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are several options in patients who are unable to take or who have an inadequate response to TNF inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"     abatacept",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"     tocilizumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"     tofacitinib",
"    </a>",
"    . The choice between these further options depends upon patient preferences regarding route of administration, patient comorbidities, and clinician preference based upon degree of experience with a given agent. There have been no head-to-head comparisons of these therapies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Nonbiologic (traditional) DMARDs",
"      </strong>",
"      &mdash; Treatment options in this setting should include the use of nonbiologic DMARDs, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      , or DMARD combinations, such as triple therapy, which were not used in the original sequence of drug regimens in a given patient. These agents may be tried before less effective biologic agents, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       anakinra",
"      </a>",
"      , or before the other nonbiologic DMARDs used infrequently in practice, such as those mentioned below. (See",
"      <a class=\"local\" href=\"#H7013910\">",
"       'Leflunomide'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7013148\">",
"       'DMARD triple therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/294?source=see_link\">",
"       Anakinra",
"      </a>",
"      &mdash; The interleukin-1 receptor antagonist, anakinra, can be used in combination with MTX but appears less effective than other biologic DMARDs in RA [",
"      <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/27\">",
"       27",
"      </a>",
"      ]. Its effectiveness in patients who have failed to respond to MTX plus a TNF inhibitor has not been evaluated. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=see_link&amp;anchor=H3#H3\">",
"       \"Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL\", section on 'Anakinra'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Other nonbiologic traditional DMARDs",
"      </strong>",
"      &mdash; Nonbiologic DMARDs that have less efficacy, greater toxicity, or both, compared with other available medications, but that may be of use in patients without other treatment options include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=see_link&amp;anchor=H15#H15\">",
"       \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\", section on 'Use in rheumatic diseases'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Gold (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25319?source=see_link\">",
"       \"Use of gold compounds in rheumatic diseases\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/98?source=see_link&amp;anchor=H9#H9\">",
"       \"Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis\", section on 'Cyclosporine and MTX'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?3/10/3240?source=see_link\">",
"       Minocycline",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link&amp;anchor=H3978675#H3978675\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Other therapies'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109285125\">",
"    <span class=\"h1\">",
"     SYMPTOMATIC DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiinflammatory drugs are used as a supplement to DMARDs under several conditions, including as bridging therapies until newly instituted DMARD regimens become effective, as adjuncts to DMARDs on a chronic basis, and for the management of disease exacerbations (flares). Analgesic effects of nonsteroidal antiinflammatory drugs (NSAIDs) or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may also give additional relief.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109285013\">",
"    <span class=\"h2\">",
"     Antiinflammatory therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We use NSAIDs or systemic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    intraarticular glucocorticoids when needed for ongoing control of inflammation, while awaiting the response to modifications in DMARD therapy. Glucocorticoids can help to rapidly control inflammation and to improve symptoms. However, they should be used in the lowest dose required once such control is achieved, and they should be tapered and discontinued as soon as feasible. Some patients require ongoing therapy with low doses of glucocorticoids to maintain remission or a low level of disease activity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H3693478#H3693478\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'NSAIDs'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H3693989#H3693989\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Glucocorticoids'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H109285224\">",
"    <span class=\"h2\">",
"     Drug therapy for flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;RA has natural exacerbations (also known as flares) and reductions of continuing disease activity. It is important to distinguish a disease flare, characterized by symptoms and by physical and laboratory findings of increased inflammatory synovitis, from noninflammatory causes of local or generalized increased pain. The severity of the flare and background drug therapy influence the choice of therapies. The treatment of such flares is described in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=see_link\">",
"     \"Clinical features of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=see_link\">",
"     \"Use of glucocorticoids in the treatment of rheumatoid arthritis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H344392649#H344392649\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Assessment of disease activity'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H169760190#H169760190\">",
"     \"General principles of management of rheumatoid arthritis in adults\", section on 'Drug therapy for flares'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2990265\">",
"    <span class=\"h2\">",
"     Analgesics",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the medications noted above, including NSAIDs, which also have analgesic effects, we use other analgesic medications, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/50/42792?source=see_link\">",
"     tramadol",
"    </a>",
"    , for additional pain relief, if required. We generally avoid the use of potent opioids because pain can be controlled in most patients with RA by effective use of antiinflammatories and DMARDs that control the disease process. Patients without evidence of very significant joint injury who appear to require opioids for adequate pain relief should be evaluated for fibromyalgia or other comorbid causes of pain (eg, fracture, tumor, spinal disorders, neuropathy, or others).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8152320\">",
"    <span class=\"h1\">",
"     DURATION OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with early, severely active RA require sustained therapy and adjustments in their treatment regimen over months to years to achieve treatment goals. In the minority of patients who achieve a sustained clinical remission of greater than one year, we cautiously try to reduce nonbiologic and biologic DMARD doses while maintaining close monitoring to facilitate recognition of any recurrence of disease activity. However, we generally avoid discontinuing all DMARD treatment. Although some patients may tolerate a reduced dose of medications, the decision to discontinue DMARDs in patients in remission remains controversial, and there is limited evidence regarding tapering of DMARDs in patients who are started on DMARDs early in their disease course or who have been treated with biologic DMARDs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/91-96\">",
"     91-96",
"    </a>",
"    ]. Our approach is based upon the available data and upon our clinical experience. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link&amp;anchor=H3697757#H3697757\">",
"     \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\", section on 'Duration of therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=see_link&amp;anchor=H7361200#H7361200\">",
"     \"Assessment of rheumatoid arthritis activity in clinical trials and clinical practice\", section on 'Remission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As an example of our approach, in a patient in clinical remission being treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    (7",
"    <span class=\"nowrap\">",
"     mg/day),",
"    </span>",
"    MTX (20",
"    <span class=\"nowrap\">",
"     mg/week),",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/week),",
"    </span>",
"    we would first try to reduce prednisone because of the risk of long-term adverse effects with glucocorticoids. In such a patient, we would lower the glucocorticoid dose slowly (no faster than 1 mg every two to four weeks), as long as there was no recurrence of disease activity.",
"   </p>",
"   <p>",
"    If",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    can be discontinued or if it cannot be completely eliminated but can be lowered to a dose no greater than 5",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    we would then reduce the dosing of the TNF inhibitor, based upon our clinical experience. We try to reduce",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"     etanercept",
"    </a>",
"    by slowly decreasing the dosing frequency (eg, to every 10 to 14 days, then gradually to every three to four weeks if dose reduction is tolerated). In patients on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , in whom dose adjustment is more feasible compared with etanercept or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , we would try to incrementally reduce the dose to as low as 3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    and to increase the interval between infusions to every eight weeks.",
"   </p>",
"   <p>",
"    In patients who are able to discontinue a biologic and who then remain in remission for at least a year, we next decrease MTX. We reduce the MTX dose in 2.5 mg increments every two to three months as tolerated but generally to no lower than 10",
"    <span class=\"nowrap\">",
"     mg/week.",
"    </span>",
"    In patients who are tolerating",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    more poorly, reduction in the methotrexate dose can be implemented before reduction in the dose of the TNF antagonist.",
"   </p>",
"   <p>",
"    Continued close monitoring is required in patients who discontinue or reduce any of their medications. The risk of disease recurrence in such patients is high, and flares of disease may occur even several years after stopping therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/92-96\">",
"     92-96",
"    </a>",
"    ]. Additionally, clinical remission can be difficult to achieve upon resumption of DMARD therapy in patients who have discontinued all DMARDs. The best candidates for achieving a drug-free remission appear to be patients who have a short duration of symptoms when treatment is started, patients who are of the male sex, patients who have an absence of autoantibodies, and patients who receive early intensive therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?41/6/42090/abstract/94,97-99\">",
"     94,97-99",
"    </a>",
"    ]. The effects on the progression of joint injury of less frequent dosing (eg, based upon symptomatic need only) have not been evaluated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H186962301\">",
"    <span class=\"h1\">",
"     PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Considerations relevant to the management of RA during pregnancy are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40791?source=see_link\">",
"     \"Rheumatoid arthritis and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=see_link\">",
"     \"Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/21/26962?source=see_link\">",
"       \"Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis treatment (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=see_link\">",
"       \"Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with rheumatoid arthritis (RA) benefit from the achievement and maintenance of tight control of disease activity, with the ideal goal of remission. Whenever possible, antiinflammatory agents, including glucocorticoids, should be used only as adjunctive agents. Patient education and other nonpharmacologic and preventive therapies, including appropriate immunizations, are needed for all patients with RA. (See",
"      <a class=\"local\" href=\"#H22353727\">",
"       'General principles and approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with RA, resistance to initial therapy with disease-modifying antirheumatic drugs (DMARDs) is defined as failure to achieve remission or low disease activity within three to six months despite the use of maximally tolerated doses within the usual therapeutic range; as a requirement, in addition to DMARDs, for excessively high doses of glucocorticoids; or as recurrent flares of disease requiring multiple courses of glucocorticoids with doses in excess of those acceptable for chronic therapy, despite maximally tolerated or acceptable doses of the DMARDs being used. (See",
"      <a class=\"local\" href=\"#H5187547\">",
"       'Definition of resistance to initial DMARDs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with active RA resistant to initial therapy after three to six months of treatment, we recommend treatment with a different or additional DMARD or with DMARD combinations to achieve control of signs and symptoms of disease, rather than continuing the initial DMARD regimen (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The choice of drug combinations in such patients depends upon prior therapy, upon the level of disease activity, upon patient preference for route of administration, upon the presence of adverse prognostic features, and upon regulatory and cost barriers to drug access. (See",
"      <a class=\"local\" href=\"#H2897438\">",
"       'Resistant to initial DMARD'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12087392\">",
"       'Choice of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients resistant to initial therapy with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2471?source=see_link\">",
"       hydroxychloroquine",
"      </a>",
"      (HCQ) or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/28/8647?source=see_link\">",
"       sulfasalazine",
"      </a>",
"      (SSZ), we suggest adding",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      (MTX) or treating with a combination of HCQ, SSZ, and MTX, rather than switching to a TNF inhibitor or to a TNF inhibitor plus MTX (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Usual doses of these medications are MTX (up to 25 mg once weekly administered orally or parenterally), HCQ (400 mg daily taken orally), and SSZ (1000 mg twice daily taken orally). (See",
"      <a class=\"local\" href=\"#H109285579\">",
"       'Resistant to HCQ and/or SSZ'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=see_link&amp;anchor=H14#H14\">",
"       \"Initial treatment of mildly active rheumatoid arthritis in adults\", section on 'Monitoring and reevaluation'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=see_link\">",
"       \"Initial treatment of moderately to severely active rheumatoid arthritis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who have not achieved treatment goals after three to six months of MTX at optimal doses, we suggest either the combination of continued MTX plus a tumor necrosis factor (TNF) inhibitor (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      ) or the use of DMARD &ldquo;triple therapy&rdquo; with MTX plus SSZ and HCQ, rather than monotherapy with another nonbiologic or biologic DMARD (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). Usual doses of these TNF inhibitors are etanercept (50 mg subcutaneously once weekly) and adalimumab (40 mg subcutaneously every two weeks). We use triple therapy in patients for whom drug cost and preference for an oral agent are important factors. (See",
"      <a class=\"local\" href=\"#H12087126\">",
"       'Resistant to MTX'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H12087392\">",
"       'Choice of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7011196\">",
"       'MTX plus TNF inhibitor'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7013148\">",
"       'DMARD triple therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom MTX plus a TNF inhibitor would otherwise be appropriate but who are unable to use a TNF inhibitor, we suggest the combination of MTX plus",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      , rather than biologic monotherapy or another DMARD combination (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Abatacept may be administered either intravenously (usually 750 mg once every four weeks) or subcutaneously (125 mg once weekly). (See",
"      <a class=\"local\" href=\"#H7013515\">",
"       'Alternatives to MTX/TNF inhibitor and to triple therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7014295\">",
"       'MTX plus abatacept'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom regulatory or cost considerations preclude use of a biologic agent despite failure of MTX or DMARD triple therapy to adequately control disease activity, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/36/19015?source=see_link\">",
"       leflunomide",
"      </a>",
"      (LEF) rather than alternative nonbiologic DMARDs (eg, gold,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7013515\">",
"       'Alternatives to MTX/TNF inhibitor and to triple therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7013910\">",
"       'Leflunomide'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients whose treatment regimen has changed, reevaluation may be required up to every four weeks for the effectiveness of therapy and for the monitoring of possible drug toxicity. We assess and monitor disease activity using a quantitative composite measure at each assessment. Further management is dependent upon disease response. (See",
"      <a class=\"local\" href=\"#H2897506\">",
"       'Reevaluation and monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In patients who do not respond adequately to therapy with an initial TNF inhibitor within three to six months, we suggest switching to a different TNF inhibitor, rather than to another class of biologic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We prefer one of the agents with which there is more experience, such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?27/31/28151?source=see_link\">",
"       etanercept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?38/24/39303?source=see_link\">",
"       adalimumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"       infliximab",
"      </a>",
"      (which is administered intravenously, usually in a dose of 3 to 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every eight weeks). An alternative approach is switching to another biologic agent with a different mechanism of action in this setting rather than to a second TNF inhibitor, particularly in patients who discontinue the initial TNF inhibitor due to an adverse reaction. (See",
"      <a class=\"local\" href=\"#H8152910\">",
"       'Resistant to one TNF inhibitor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who do not respond adequately to the therapies above, including trials of MTX and trials of two TNF inhibitors, we suggest the use of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/14/18662?source=see_link\">",
"       abatacept",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=see_link\">",
"       tocilizumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , rather than the administration of a third TNF inhibitor (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?17/49/18198?source=see_link\">",
"       Tofacitinib",
"      </a>",
"      is an alternative agent in such patients. Choice between these agents depends primarily upon patient preference; upon regulatory, insurance, and cost limitations; upon comorbidities; and upon clinician experience. (See",
"      <a class=\"local\" href=\"#H8152313\">",
"       'Resistant to two TNF inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7014677\">",
"       'Choice of therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1503703\">",
"       'Dosing and efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We continue nonbiologic and biologic DMARD therapy at reduced doses, if possible, for patients in remission, rather than discontinuing treatment with DMARDs. (See",
"      <a class=\"local\" href=\"#H8152320\">",
"       'Duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients experiencing a disease flare that is not controlled with NSAIDs, we suggest treatment with intraarticular or oral glucocorticoids rather than switching or continuing NSAIDs as the only additional agent (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). We use antiinflammatory drug therapy, including nonsteroidal antiinflammatory drugs (NSAIDs) or glucocorticoids, on a temporary basis to quickly achieve control of signs and symptoms of disease, and we then taper and withdraw these medications once a new DMARD regimen has taken effect. Some patients benefit from chronic low-dose glucocorticoid therapy (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      to 5 to 7.5 mg daily). (See",
"      <a class=\"local\" href=\"#H109285125\">",
"       'Symptomatic drug therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H109285013\">",
"       'Antiinflammatory therapy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H109285224\">",
"       'Drug therapy for flares'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=see_link&amp;anchor=H169760190#H169760190\">",
"       \"General principles of management of rheumatoid arthritis in adults\", section on 'Drug therapy for flares'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/1\">",
"      Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000; 43:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/2\">",
"      Schoels M, Knevel R, Aletaha D, et al. Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. Ann Rheum Dis 2010; 69:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/3\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005; 52:3381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/4\">",
"      Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann Intern Med 2007; 146:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/5\">",
"      de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. Arthritis Rheum 2008; 58:1293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/6\">",
"      M&ouml;tt&ouml;nen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 1999; 353:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/7\">",
"      Puolakka K, Kautiainen H, M&ouml;tt&ouml;nen T, et al. Impact of initial aggressive drug treatment with a combination of disease-modifying antirheumatic drugs on the development of work disability in early rheumatoid arthritis: a five-year randomized followup trial. Arthritis Rheum 2004; 50:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/8\">",
"      Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. Arthritis Rheum 2009; 60:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/9\">",
"      Grigor C, Capell H, Stirling A, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004; 364:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/10\">",
"      Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). Ann Rheum Dis 2007; 66:1443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/11\">",
"      Lee DM, Weinblatt ME. Rheumatoid arthritis. Lancet 2001; 358:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/12\">",
"      Sokka T, Kautiainen H, H&auml;kkinen A, Hannonen P. Radiographic progression is getting milder in patients with early rheumatoid arthritis. Results of 3 cohorts over 5 years. J Rheumatol 2004; 31:1073.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/13\">",
"      American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis: 2002 Update. Arthritis Rheum 2002; 46:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/14\">",
"      Maetzel A, Bombardier C, Strand V, et al. How Canadian and US rheumatologists treat moderate or aggressive rheumatoid arthritis: a survey. J Rheumatol 1998; 25:2331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/15\">",
"      van Vollenhoven RF. Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 2009; 5:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/16\">",
"      Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2000; 39:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/17\">",
"      Choi HK, Hern&aacute;n MA, Seeger JD, et al. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002; 359:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/18\">",
"      Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/19\">",
"      Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/20\">",
"      Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. Arthritis Rheum 2010; 62:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/21\">",
"      St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 2004; 50:3432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/22\">",
"      Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet 2009; 374:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/23\">",
"      Moreland LW, O'Dell JR, Paulus H, et al. TEAR: Treatment of early aggressive RA: A randomized, double-blind, 2-year trial comparing immediate triple DMARD versus MTX plus etanercept to step-up from initial MTX monotherapy. Arthritis Rheum 2009; 60:S707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/24\">",
"      Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/25\">",
"      Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and Cochrane overview. Cochrane Database Syst Rev 2011; :CD008794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/26\">",
"      Drugs for rheumatoid arthritis. Treat Guidel Med Lett 2012; 10:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/27\">",
"      Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009; 181:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/28\">",
"      McInnes IB, O'Dell JR. State-of-the-art: rheumatoid arthritis. Ann Rheum Dis 2010; 69:1898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/29\">",
"      Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. Ann Intern Med 2008; 148:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/30\">",
"      Choy EH, Smith C, Dor&eacute; CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining disease-modifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology (Oxford) 2005; 44:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/31\">",
"      Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/32\">",
"      Salliot C, Finckh A, Katchamart W, et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann Rheum Dis 2011; 70:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/33\">",
"      Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004; 363:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/34\">",
"      Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/35\">",
"      Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. Arthritis Rheum 2006; 54:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/36\">",
"      van Riel PL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: the ADORE study. Ann Rheum Dis 2006; 65:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/37\">",
"      Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2006; 54:1786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/38\">",
"      Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. Arthritis Res Ther 2006; 8:R174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/39\">",
"      Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. Ann Rheum Dis 2009; 68:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/40\">",
"      Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. Arthritis Rheum 2010; 62:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/41\">",
"      Taylor PC, Ritchlin C, Mendelsohn A, et al. Maintenance of efficacy and safety with subcutaneous golimumab among patients with active rheumatoid arthritis who previously received intravenous golimumab. J Rheumatol 2011; 38:2572.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/42\">",
"      Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013; 72:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/43\">",
"      Which TNF inhibitor for rheumatoid arthritis? Med Lett Drugs Ther 2010; 52:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/44\">",
"      Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009; 60:1884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/45\">",
"      Lopez-Olivo MA, Tayar JH, Martinez-Lopez JA, et al. Risk of malignancies in patients with rheumatoid arthritis treated with biologic therapy: a meta-analysis. JAMA 2012; 308:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/46\">",
"      Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? Arthritis Rheum 2009; 60:3180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/47\">",
"      van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009; 374:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/48\">",
"      van Vollenhoven RF, Geborek P, Forslind K, et al. Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012; 379:1712.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/49\">",
"      Moreland LW, O'Dell JR, Paulus HE, et al. A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. Arthritis Rheum 2012; 64:2824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/50\">",
"      Bruynesteyn K, Van Der Heijde D, Boers M, et al. Detecting radiological changes in rheumatoid arthritis that are considered important by clinical experts: influence of reading with or without known sequence. J Rheumatol 2002; 29:2306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/51\">",
"      Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008; 67:1096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/52\">",
"      Schiff M, Fleischmann R, Weinblatt M, et al. Abatacept SC versus adalimumab on background methotrexate in RA: One year results from the AMPLE study. Ann Rheum Dis 2012; 71(Suppl3):60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/53\">",
"      Guyot P, Taylor P, Christensen R, et al. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther 2011; 13:R204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/54\">",
"      Maxwell LJ, Singh JA. Abatacept for rheumatoid arthritis: a Cochrane systematic review. J Rheumatol 2010; 37:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/55\">",
"      Genovese MC, Covarrubias A, Leon G, et al. Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate. Arthritis Rheum 2011; 63:2854.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/56\">",
"      Osiri M, Shea B, Robinson V, et al. Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/57\">",
"      Strand V, Cohen S, Schiff M, et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999; 159:2542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/58\">",
"      Emery P, Breedveld FC, Lemmel EM, et al. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/59\">",
"      Karanikolas G, Charalambopoulos D, Andrianakos A, et al. Combination of cyclosporine and leflunomide versus single therapy in severe rheumatoid arthritis. J Rheumatol 2006; 33:486.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/60\">",
"      Kremer JM, Genovese MC, Cannon GW, et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137:726.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: New boxed warning for severe liver injury with arthritis drug Arava (leflunomide) file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm218679.htm (Accessed on September 15, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/62\">",
"      Bykerk VP, Akhavan P, Hazlewood GS, et al. Canadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. J Rheumatol 2012; 39:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/63\">",
"      Singer O, Gibofsky A. Methotrexate versus leflunomide in rheumatoid arthritis: what is new in 2011? Curr Opin Rheumatol 2011; 23:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/64\">",
"      Finckh A, Dehler S, Gabay C, SCQM doctors. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. Ann Rheum Dis 2009; 68:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/65\">",
"      Jain R, Lipsky PE. Treatment of rheumatoid arthritis. Med Clin North Am 1997; 81:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/66\">",
"      Guidelines for the management of rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/67\">",
"      Guidelines for monitoring drug therapy in rheumatoid arthritis. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Arthritis Rheum 1996; 39:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/68\">",
"      Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/69\">",
"      van Vollenhoven RF. Switching between anti-tumour necrosis factors: trying to get a handle on a complex issue. Ann Rheum Dis 2007; 66:849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/70\">",
"      Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. Lancet 2009; 374:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/71\">",
"      Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis 2007; 66:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/72\">",
"      Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. Arthritis Rheum 2007; 56:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/73\">",
"      Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. Rheumatology (Oxford) 2008; 47:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/74\">",
"      Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 2010; 69:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/75\">",
"      Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/76\">",
"      Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006; 54:2793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/77\">",
"      Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008; 67:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/78\">",
"      Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. Arthritis Rheum 2006; 54:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/79\">",
"      Emery P. Optimizing outcomes in patients with rheumatoid arthritis and an inadequate response to anti-TNF treatment. Rheumatology (Oxford) 2012; 51 Suppl 5:v22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/80\">",
"      Schoels M, Aletaha D, Smolen JS, Wong JB. Comparative effectiveness and safety of biological treatment options after tumour necrosis factor &alpha; inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. Ann Rheum Dis 2012; 71:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/81\">",
"      Isaacs JD, Cohen SB, Emery P, et al. Effect of baseline rheumatoid factor and anticitrullinated peptide antibody serotype on rituximab clinical response: a meta-analysis. Ann Rheum Dis 2013; 72:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/82\">",
"      Chatzidionysiou K, Lie E, Nasonov E, et al. Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Ann Rheum Dis 2011; 70:1575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/83\">",
"      Singh JA, Christensen R, Wells GA, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009; :CD007848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/84\">",
"      Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis 2009; 68:1708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/85\">",
"      Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. J Rheumatol 2010; 37:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/86\">",
"      Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012; 367:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/87\">",
"      van Vollenhoven RF, Fleischmann R, Cohen S, et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012; 367:508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/88\">",
"      Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009; 60:1895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/89\">",
"      Tanaka Y, Suzuki M, Nakamura H, et al. Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate. Arthritis Care Res (Hoboken) 2011; 63:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/90\">",
"      Fleischmann R, Cutolo M, Genovese MC, et al. Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs. Arthritis Rheum 2012; 64:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/91\">",
"      Smolen JS, Landew&eacute; R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis 2010; 69:964.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/92\">",
"      ten Wolde S, Breedveld FC, Hermans J, et al. Randomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritis. Lancet 1996; 347:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/93\">",
"      Tiippana-Kinnunen T, Paimela L, Kautiainen H, et al. Can disease-modifying anti-rheumatic drugs be discontinued in long-standing rheumatoid arthritis? A 15-year follow-up. Scand J Rheumatol 2010; 39:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/94\">",
"      Goekoop-Ruiterman YP, Huizinga TW. Rheumatoid arthritis: can we achieve true drug-free remission in patients with RA? Nat Rev Rheumatol 2010; 6:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/95\">",
"      O'Mahony R, Richards A, Deighton C, Scott D. Withdrawal of disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis 2010; 69:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/96\">",
"      Berthelot JM, Varin S. Is dosage reduction appropriate in patients who respond well to anti-TNF-alpha agents? Joint Bone Spine 2004; 71:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/97\">",
"      van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. Ann Rheum Dis 2009; 68:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/98\">",
"      Tanaka Y. Intensive treatment and treatment holiday of TNF-inhibitors in rheumatoid arthritis. Curr Opin Rheumatol 2012; 24:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?41/6/42090/abstract/99\">",
"      Breedveld FC, Combe B. Understanding emerging treatment paradigms in rheumatoid arthritis. Arthritis Res Ther 2011; 13 Suppl 1:S3.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7490 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.55.141.10-5088ACF45B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42090=[""].join("\n");
var outline_f41_6_42090=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22353727\">",
"      GENERAL PRINCIPLES AND APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2892723\">",
"      Principles of management",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5187547\">",
"      Definition of resistance to initial DMARDs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H186961554\">",
"      Nonpharmacologic and preventive therapies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109283721\">",
"      Approach to drug therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3026408\">",
"      PRETREATMENT INTERVENTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2897438\">",
"      RESISTANT TO INITIAL DMARD",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109285579\">",
"      Resistant to HCQ and/or SSZ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12087126\">",
"      Resistant to MTX",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12087392\">",
"      - Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7011196\">",
"      - MTX plus TNF inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7011759\">",
"      Efficacy of MTX/TNF inhibitor versus triple therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7012229\">",
"      Efficacy of MTX/TNF inhibitor versus MTX/abatacept",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7013148\">",
"      - DMARD triple therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7013515\">",
"      - Alternatives to MTX/TNF inhibitor and to triple therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7014295\">",
"      MTX plus abatacept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H7013910\">",
"      Leflunomide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2897506\">",
"      REEVALUATION AND MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2897446\">",
"      RESISTANT TO TNF INHIBITOR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8152910\">",
"      Resistant to one TNF inhibitor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8152313\">",
"      Resistant to two TNF inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7014677\">",
"      - Choice of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1503703\">",
"      - Dosing and efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110291223\">",
"      Abatacept",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110291231\">",
"      Tocilizumab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110291285\">",
"      Rituximab",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H110291293\">",
"      Tofacitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H266402509\">",
"      Resistant to standard therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H109285125\">",
"      SYMPTOMATIC DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109285013\">",
"      Antiinflammatory therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H109285224\">",
"      Drug therapy for flares",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2990265\">",
"      Analgesics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8152320\">",
"      DURATION OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H186962301\">",
"      PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/9/43161?source=related_link\">",
"      Antimalarial drugs in the treatment of rheumatic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/33/7706?source=related_link\">",
"      Assessment of rheumatoid arthritis activity in clinical trials and clinical practice",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/46/13033?source=related_link\">",
"      Clinical features of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/13/7385?source=related_link\">",
"      Clinical trials of combination therapy in persistently active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/22/16746?source=related_link\">",
"      Cytokine networks in rheumatic diseases: Implications for therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/10/20648?source=related_link\">",
"      Diagnosis of latent tuberculosis infection in HIV-negative adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37861?source=related_link\">",
"      Evaluation and medical management of end-stage rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/11/39098?source=related_link\">",
"      General principles of management of rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/25/26009?source=related_link\">",
"      Hepatitis B virus reactivation associated with immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/1/15385?source=related_link\">",
"      Initial treatment of mildly active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/3/31802?source=related_link\">",
"      Initial treatment of moderately to severely active rheumatoid arthritis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/59/10169?source=related_link\">",
"      Leflunomide in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/17/13591?source=related_link\">",
"      Nonpharmacologic and preventive therapies of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?26/21/26962?source=related_link\">",
"      Patient information: Disease modifying antirheumatic drugs (DMARDs) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/31/16883?source=related_link\">",
"      Patient information: Rheumatoid arthritis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/61/21463?source=related_link\">",
"      Patient information: Rheumatoid arthritis symptoms and diagnosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?23/44/24264?source=related_link\">",
"      Patient information: Rheumatoid arthritis treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/3/26681?source=related_link\">",
"      Progressive multifocal leukoencephalopathy: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/12/35016?source=related_link\">",
"      Randomized clinical trials in rheumatoid arthritis of biologic agents that inhibit IL-1, IL-6, and RANKL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/6/98?source=related_link\">",
"      Randomized clinical trials of combinations of nonbiologic DMARDs in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/10/10410?source=related_link\">",
"      Randomized clinical trials of tumor necrosis factor inhibitors in rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/53/40791?source=related_link\">",
"      Rheumatoid arthritis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/40/21130?source=related_link\">",
"      Rituximab and other B cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/27/2490?source=related_link\">",
"      Sulfasalazine in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/0/9223?source=related_link\">",
"      T cell targeted therapies for rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?43/19/44342?source=related_link\">",
"      Tocilizumab: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/20/32073?source=related_link\">",
"      Total joint replacement for severe rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/32/14856?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in primary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/53/33624?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/59/38842?source=related_link\">",
"      Use of antiinflammatory and immunosuppressive drugs in rheumatic diseases during pregnancy and lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41065?source=related_link\">",
"      Use of glucocorticoids in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/46/25319?source=related_link\">",
"      Use of gold compounds in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f41_6_42091="Patch efficacy";
var content_f41_6_42091=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F77359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F77359&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of the transdermal contraceptive patch*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Study",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cycles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pregnancies",
"       </td>",
"       <td class=\"subtitle1\">",
"        Perfect use&bull;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Typical use&Delta;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Non-comparative trial",
"       </td>",
"       <td>",
"        10,994",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0.59",
"       </td>",
"       <td>",
"        0.71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptive, comparative trial",
"       </td>",
"       <td>",
"        5921",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.66",
"       </td>",
"       <td>",
"        0.88",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Oral contraceptive, comparative trial",
"       </td>",
"       <td>",
"        5240",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.99",
"       </td>",
"       <td>",
"        1.24",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Combined total",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         22,155",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         15",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.70",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         0.88",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Pregnancies per 100 women-years.",
"     <br>",
"      &bull; Failure (pregnancy) when taking correctly.",
"      <br>",
"       &Delta; Perfect use failure plus user failure.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Burkman, RT. The transdermal contraceptive patch: a new approach to hormonal contraception. Int J Fertil Womens Med. 2002; 47(2): 69-76. Copyright &copy;2002 MSP International, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42091=[""].join("\n");
var outline_f41_6_42091=null;
var title_f41_6_42092="Treatment of blastomycosis";
var content_f41_6_42092=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60486&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of blastomycosis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Manifestation",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preferred treatment",
"      </td>",
"      <td class=\"subtitle1\">",
"       Comments",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Moderately severe to severe pulmonary",
"      </td>",
"      <td>",
"       Lipid AmB, 3-5 mg/kg per day, or deoxycholate AmB, 0.7-1 mg/kg per day, for 1-2 weeks, followed by itraconazole, 200 mg bid for 6-12 months",
"      </td>",
"      <td>",
"       The entire course of therapy can be given with deoxycholate AmB to a total of 2 g; however, most clinicians prefer to use step-down itraconazole therapy after the patient's condition improves. The lipid formulations of AmB have fewer adverse effects.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mild to moderate pulmonary",
"      </td>",
"      <td>",
"       Itraconazole, 200 mg once or twice per day for 6-12 months",
"      </td>",
"      <td>",
"       &nbsp;",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Moderately severe to severe disseminated",
"      </td>",
"      <td>",
"       Lipid AmB, 3-5 mg/kg per day, or deoxycholate AmB, 0.7-1 mg/kg per day, for 1-2 weeks, followed by itraconazole, 200 mg bid for 12 months",
"      </td>",
"      <td>",
"       The entire course of therapy can be given with deoxycholate AmB to a total of 2 g; however, most clinicians prefer to use step-down itraconazole therapy after the patient's condition improves. The lipid formulations of AmB have fewer adverse effects. Treat osteoarticular disease for 12 months.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mild to moderate disseminated",
"      </td>",
"      <td>",
"       Itraconazole, 200 mg once or twice per day for 6-12 months",
"      </td>",
"      <td>",
"       Treat osteoarticular disease for 12 months.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       CNS disease",
"      </td>",
"      <td>",
"       Lipid AmB, 5 mg/kg per day for 4-6 weeks is preferred*, followed by an oral azole for at least 1 year",
"      </td>",
"      <td>",
"       Step-down therapy can be with fluconazole, 800 mg per day, itraconazole, 200 mg 2-3 times per day, or voriconazole, 200-400 mg twice per day. Longer treatment may be required for immunosuppressed patients.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Immunosuppressed patients",
"      </td>",
"      <td>",
"       Lipid AmB, 3-5 mg/kg per day, or deoxycholate AmB, 0.7-1 mg/kg per day, for 1-2 weeks, followed by itraconazole, 200 mg bid for 12 months",
"      </td>",
"      <td>",
"       Life-long suppressive treatment may be required if immunosuppression cannot be reversed.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pregnant women",
"      </td>",
"      <td>",
"       Lipid AmB, 3-5 mg/kg per day",
"      </td>",
"      <td>",
"       Azoles should not be used during pregnancy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Children with moderately severe to severe disease",
"      </td>",
"      <td>",
"       Deoxycholate AmB, 0.7-1 mg/kg per day, or lipid AmB, 3-5 mg/kg per day, for 1-2 weeks, followed by itraconazole, 10 mg/kg per day for 12 months",
"      </td>",
"      <td>",
"       Children tolerate deoxycholate AmB better than adults do; maximum dose of itraconazole should be 400 mg per day.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Children with mild to moderate disease",
"      </td>",
"      <td>",
"       Itraconazole, 10 mg/kg per day for 6-12 months",
"      </td>",
"      <td>",
"       Maximum dose, 400 mg per day.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AmB: amphotericin; B: bid, twice per day.",
"     <br>",
"      * In animal models of fungal meningitis, liposomal AmB achieves higher CNS levels than do other lipid formulations. Hence, many infectious diseases experts recommend liposomal AmB as the preferred lipid formulation for the treatment of CNS fungal infections.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Chapman, SW, Dismukes, WE, Proia, LA, et al. Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:1801. Copyright &copy;2008 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42092=[""].join("\n");
var outline_f41_6_42092=null;
var title_f41_6_42093="Relationship between cerebral palsy and last BPS";
var content_f41_6_42093=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54595&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inverse relationship between the last fetal biophysical profile score (BPS) and cerebral palsy (CP)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 450px; height: 321px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The relationship between the fetal biophysical profile score and CP is inverse, exponential, and highly significant R",
"    <sup>",
"     2",
"    </sup>",
"    = -.096; P &lt;.001. Infants were followed for five years after birth.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Manning, FA, Harman, CR, Meticoglou, S, et al. Fetal assessment by fetal biophysical profile score. IV: The incidence of cerebral palsy among tested and non-tested perinates. Am J Obstet Gynecol 1998; 178:696. Copyright &copy; 1998 Mosby, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42093=[""].join("\n");
var outline_f41_6_42093=null;
var title_f41_6_42094="Round cals";
var content_f41_6_42094=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F52281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F52281&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Round mammographic calcifications",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnified oblique mammogram showing scattered, well-defined, round calcifications that can be characterized as benign. These findings are benign and would be described as BIRADS-2.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Lisa E Esserman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42094=[""].join("\n");
var outline_f41_6_42094=null;
var title_f41_6_42095="Complicated crown fracture";
var content_f41_6_42095=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Complicated crown fracture",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 246px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This fracture of the upper central incisor exposes the neurovascular pulp.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: McTigue, DJ. Managing traumatic injuries in the young permanent dentition. In: Pediatric Dentistry: Infancy through adolescence, 4th ed, WB Saunders, Philadelphia 2005. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f41_6_42095=[""].join("\n");
var outline_f41_6_42095=null;
